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1 Abbreviations 
 
AA   arachidonic  acid 
AC   adenylyl  cyclase 
A(β)BA 3-O-acetyl-(β-)BA 
(A)KBA (3-O-acetyl-)11-keto-BA 
A(D/T)P adenosine  (bis/tris)phosphate 
ATL   aspirin-triggered  lipoxin 
(β-)BA   (β-)boswellic acid 
BC-4   mixture  of  α-BA and β-ABA (1:1) extracted from B. carterii 
B. spec   Boswellia species 
CaLB   Ca
2+/lipid binding domain 
CaMK   Ca
2+/calmodulin-dependent kinase 
(c/s/i)PLA2 (cytosolic/secretory/Ca
2+-independent) phospholipase A2 
cGMP   cyclic guanosine monophosphate 
CNS    central nervous system 
CSF   colony-stimulating  factor 
COX   cyclooxygenase 
CYP   cytochrome  P450 
cys-LT   cysteinyl leukotriene 
DAG   diacylglycerol 
DCF-DA dichlorofluorescein  diacetate 
EET   epoxyeicosatrienoic  acid 
ER/SR   endoplasmatic/sarcoplasmatic reticulum 
ERK   extracellular  signal-regulated kinase 
ETP   endogenous  thrombin  potential 
FLAP   5-lipoxygenase-activating protein 
fMLP   N-formyl-methionyl-leucyl-phenylalanine 
G(D/T)P guanosine  (bis/tris)phosphate 
GEF    guanine exchange factor 
GM-CSF granulocyte/macrophage colony stimulating factor 
GP   glycoprotein 
GPx   glutathione  peroxidase 
GPCR   G protein-coupled receptor 
Grb-2   growth  factor  receptor-bound protein 2 
GSH   glutathione  (reduced  state) 
(12-)HHT (12-)hydroxyheptadecatrienoic  acid 
HL-60   human leukaemia cell line 
HLE    human leukocyte elastase 
H(P)ETE hydro(pero)xy-eicosatetraenoic acid 
(13-)HPODE (13-)hydroperoxyoctadecadienoic acid 
IFN   interferone 
IKK   inhibitor  of  NF-κB (IκB)-kinase Abbreviations 4 
IL   interleukin 
IP3   inositol  trisphosphate 
JNK   c-Jun  N-terminal kinases 
LDL   low-density  lipoprotein 
LPS   lipopolysaccharide 
LO   lipoxygenase 
LT   leukotriene 
LTA4H LTA4 hydrolase 
LTC4S   LTC4 synthase 
LX   lipoxin 
Mac-1   macrophage antigen-1 
MAPEG  membrane associated proteins in eicosanoid and GSH metabolism 
MAPK(KK) mitogen-activated  protein kinase (kinase kinase) 
MAPKAPK  MAPK-activating protein kinase 
MEK    MAPK and ERK kinase 
MMP   matrix  metalloproteinase 
MNK   MAPK-integrating  kinase 
MK-2/3 MAPKAPK-2/3 
NF-κB   nuclear factor κB 
NO   nitric  oxide 
PAF(-AH) platelet-activating factor (acetylhydrolase) 
PAR    protease activated receptor 
PDGF   platelet-derived growth factor 
PG   prostaglandin 
PGI2   prostacyclin 
PH   pleckstrin  homology 
PIP2   phosphatidylinositol-4,5-bisphosphate 
PI-3 K   phosphoinositide-3 kinase 
PL   phospholipase 
PMA    phorbol 12-myristate 13-acetate 
PMCA   plasma membrane Ca
2+-ATPase 
PMNL   polymorphonuclear leukocytes 
PK(A/C)  protein kinase A/C 
PSGL    P-selectin glycoprotein ligand 
PT   pentacyclic  triterpene 
PTx   pertussis  toxin 
PtdCho/Ins phosphatidyl  choline/inositol 
p-tyr   phospho-tyrosine 
p12-LO platelet-type  12-lipoxygenase 
RA   rheumatoid  arthritis 
RGS    regulators of G protein signalling 
ROS    reactive oxygen species 
RTK    receptor tyrosine kinase 
SAPK   stress-activated protein kinase Abbreviations 5 
SERCA SR/ER  Ca
2+-ATPase 
SH(2/3)  src homology (2/3) domain 
SOCE   store-operated Ca
2+ entry 
TA   tirucallic  acid 
TF   tissue  factor 
TGF    transforming growth factor 
TLR   Toll-like  receptor 
TM   transmembrane 
TNF    tumour necrosis factor 
TRAP   thrombin receptor-activated peptide 
Tx   thromboxane 
vWf   von  Willebrand  factor Introduction 6 
2 Introduction 
 
2.1. Inflammation 
Inflammation is the physiological reaction of the immune defence system to a variety of 
noxae, including internal stimuli (tissue injury, lesions) and external stimuli (pathogen 
infection, bacterial toxins). On the one hand, inflammation consists of an exudative 
component, resulting in blood vessel dilatation and enhanced capillary permeability 
around the site of irritation or infection. As a consequence, redness, heat, swelling (edema) 
and pain are caused. On the other hand, the second (cellular) component of inflammation 
involves leukocytes, capable to enter the tissue through permeabilised capillary walls. At 
the first stage, phagocytes attempt to eliminate the infectious stimuli, but if the 
inflammatory stimulus persists, cytokines (interleukin-1 (IL-1), tumor necrosis factor 
(TNF)) are released that activate the endothelium in order to upregulate the expression of 
adhesion receptors (VCAM, ICAM, selectins). Other inflammatory cells such as 
additional granulocytes, monocytes, T and B cells are recruited to the inflamed tissue. 
Typically, neutrophilic granulocytes, also termed polymorphonuclear leukocytes (PMNL), 
are found in acute states of inflammation, where they are responsible for phagocytosis and 
chemokine/second messenger release so as to promote and finally terminate the 
inflammatory process. At the infectious site, they can undergo a respiratory burst to attack 
intruders, and secrete proteases to finally cleanse damaged tissue. In wound repair, 
initially blood platelets are triggered by tissue collagen to release mediators, express 
glycoproteins and aggregate, resulting in the formation of a fibrin/fibronectin-based clot, 
that attracts other cells like PMNL. In subsequent processes, collagen deposition leads to 
the re-formation of the extracellular matrix (ECM), and angiogenesis is induced (for 
reviews, see [1, 2]).  
In chronic or persisting inflammation, however, the short-lived neutrophils are gradually 
substituted by monocytes from the peripheral blood. At the infected or inflamed tissue, 
monocytes enter the tissue and mature into macrophages, which eliminate apoptotic 
PMNLs after a few days [2, 3]. Macrophages are powerful producers of reactive oxygen 
species (ROS), supposed as a defence mechanism but also causing destruction to the 
surrounding tissue if the cells remain too long at the infectious site [4]. Thus, in many 
diseases with chronic inflammation (arthritis, rheumatism), it is beneficial to downregulate 
the activity of leukocytes by pharmacological agents in order to prevent progressive tissue 
degradation. 
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2.1.1.  Inducers/Mediators of inflammation 
In case of exogenous infections, the tripeptide N-formyl-methionyl-leucyl-phenylalanine 
(fMLP) may be secreted by bacteria [5]. fMLP is a potent chemotactic for neutrophils, 
where it binds to a specific G protein-coupled receptor (GPCR) [6, 7], causing neutrophil 
activation via intracellular mobilisation of Ca
2+ and activation of protein kinases such as 
the mitogen-activated protein (MAP) kinase cascade [8, 9] but also of cytosolic 
phospholipase (cPL)A2 [10].  
Cytosolic phospholipase (cPL)A2 predominantly liberates AA which either functions as 
mediator itself, inducing PMNL adhesion to the endothelium, ROS formation, chemotaxis 
and MAP kinase activation [11-13], or serves as a precursor for bioactive lipid mediators 
(platelet-activating factor, PAF) and eicosanoids. These include prostaglandins (PGD2, 
PGE2), prostacyclin (PGI2), and thromboxane (TxA), derived from cyclooxygenase (COX) 
and PGE synthases, as well as hydroxyl-eicosatetraenoic acids (HETEs), leukotriene 
(LT)B4, cysteinyl (Cys)-LTs, and lipoxins, synthesised by lipoxygenases. PAF, derived 
from lyso-PAF, attracts and stimulates granulocytes and monocytes/macrophages, 
enhances vascular permeability and aids to maintain an inflammatory state [14]. PAF also 
participates in platelet activation by binding to its corresponding Gi- and/or Gq-coupled 
receptor [15]. Per se, PAF is a moderate stimulus for neutrophils and a strong stimulus for 
eosinophils, that for instance causes substantial superoxide anion (
.O2
-) formation and 
generally shares many biological effects with fMLP [16]. COX products usually activate 
specific GPCRs and have diverse physiological effects mainly related to pain sensation, 
vascular homeostasis, and inflammation. Lipoxygenase (LO) products are discussed in a 
later section. Taken together, eicosanoids act as local hormones with short half-life. In 
contrast, cytokines share many features with “classical” hormones. They are polypeptides, 
synthesised and released by many inflammatory and other cells, encompassing 
interleukins (ILs), interferones (IFNs), colony stimulating factors (CSF), tumor necrosis 
factors (TNFs), transforming growth factor β (TGF-β), and chemotactic cytokines 
(chemokines) [17]. Cytokines bind to membrane-embedded cytokine receptors that induce 
cytosolic responses but also modulate transcription factors via members of the MAP 
kinase family, the c-Jun N-terminal kinases (JNKs). They have proinflammatory and 
immunostimulant properties, modulate the haematopoietic system and control 
proliferation, differentiation and cell survival [18]. Chemokines are the largest group of 
cytokines (>40 human members), and act via specific GPCRs to mediate leukocyte 
activation [19, 20]. Accordingly, leukocyte- or fibroblast-derived IL-8 is the most 
important chemokine for neutrophil activation, inducing a respiratory burst [21]. Introduction 8 
2.2.  Physiology of haematopoietic cells 
2.2.1.  Polymorphonuclear leukocytes (PMNL) 
Mature PMNL evolve in about 14 days from myeloblasts via myelocytes. They contain 
numerous ribosomes, mitochondria, and granules, as well as a spectrum of receptors 
linked to the innate immune defence [22]. Regularly, PMNLs roll along walls of 
postcapillary venules or various membranes and tissues for signs of chemoattractants. For 
proper recruitment to sites of infection, PMNLs require priming by a variety of agents 
such as cytokines, chemokines (IL-8), growth factors, lipid mediators, adhesion factors, or 
bacterial stimuli (fMLP). Many of these agents act on Toll-like receptors (TLRs) of 
neutrophils, inducing mobilisation of secretory vesicles but not yet full activation. That is, 
in turn, achieved by direct interaction with pathogen-derived structures (peptidoglycans, 
lipopolysaccharides) via TLRs, CD14, and other cell-surface receptors, resulting in 
prolonged cell survival, phagocytosis, respiratory burst and degranulation [23]. In 
addition, complement-opsonised microbes are easily recognised by PMNL complement 
receptors, further triggering PMNL activation. 
Neutrophil degranulation occurs in conjunction with phagocytosis, as granules either 
exocytose or fuse with phagosomes. Granules contain various anti-bacterial proteins such 
as α-defensins, cathepsins, proteinase-3, elastase and lysozyme, supposed to permeabilise 
and degrade microbial structures [22]. The regulatory mechanisms that govern 
degranulation are not yet fully elucidated but are believed to comprise, amongst other 
things, intracellular Ca
2+ mobilisation, Src family kinase and p38 MAPK activation [23, 
24]. As an unwanted side effect, protease release also causes destruction of healthy tissue, 
a process that may contribute to some chronic disease states. 
The neutrophil respiratory burst has important bactericidal effects. It consists of reactive 
.O2
- produced primarily by the membrane-bound NADPH oxidase complex [25]. Other 
sources are the mitochondrial respiratory chain, xanthine oxidase, COX and LOs (yielding 
lipid hydroperoxides as side products) and the cytochrome p450 system. The NADPH 
oxidase complex consists of components that normally reside in the cytosol (p40
phox, 
p47
phox, p67
phox, Rac2) as well as in membrane compartments (gp91
phox/p22
phox, Rap1A) 
that associate at the membrane upon neutrophil activation. Phosphorylation of the 
cytosolic components by protein kinase (PK)C but also by ERKs and p38 MAPK are 
major inducers of membrane translocation [26]. The active enzyme transfers electrons 
from NADPH to intraphagosomal molecular oxygen, yielding 
.O2
- that has destructive 
properties within phagosomes. The short-lived superoxide anion is rapidly dismutated to 
H2O2 and derivatives like hydroxyl radicals (
.OH) and singlet oxygen (
1O2), which act Introduction 9 
efficiently on bacteria [27]. Moreover, these oxidants activate matrix metalloproteinases 
(MMPs) that promote tissue breakdown [28]. Within granulocytes, catalases and 
glutathione peroxidases (GPx) provide intracellular protection against oxidants. In many 
pathophysiological settings such as tumor progression, neurodegeneration, atherosclerosis, 
but also Diabetes mellitus and aging, an imbalance between generated reactive oxygen 
species (ROS) and antioxidative effectors exists, causing ‘oxidative stress’ that includes 
the destruction of intact tissue by often chronically activated inflammatory cells [29]. Here 
again, intervention with pharmacological agents can reasonably cause a slowdown of 
disease progression. Notably, patients suffering from a genetic disorder called chronic 
granulomatous disease express defective subunits of the NADPH oxidase, unable to 
generate sufficient amounts of H2O2 and other reactive oxygen radicals. These patients 
sustain recurrent infections and have a remarkably reduced lifespan, thereby underlining 
the crucial importance of ROS generation in host defence [30]. 
Finally, the resolution of an infection is accompanied by PMNL apoptosis. Aged PMNL 
typically undergo spontaneous apoptosis after few days [31], but this can be delayed by 
cytokine stimulation (tumour necrosis factor (TNF)-α, lipopolysaccharide (LPS), toxins) 
to allow proper pathogen clearance. In contrast, bacterial ingestion by PMNL accelerates 
apoptosis, followed by encirclement and degradation by neighbouring macrophages [32]. 
Thus, neutrophil apoptosis is an essential process in the termination of an infection and 
health maintenance. 
 
2.2.2. Monocytes  and  macrophages 
Monocytes are myeloid cells that circulate in the blood for 1 to 2 days before they 
extravasate into tissues for terminal maturation to ‘tissue’ macrophages. This process 
occurs regularly, therefore resident tissue macrophages represent an important component 
of the vigilant unspecific host defence in the body. At sites of infection or irritation, they 
accumulate in large numbers [33]. Extensive macrophage extravasation is an early event 
in the onset of inflammation, various diseases, and wound healing. As stated above, the 
initial infiltration occurs through neutrophils with a maximum after 1 to 2 days, followed 
by monocyte recruitment that peaks not until 2 to 5 days after the wounding. In damaged 
tissue, macrophages are responsible for debris clearance and attraction of other cell types 
by release of cytokines and chemokines. The late phase of an inflammation is 
characterised by macrophages acting in concert with lymphocytes and epithelial cells by 
virtue of mutual cytokine stimulation (IL-12, IFN-γ, TGF-β) to induce tissue repair [34]. 
Furthermore, macrophages release ‘secretory leukocyte protease inhibitor’ (SLPI) which Introduction 10 
can be regarded as a marker indicating the switch from tissue damage to tissue repair. 
SPLI has anti-inflammatory and wound-healing effects, and together with the action of 
fibroblasts, lymphocytes and endothelial cells, subsequent processes like tissue 
remodelling and angiogenesis are induced [34, 35]. However, macrophages are also 
implicated in tumour growth, since they are recruited by tumour-derived chemoattractants 
and associate with tumours. They may even constitute a large portion of the tumour mass 
[36]. By secretion of various factors, these cells participate in tumour proliferation, 
survival, metastasis and angiogenesis [37]. Intriguingly, in many aspects (cytokine 
equipment, receptor expression, or motility) macrophages resemble tumour cells [33], and 
not surprisingly, more than 15 percent of cancers worldwide evolve from chronic 
inflammations initiated by infections [20]. 
With their capacitiy to secrete proangiogenic cytokines and enzymes, macrophages exert 
beneficial action in wound healing but at the same time cause unwanted effects in 
rheumatoid arthritis (RA). RA consists of a chronic inflammation of the synovium in 
joints, bearing infiltrated leukocytes and hyper-proliferative fibroblasts [38]. Persistent 
presence of macrophages is linked to tissue damage by formation of ROS, but also to the 
generation of new blood vessels that facilitates migration of leukocytes and fibroblasts. 
Angiogenesis is a prominent feature of RA which is promoted by macrophages [33]. 
Lastly, macrophages play an important role in atherosclerosis, a process due to 
dysfunction of endothelial cells. Monocytes infiltrate into arterial intima, differentiate into 
macrophages and ingest large quantities of oxidised low-density lipoprotein (LDL), thus 
becoming “foam” cells at the arterial wall [39]. In disease progression, the arterial wall 
thickens and the diameter decreases, causing hypoxic conditions and promoting vessel 
obstruction [33]. Altogether, there are several disease types where pharmacological 
regulation of macrophage activity appears favourable regarding disease progression [37]. 
 
2.2.3. Platelets 
Platelets play a central role during vascular wound healing. Injured endothelium allows 
blood components to interact with the subendothelial matrix, leading to multiple 
interactions between endothelium, neutrophils, monocytes, and platelets. Initial platelet 
tethering under shear conditions is governed by interaction of its two main adhesion 
receptors, platelet glycoprotein (GP) Ibα and GPVI, to von Willebrand factor (vWf) and 
collagen, respectively [40]. Monocytes and PMNL are recruited via P-selectin expression 
on collagen-bound platelets and endothelial cells. Monocyte interaction with platelets and 
endothelium relies on the binding of monocyte P-selectin GP ligand-1 (PSGL-1) to P-Introduction 11 
selectin [41], and is further strengthened by activation of macrophage antigen-1 (Mac-1) 
by its corresponding ligand on adherent platelets (MCP-1, monocytic chemotactic protein-
1) [42]. Meanwhile, the coagulation process is initiated by exposure of extravascular tissue 
factor (TF) to blood components, but also by TF on microvesicles released by stimulated 
monocytes at injured vessel walls [43]. TF-bearing vesicles concentrate at these sites in 
close proximity to adhered platelets, inducing the coagulation cascade. The cascade is 
spatially directed to the platelet surface by means of the prothrombinase complex (factor 
Xa) which cleaves plasma prothrombin into thrombin, thus generating a pivotal 
coagulation stimulus [44]. Interestingly, this prothrombinase complex can also be 
associated on monocytes, where neutrophil-derived cathepsin G activates factor X to 
factor Xa bound to the monocyte integrin Mac-1 (αMβ2). Thrombin is a strong pro-
aggregatory stimulus, but its effect can still be enhanced by cathepsin G and elastase 
released from PMNL that cleave the αIIb subunit of platelet integrin αIIbβ3, enabling it to 
bind fibrinogen and hence induce aggregation [45]. More platelets are attracted by binding 
of GPIb-IX-V complex to vWf released from endothelial cells which respond in this way 
upon exposure to ROS generated by activated adherent leukocytes [46]. GPIb-IX-V 
receptor occupation induces diverse intracellular signalling events by integration of 
multiple stimuli. Activation of the second major adhesion receptor GPVI, predominantly 
by collagen, induces activation of the platelet integrins α2β1 and αIIbβ3 (GPIIb-IIIa) by 
virtue of tyrosine kinase activation, thus allowing firm adhesion to collagen and promoting 
aggregation [47]. 
Thrombin is a protease that acts on protease-activated receptors (PARs), present on 
platelets but also on PMNL and monocytes, where it acts as a chemotactic factor. In 
platelets, however, activation of PARs induces G protein signalling and massive 
intracellular Ca
2+ mobilisation that reinforces αIIbβ3-dependent aggregation. Collagen and 
thrombin agonism on platelets further induces an auto-stimulatory loop involving ADP. 
The nucleotide is stored in dense vesicles and released upon binding of strong agonists, 
immediately stimulating platelet purinergic P2Y1 and P2Y12 receptors that strengthen 
platelet activation [47]. Concomitantly, α-granules containing soluble vWf and P-selectin 
are secreted. Traditionally, platelet shape change was considered as a prerequisite for 
aggregation [48], comprising the rearrangement of cytoskeletal elements in order to 
facilitate granule secretion, integrin externalisation and cell-cell interactions. However, 
current evidence suggests that shape change rather occurs after than before aggregation 
itself [49]. Introduction 12 
Besides execution of the coagulation cascade, local inflammation is promoted by various 
released factors of the intertwined cells, such as neutrophil release of chemokines and AA. 
AA and derivatives serve as substrate in transcellular metabolism for COX and 12-LO 
enzymes to generate pro-inflammatory and aggregation-conveying eicosanoids [44]. The 
intimate physical association between activated platelets and leukocytes via P-selectin 
binding to PSGL-1 [50] and/or GPIbα association with Mac-1 [51] thus suggests an 
important contribution of platelets to the progression of an inflammatory response at least 
in terms of vessel injuries, pointing out platelets as a noteworthy target for the 
development of anti-inflammatory drugs. 
 
2.3.  Typical signalling pathways 
2.3.1. Cell  surface  receptors 
Cell surface receptors transduce signals from external, mostly not membrane-permeant, 
agonists into intracellular signalling events. Four classes of receptors have been defined, 
(1) ligand-gated ion channels, (2) transmembrane (TM) receptors with intrinsic enzymatic 
activity, (3) TM receptors with associated tyrosine kinase activity, and (4) G protein-
coupled receptors (GPCRs). The first group is mainly found in neuronal tissues for the 
purpose of rapid synaptic signal transmission. Nonetheless, the IP3 receptor, a ligand (IP3)-
gated ion (Ca
2+) channel, is a prominent representative of this group with high impact in 
Ca
2+ signalling in all tissues. Growth factors are important ligands of the second group of 
receptors; these receptors often possess an intrinsic tyrosine kinase activity on the 
intracellular domain and are called receptor tyrosine kinases (RTKs). Also the third 
category of receptors may bind growth factors, but at the cytosolic part, soluble tyrosine 
kinases have to be recruited for further signal transduction. GPCRs, the fourth group, are 
intracellularly linked to heterotrimeric G proteins that can bind guanine nucleotides (GDP, 
GTP). GPCR ligands are mostly peptides or polypeptides, and GPCRs constitute 
nowadays the main drug targets. 
Cell proliferation or differentiation is regulated by growth factors and cytokines via RTKs. 
RTKs are receptors with one TM helix. Upon binding, RTKs dimerise and 
autophosphorylate vice versa on tyrosine residues, but they may also phosphorylate other 
associated proteins [52]. Phosphorylated tyrosine (p-tyr) residues provide a binding matrix 
for proteins bearing ‘SH2’ domains. SH2 domains are considerably widespread among 
intracellular proteins, allowing a multitude of signalling cascades to be initiated. Examples 
are the members of the Ras-Raf activation complex, consisting of the growth factor 
receptor-bound protein 2 (Grb-2) and associated cytosolic adaptor proteins (Sos, Shc) that Introduction 13 
promote activation of the membrane-anchored small G protein Ras and subsequently of 
the serine/threonine kinase c-Raf. Ras and c-Raf have diverse targets; one central effector, 
the MAP kinase ERK, is introduced below (section 2.3.3.). As can be appreciated, RTKs 
function as a site of conjunction for several effector proteins that need to associate for 
further signal transduction. A second effect of the formation of this ‘activation complex’ is 
the amplification of small initial signals to robust cellular responses at the end of the 
cascade. RTKs are also essential for the activation of PLCγ, since upon association of its 
two SH2 domains to p-tyr residues on RTKs, PLCγ gains access to its substrate, 
phosphatidylinositol-4,5-bisphosphate (PIP2), and can initialise a cascade leading to Ca
2+ 
mobilisation and PKC activation [53](see below, 2.3.2.). 
GPCRs consist of seven TM helices and possess an intracellular guanine exchange factor 
(GEF) activity. After receptor occupation by specific ligands, conformational changes 
allow GDP-bound (inactive) heterotrimeric G proteins to bind to the cytosolic portion of 
the receptor, which catalyses the exchange of GDP to GTP. GTP binding destabilises the 
heterotrimer, and the α subunit dissociates from the βγ complex in order to activate or 
inhibit effector proteins. Intrinsic GTPase activity of the α subunit finally terminates its 
activity and facilitates re-association of the trimer in its inactive form. Currently four 
major groups of Gα proteins have been defined, named according to their most prominent 
members Gαs (stimulating adenylyl cyclase (AC)), Gαi (inhibiting AC), Gαq (activating 
e.g. PLCβ isoforms), and Gα12/13 (targeting e.g. cytoskeletal proteins, Rho GEFs). Also the 
Gβγ complex modulates the activity of effector proteins, for instance PLCβ2 or 
phosphoinositide-3 kinase (PI-3 K) [54, 55]. Examples for specific GPCRs on leukocytes 
are the fMLP and PAF receptors that are linked to Gαi and Gαi/ Gαq proteins [56]. A 
hallmark of platelet activation is the activation of PAR receptors by thrombin. PARs are 
unique GPCRs, because they are activated by proteolysis of their N-terminal portion, 
thereby unmasking the endogenous ligand of the receptor. This special mechanism 
requires subsequent internalisation and degradation, thus, PAR cleavage is a critical step 
in irreversible platelet activation [55]. The expression pattern of GPCRs varies depending 
on the cell type, but due to the enormous intracellular amplification of GPCR signals, even 
limited numbers of expressed GPCRs and low agonist concentrations enable cells to 
generate a prominent functional response. 
 
2.3.2.  The role of Ca
2+ 
Ca
2+ is a cofactor for many proteins and at the same time second messenger within 
intracellular signalling events. The crucial role of Ca
2+ relies on the tight regulation of its Introduction 14 
intracellular availability; the concentration between cytosol (10-100 nM) and extracellular 
space (1.5-2 mM) differs by factor 10
4 to 10
5 [57]. By opening of Ca
2+ channels on 
intracellular stores or in the plasma membrane, the cytosolic [Ca
2+]i can instantly be 
elevated to 500-1000 nM, thus representing a powerful means for the cell to regulate 
intracellular components and physiological effects [18]. Agonists that induce Ca
2+ influx 
in cells such as leukocytes and platelets usually act via GPCRs, since these receptors are 
mostly employed in rapid signalling. Typically, stimuli like fMLP, PAF, or LTB4 cause 
activation of G proteins that recruit PLC isoforms. The following steps are collectively 
referred to as “store-operated Ca
2+ entry” (SOCE) [58]. First, PLC hydrolyses PIP2, 
yielding membrane-embedded diacylglycerol (DAG) and soluble inositol trisphosphate 
(IP3). Second, IP3 activates specific IP3 receptors (ligand-gated Ca
2+ channels) on the 
endoplasmic reticulum (ER), promoting efflux of stored Ca
2+ into the cytosol, generating a 
moderate intracellular Ca
2+ elevation. Third, the depletion of intracellular Ca
2+ stores is 
immediately coupled to the opening of plasma membrane Ca
2+ channels by a yet 
unresolved mechanism that may include “conformational coupling” of the participating 
compartments [59]. As a result, massive Ca
2+ influx superimposes the intracellular 
fraction to a substantial elevation that in most cases is rapidly counteracted by activated 
Ca
2+ pumps, since sustained elevations of cytosolic Ca
2+ levels are cytotoxic. Therefore 
Ca
2+-ATPases (located in the plasma membrane, termed PMCA, and in the ER/SR, termed 
SERCA) rapidly pump Ca
2+ back into intracellular storage sites or the external lumen [60]. 
Besides central roles for Ca
2+ in muscle contraction and the execution of apoptosis, Ca
2+ 
has ubiquitous functions as cofactor for various proteins. It is involved in vesicle 
exocytosis by binding to cytoskeletal elements, cell-matrix interactions, and membrane 
association of proteins bearing so-called C2 domains [61]. C2 and C2-like domains are 
found in several enzymes related to intracellular protein kinase cascades and lipid 
signalling, such as cPLA2, PKC, PLC, and LOs [62, 63]. Binding of Ca
2+ to C2 domains 
causes conformational changes, thereby increasing the affinity for membrane 
phospholipids. As a consequence, the enzymes (like 5-LO, 12-LO, cPLA2, PKC, PLC, and 
PI-3 K) translocate to membrane compartments where they encounter substrate, binding 
partners, or additional modifications [63-65].  
 
2.3.3.  MAP kinase cascades 
MAPKs are central regulators of a vast array of physiological processes in all cell types of 
multicellular organisms. They are regulated by a evolutionary conserved mechanism of 
sequential phosphorylations in a three-component cascade (figure 1). Moreover, three Introduction 15 
major MAPK pathways have been characterised, culminating in three families of 
‘terminal’ MAPK termed ERKs, JNKs, and p38 MAPK [66]. 
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Figure 1: MAPK phosphorylation cascades (a.o., and others) 
 
Humans express two major isoforms of ERKs, previously designated p42/p44 MAPKs. 
They are activated by various stimuli, such as growth factors, cytokines, GPCR ligands, or 
mitogens, that converge at the stage of Ras, a small membrane-associated G protein. 
Activated Ras
.GTP recruits Raf, the first member of the tripartite MAPK cascade, as well 
as other effector proteins like PI-3 kinase (PI-3 K), to the plasma membrane. Raf, which 
exists in three isoforms (A-Raf, B-Raf, (c-)Raf-1), is a serine/threonine (Ser/Thr) protein 
kinase, that phosphorylates the downstream kinase MEK (MAPK and ERK kinase) at two 
serines in its ‘activation loop’. Besides, roles for Raf-1 as an inhibitor of apoptosis and 
activator of the Rho pathway (controlling cytoskeletal remodelling) have recently been 
suggested [67, 68]. Activated MEK has only one known substrate, that is the ERK 
members. Interestingly, MEK is a dual-specificity protein kinase that exists in two 
isoforms in mammals, introducing two phosphate groups at a threonine and a tyrosine 
residue in the phosphorylation motif TEY. ERKs control cell division, stimulate 
proliferation, with implications for tumour growth, regulate motility, and influence 
metabolism. Important targets for ERKs related to eicosanoid generation are cPLA2 and 5-
LO [69]. As multifaceted MAPK, activated ERKs are found in the nucleus, cytosol, 
membrane and cytoskeletal compartments [66, 70]. The analysis of ERK1/2 Introduction 16 
phosphorylation at Thr185/Tyr187 in cellular samples generally indicates the activation 
state of the MAPK, reflecting the responsiveness of the cell to the selected stimulus. 
JNKs were originally designated “stress-activated protein kinases” (SAPKs, together with 
p38 MAPK) and are now being recognised as important transcriptional regulators. They 
form part of the AP-1 transcription complex, thereby controlling many cytokine genes, 
involving the regulation of apoptosis. In turn, JNKs are activated upon exposure to 
environmental stress and growth factors in an extremely complex manner by at least 13 
enzymes at the stage of MAPKKKs [71]. 
p38 MAPK also belongs to the SAPKs, because its activation occurs in response to 
cellular stress factors like radiation, UV light, genotoxic stress, or osmotic shock. Some 
stimuli like inflammatory cytokines act via GPCRs or RTKs, indicating a role for p38 
MAPK in the onset of an inflammatory response, but also in diseases like asthma and 
autoimmunity [66]. Notably, MAPKAP kinase-2/3 has been identified as target for p38 
MAPK. This enzyme is important for the activation of 5-LO (see below), thus providing a 
link between inflammation/cell stress and the generation of bioactive eicosanoids from 
free AA [72]. To date, there are four major p38 MAPK isoforms known (α, β, γ, δ). p38α 
is most widely expressed and represents the primary isoform in all inflammatory cells 
[73]. In addition to the established MAPKKK-MAPKK-MAPK cascade, p38α is activated 
by the protein TAB1 at the top stage. Intriguingly, TAB1 is not a protein kinase but rather 
a scaffold protein without catalytic activity, thus representing an alternative mechanism of 
activating the MAPK cascade [66]. 
Termination of MAPK activity is effectuated by a battery of specific phosphatases. By 
cleaving off the phosphate(s), these enzymes render members of the MAPK cascade 
inactive again. Specific regulation of phosphatases permits to define the duration and 
potency of MAPK activity and is therefore a key regulator of MAPK cascades in general 
[74]. 
Regarding neutrophil physiology, inflammatory mediators have merely selective effects 
on the activation of certain members of the MAPK families. For instance, TNF-α 
specifically activates p38α and δ, whereas GM-CSF, fMLP, or IL-8 primarily activate 
ERK1/2. However, it has to be noted that MAPK pathways are a complex network, 
allowing individual members to cross-modulate adjacent routes and vice versa. Thus, 
determination of the phosphorylation state of single MAPK members solely indicates its 
potential activity, but does not necessarily elucidate the upstream signalling cascade that 
led to its activation. 
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2.4.  The arachidonic acid cascade 
Arachidonic acid (all-cis-5,8,11,14-eicosatetraenoic acid; 20:4/n-6; AA) is a poly-
unsaturated, essential (for mammals) fatty acid that is abundantly present in cellular 
membranes, where it exists in esterified form incorporated into phospholipids (e.g. 
phosphatidylcholine, PtdCho). AA can be released from phospholipids by the action of 
phospholipases (PL), foremost cPLA2. Short-lived free AA itself constitutes a second 
messenger with impact on signalling pathways in the cell, but also serves as a precursor 
for the generation of eicosanoids by cyclooxygenases (COX), lipoxygenases (LO), and 
cytochrome p450 enzymes (CYPs). A scheme is presented at the end of chapter 2.4. 
(figure 4). Alternatively, AA can be re-incorporated into phospholipids, diffuse to the 
extracellular space, or be degraded enzymatically [75] (figure 2). Since AA represents the 
precursor for a number of pro-inflammatory metabolites, its release is often induced by 
primary inflammatory mediators. 
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Figure 2: Possible fates of arachidonic acid (AA) 
 
 
2.4.1. Cytosolic  phospholipase  A2 
Phospholipases A2 (PLA2) comprise a large family of at least 12 members [76], 
subdivided into four subfamilies of cytosolic (c), secretory (s), and Ca
2+-independent (i) 
PLA2s as well as PAF acetylhydrolases (PAF-AHs). The most important subgroup, group 
IV cPLA2, contains four cPLA2 paralogs that are expressed in mammals; designated 
cPLA2-α, -β, -γ, and -δ. With a molecular weight of 85 kDa, cPLA2-α is the best Introduction 18 
characterised isoform in humans and regarded to be primarily responsible for the 
liberation of substantial amounts of AA in the cell. Accordingly, cPLA2-α-deficient mice 
fail to produce leukotrienes, prostaglandins, and PAF [77]. Chemically, cPLA2 hydrolyses 
glycerophospholipids at the sn2-position, yielding free AA and lysophospholipids. The 
latter can be further converted to PAF, provided the sn-1 position contains an alkyl ether 
linkage. 
cPLA2s differ from the other subfamilies in their pronounced sensitivity for Ca
2+, which 
binds to the Ca
2+/lipid binding (CaLB) domain of the enzyme. sPLA2s, which are much 
smaller (14 kDa), require millimolar concentrations of Ca
2+ for catalytic activity, play 
roles in chronic inflammation, and are involved in AA release, lipid digestion, and 
receptor activation [65]. iPLA2s have molecular masses from 85 to 88 kDa but are 
structurally different from cPLA2s. They might play a role in lipid remodelling [78]. PAF-
AHs are also Ca
2+-independent and exist in intracellular and serum isoforms, with 
different molecular weights. Of all PLA2 subfamilies, only group IV cPLA2s possess 
specificity to sn-2 linked AA, with a preference for PtdCho and Ptd-inositol (PtdIns) as 
substrates [79]. 
Posttranslational regulation of cPLA2s includes Ca
2+ binding via its CaLB-domain and 
phosphorylation events. Importantly, Ca
2+ binding promotes translocation of the enzyme 
from soluble compartments to nuclear, ER, or plasmalemmal membranes, where cPLA2 
can access and metabolise its substrate [79]. Membrane binding is further facilitated by 
cPLA2 association with PIP2 [80]. Phosphorylation, in turn, occurs at serines 505, 515 
and/or 727 by ERK2, Ca
2+/calmodulin-dependent kinase II (CaMK-II), and the p38-
downstream MAPK-integrating kinase (MNK-1), respectively, activates the enzyme, and 
induces membrane translocation [81, 82]. However, phosphorylation by these kinases is 
partly cell type-specific (for instance, ERKs do not activate cPLA2 in platelets), and also 
other kinases (PKC) have been suggested as modulators of cPLA2 activity [79]. 
Neither mode of activation is obligate, and the degree of cPLA2 activation depends on the 
stimulus applied. A wide range of extracellular agonists activate cPLA2, including growth 
factors, cytokines, interferones, integrin engagement or Fc receptor crosslinking, but also 
non-receptor stimuli such as oxidative stress (at sites of inflammation), shear stress, or UV 
light [79]. Since induction of cPLA2 yields primarily pro-inflammatory eicosanoids, 
pharmacological interference with cPLA2 activity (or its activation pathways) may limit 
the extent of an inflammatory response. 
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2.4.2. Lipoxygenases 
Lipoxygenases (LOs) are a family of enzymes which catalyse the oxygenation of AA and 
other poly-unsaturated fatty acids. Each lipoxygenase forms a distinct 
hydroperoxyeicosatetraenoic acid (HPETE) that is subsequently reduced to the 
corresponding alcohol (HETE). LOs are found in all higher eukaryotic organisms (not in 
yeast). Their specific designation (5-, 8-, 12-, 15-LO) reflects the position at which 
molecular oxygen is introduced into the C-20 carbon chain of AA. More than 18 different 
sequences of mammalian LOs are known; of which six important enzymes are expressed 
in humans (figure 3) [83, 84]. These are 5(S)-LO, reticulocyte-type 12-/15(S)-LO-I, 15(S)-
LO-II, platelet-type (p12(S)-LO),  and epidermis-type (e12(R)-LO) [84, 85]. Rat 
leukocyte-type 12(S)-LO does not exist in humans, the 12-/15-LO-I is the closest human 
homologue. Mammalian LOs have molecular weights in the range of 72 to 78 kDa and 
bear N-terminal β-barrel domains that resemble C2 domains in structure and function, thus 
termed ‘C2-like domains’ [61, 63]. The C-terminal portion contains the catalytic centre, 
with a non-heme iron coordinated by three histidines, one asparagine, one isoleucine, and 
a flexible water molecule in the active site of 5-LO [86]. Today, only the crystal structure 
of one mammalian LO is available, namely rabbit reticulocyte 15-LO [87]. On the basis of 
that structure, a model for the tertiary structure of human 5-LO was calculated [88].  
 
 
 
Figure 3: Phylogenetic tree of mammalian LOs (taken from [83], dated 1999). 
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2.4.2.1. 5-Lipoxygenase 
Catalysis 
5-LO was first described in rabbit PMNL in the late 1970s, and details of the 5-LO 
pathway rapidly began to emerge [89, 90]. Two sequential reactions are catalysed by 5-
LO, that include first an oxygenase reaction and second the conversion of a formed 
peroxide into an epoxide (LTA4 synthase reaction, figure 4). In the first reaction, 
molecular oxygen is incorporated into AA in a stereospecific manner, by means of a non-
heme iron switching between ferrous (Fe
2+) and ferric (Fe
3+) forms. Importantly, for the 
initiation of the reaction, the iron has to be present in the ferric state, a condition that is 
regulated by the cellular redox tone, e.g. by lipid hydroperoxides. The product of the 
oxygenation reaction contains a peroxide moiety and is termed 5(S)-hydroperoxy-6-trans-
8,11,14-cis-eicosatetraenoic acid (5(S)-HPETE). It is immediately converted into the 
instable epoxide LTA4 by the LTA4 synthase reaction. This step, too, requires redox 
cycling of the iron, finally recovering it in the ferric form under release of a water 
molecule [86]. Continuous activity of 5-LO eventually results in irreversible inactivation 
(after minutes), also called suicide inactivation, and is characterised by the inability to 
recover the reduced state of the iron [91]. At the stage of 5-HPETE, parts of the formed 
products escape subsequent conversion and are reduced (e.g. by GPx) to give 5-hydroxy-
eicosatetraenoic acid (5-HETE), that also possesses biological functions and serves as a 
precursor for 5-oxo-ETE, a highly potent granulocyte chemoattractant [92]. 
Gene / protein expression 
The 5-LO gene is located on chromosome 10 in humans, its expression yields a protein of 
672 amino acids in length. It has an unusual promoter structure lacking typical TATA or 
CCAAT transcriptional initiation elements but is rich in GC sequences. Accordingly, 
several tandem GC boxes were identified, constituting potential response elements for the 
transcription factors Sp-1 and Egr-1 that have shown to be required for basal 5-LO 
transcription [93-95]. Besides, multiple response elements for other transcription factors 
exist. 5-LO is expressed in cells of myeloid origin, but not in red blood cells, platelets, or 
endothelial cells. Its expression occurs mainly in parallel with that of 5-LO-activating 
protein (FLAP, see below). Some other tissues, especially parts of the central nervous 
system (CNS), also express 5-LO [96]. 
Crucial factors inducing 5-LO expression are TGF-β and calcitriol (vitamine D3) that 
upregulate 5-LO mRNA synthesis and protein levels [97, 98]. Furthermore, they modulate 
5-LO enzymatic activity in intact cells. In human PMNL and monocytes, GM-CSF is an 
additional activator of 5-LO and FLAP protein expression [96]. In cells that do not Introduction 21 
synthesise 5-LO protein, its transcription is inhibited by histone acetylation and DNA 
methylation of the 5-LO gene [99, 100]. 
Regulation of 5-LO activity: cofactors and activation pathways 
Early investigations revealed that 5-LO can be activated by Ca
2+, ATP, and phospholipids 
[101]. Without Ca
2+, the enzyme is virtually inactive, and 1-2 µM of Ca
2+ are required for 
half-maximal activity in vitro [102]. However, in the cell, only 150-350 nM of Ca
2+ are 
sufficient to activate 5-LO [103]. Binding of Ca
2+ to the C2-like domain facilitates 
selective association with PtdCho, thus directing 5-LO towards membranes, and confers 
resistance to an endogenous inhibitor, glutathione peroxidase (GPx)-1 [96]. Whereas Ca
2+ 
binds in a molar ratio of 2:1 to 5-LO, ATP is bound in equimolar ratio. Presence of ATP 
enhances 5-LO activity in vitro by factor 6, and is already maximal at a concentration of 
0.1 mM, about 10- to 15-fold less than the intracellular concentration [91, 104]. 
In most leukocytes, 5-LO resides in the cytosol in resting cells and translocates to the 
nuclear membrane upon activation [105]. In some cell types (alveolar macrophages, 
mouse mast cells), however, 5-LO is constitutively present within the nucleus [106]. Many 
proinflammatory stimuli mobilise intracellular Ca
2+, as discussed above in the cPLA2 
section, hence they also facilitate membrane translocation of 5-LO. Cell stimulation by 
stress often results in p38 MAPK activation, which is an activator of MAPK-activated 
protein (MAPKAP) kinases (MK)-2 and -3. Alternative pathways may result in ERK 
activation. Both enzymes, MK-2/-3 and ERK2, can phosphorylate 5-LO at Ser271 and 
Ser663, respectively, thereby promoting membrane translocation and induction of full 
activity [107, 108]. Intriguingly, the presence of free AA strongly enhances 
phosphorylation of 5-LO [109], suggesting a second regulatory mechanism to selectively 
activate 5-LO under inflammatory conditions. In contrast, activation of PKA counteracts 
5-LO activation and prevents translocation, due to phosphorylation of 5-LO at Ser523 
[110]. 
Once 5-LO associates with the membrane, it moves in close proximity of cPLA2, 
providing the 5-LO substrate (AA), and to the accessory protein FLAP. FLAP is an 18 
kDa membrane-bound protein of the MAPEG superfamily (see section 2.4.3.) and in most 
tissues it is co-expressed with 5-LO. Its exact function is still elusive, but it was shown 
that FLAP stimulates 5-LO activity resulting in LTA4 synthesis [96]. Thus, co-localisation 
with FLAP and cPLA2 strongly stimulate 5-LO catalysis, therefore the induction of 
membrane translocation must be regarded as key regulatory step of 5-LO activation. Yet, 
some additional proteins have been found to bind 5-LO, including Grb-2, TRAP-1, CLP, Introduction 22 
RNaseIII, and actin/α-actinin, but the functional relevance of these proteins regarding 5-
LO activation will have to be determined [96]. 
 
2.4.2.2. 12-Lipoxygenase 
Three types of 12-LO are known today, although the individual tissue expression patterns 
vary between species or are not yet fully elucidated. The leukocyte-type 12(S)-LO has 
been detected in some glands of the mouse (pineal, pituitary, adrenal, and pancreas) and 
tissues related to the immune defence, lung and kidney. It is also present in macrophages, 
leukocytes, and reticulocytes (immature red blood cells). In humans, there is only a 12-
/15-LO isoform expressed in reticulocytes and eosinophils, capable to synthesise 12- and 
15-HPETE [83, 111]. Epidermal 12(S)-LO is specifically expressed in differentiated 
keratinocytes of mouse epidermis and in the root of hair follicles, but in humans only as a 
pseudogene in skin and hair follicles [112]. Platelet-type 12(S)-LO (p12-LO) is primarily 
present in platelets and epidermis, independent of species [113, 114]. Interestingly, 
leukocyte-type 12(S)-LO is the primary LO in rat brain, expressed by mature 
oligodendrocytes and astrocytes [115, 116]. The three 12(S)-LO isozymes show about 
60% sequence identity amongst each other and 40% identity in comparison to 5-LO. The 
most closely related LO is 15-LO with 71-86% identity, which is underlined by the fact 
that all human 12-LOs and 15-LOs are arranged in a gene cluster on chromosome 17 
[111]. In contrast to the 5-LO promoter, the p12-LO cis-acting regulatory elements contain 
a TATA box, as well as three GC boxes for potential Sp-1 binding. In addition, NF-κB 
and glucocorticoid-responsive elements were detected in a further upstream region of the 
gene. Accordingly, NF-κB heterodimers were demonstrated to negatively regulate the 
expression of the human p12-LO gene [117], but otherwise functional implications of 
these regulatory sites are unknown. On the other hand, several inducers of 12(S)-LO gene 
expression have been recognised, such as TGF-α and phorbol 12-myristate 13-acetate 
(PMA) in human epidermis, PDGF in porcine smooth muscle, bradykinin and PAF in rat 
skin, and angiotensin II in mesangial cells [118, 119]. 
From a catalytic point of view, 12-LOs function basically in the same way as 5-LO in the 
first step, except that the introduction of oxygen occurs at position C-12 of the main 
substrate, AA. The three isoforms differ regarding their product profile. p12-LO primarily 
generates 12(S)-HPETE from AA, whereas leukocyte-type 12-LO generates considerable 
amounts of 15-HPETE as well, depending on the species in a ratio between 3:1 and 11:1 
(12-HPETE : 15-HPETE). Consistently, by mutation of only two amino acids, porcine 12-
LO could be converted into a 15-LO [120]. 12-HPETE is either reduced to the Introduction 23 
corresponding alcohol (12-HETE), or may be further enzymatically transformed to 
diHETEs and hepoxilins. As in 5-LO, 12(S)-LO presumably consists of a N-terminal β-
barrel domain (bearing the Ca
2+ binding site) and a C-terminal portion containing a 
hydrophobic binding pocket. Three crucial histidines (361, 366, 541) and the C-terminal 
isoleucine have been identified as essential residues for coordination of the iron in the 
porcine leukocyte isoform [120]. 
AA is not the only substrate for 12-LOs. Especially (porcine/murine) leukocyte-type 
12(S)-LO also accepts various C-18 and C-20 fatty acids but can also act on esterified 
substrates, such as phospholipids, cholesterol esters, and LDL [111, 121-123]. For 
example, lineleic acid (C18:2) is transformed into 13-hydroperoxyoctadecadienoic acid 
(13-HPODE), a bioactive lipid hydroperoxide [124]. In contrast, the tolerance for other 
substrates than AA exhibited by p12-LO is rather low. In analogy to 5-LO, leukocyte-type 
12(S)-LO is rapidly suicide inactivated (within minutes), whereas no self-inactivation was 
reported for p12-LO [83, 111]. 
The subcellular localisation of 12(S)-LOs differs depending on the activation state of the 
cells. Porcine leukocyte-type 12(S)-LO as well as rat and human p12-LO were found to 
reside in the cytosol of PMNL and platelets, respectively, and activation of human p12-LO 
goes along with translocation to the plasma membrane, when a strong stimulus like 
thrombin is applied [111]. Moreover, binding of Ca
2+ apparently promotes membrane 
association of rat p12-LO [64]. At membranes, p12-LO was reported to associate with 
cPLA2 and sPLA2 upon collagen stimulation via the GPVI receptor, hence supporting the 
view of membrane compartments as site where catalysis of p12-LO occurs [125]. 
Other regulatory factors for 12(S)-LO have not been established so far. Evidence is 
lacking for an involvement of FLAP and ATP in promoting catalysis, and also the role of 
phosphorylation is unclear. Recently, activation of 12-LO in oligodendrocytes was 
suggested to be the consequence of ERK activation, but no evidence for direct 
phosphorylation of 12-LO was given [126].  
The physiological consequences of 12-LO activation are described below in the 12-HETE 
section (2.5.2.). Besides enhanced formation of 12-LO products, altered 12-LO expression 
gives rise to some clinical implications (for review, see [111]). For example, p12-LO 
deficiency enhances the risk of hemorrhages rather than thrombosis, accompanied by 
bleeding complications. Mice lacking p12-LO showed increased platelet sensitivity to 
ADP, indicating that an anti-aggregatory product is formed by p12-LO. Generally, 12(S)-
LO seems to be associated with blood vessel disorders and inflammation. Furthermore, the 
leukocyte-type 12-LO gene is important for the development of atherosclerosis in mice, Introduction 24 
probably due to increased LDL oxidation by 12-LO [127]. A role for p12-LO was also 
determined in human rheumatoid arthritis [111]. Regarding cancer progression, p12-LO 
mRNA was found to be elevated in prostate cancer tissues, implying that p12-LO 
promotes tumour growth, angiogenesis, and metastasis [128, 129]. Likewise, breast cancer 
patients show elevated levels of leukocyte-type 12(S)-LO in tissue sections as compared to 
healthy control persons [130]. 
 
2.4.2.3. 15-Lipoxygenase 
Two isoforms of arachidonate 15-LOs are known at present, designated according to their 
tissue origin reticulocyte-type (type I)-15LO and epidermis-type (type II)-15-LO. 15-LO-
II has only 40 % amino acid identity with type I and occurs in prostate, skin, and cornea 
[131]. Since especially the type I enzyme shares many properties with human leukocyte-
type 12-LO, these enzymes are considered as orthologs, hence uniformly referred to as 
12/15-LOs [127, 132]. For that reason, 15-LOs shall be discussed here only briefly. 
The main products of 15-LO-I are 15(S)-HETE (80 %) and 12(S)-HETE (20 %), when 
AA is used as substrate. Catalytic activity lasts only for 1-2 minutes until turnover-related 
inactivation of the enzyme. In contrast, 15-LO-II converts AA purely to 15(S)-HETE and 
is catalytically active for more than one hour [131, 132]. Importantly, the concomitant 
presence of 12- and 15-LOs as well as 5-LO in eosinophils, monocytes/macrophages, and 
other tissues allows the immediate generation of bioactive diHETEs and lipoxins 
(lipoxygenase interacting products, containing a trihydroxytetraene structure). DiHETEs 
are considered to possess pro-inflammatory, neutrophil chemoattractant properties [133], 
whereas lipoxins (LXA4, LXB4) exert anti-inflammatory effects via specific GPCRs. 
Lipoxins are involved in the late phase of a local inflammation, promoting tissue repair 
and debris clearance by macrophages, meanwhile inhibiting neutrophil chemotaxis [134, 
135]. Accordingly, 15-LO expression is enhanced by T helper cell-derived IL-4 and IL-13, 
and overexpressed 15-LO in monocyte/macrophages mediate protective effects in early 
atherosclerosis by preventing lipid deposition in vessel walls [111]. 15-LO-II apparently 
functions as negative regulator of cell proliferation, and is downregulated during 
malignant transformation of prostate cells [131]. 15(S)-HETE, in turn, was shown to have 
inhibitory effects on p12-LO and neutrophil 5-LO, indicating interrelations between LOs 
and their products [136]. Transcriptional regulation of 15-LOs is comparable to 12-LO, 
and as post-translational regulatory effectors the peroxide tone, nitric oxide, Ca
2+-
dependent membrane binding, and suicide inactivation have been described, whereas 
again no role was evident for a phosphorylation/dephosphorylation cycle [137]. Introduction 25 
2.4.3. LTA4 hydrolase and LTC4 synthase 
LTA4 hydrolase (LTA4H) converts LTA4 to LTB4, a potent lipid mediator with 
chemotactic and chemokinetic properties towards leukocytes [138]. LTA4H, a protein of 
69 kDa (610 amino acids), is an epoxide hydrolase with a second enzymatic function, an 
anion-dependent aminopeptidase activity. Its crystal structure was published some years 
ago [139]. The enzyme can be inhibited by covalent binding of its substrate and by 
divalent cations. It is widely distributed among mammalian tissues and hematopoietic 
cells [140, 141]. The occurrence of LTA4H does not generally coincide with 5-LO 
expression, hence giving rise to putative transcellular metabolism [142]. In mature cells, 
LTA4H normally resides in the cytosol, but depending on the differentiation state also 
nuclear localisation was observed [143]. 
LTC4 synthase (LTC4S) is the other enzyme that metabolises LTA4 [144]. By conjugation 
with glutathione (GSH), the cysteinyl-leukotriene (Cys-LT) LTC4 is formed, which can be 
further converted to LTD4 and LTE4 by extracellular enzymes (γ-glutamyl-transpeptidase, 
followed by a dipeptidase) [145-147]. Cys-LTs are potent bronchoconstrictors and pro-
inflammatory mediators, mainly generated by activated eosinophils, basophils, mast cells, 
macrophages, and platelets, whereas neutrophils preferentially convert LTA4 into LTB4 
[148]. LTC4S is a structural homologue to FLAP, both belonging to the MAPEG 
(membrane associated proteins in eicosanoid and GSH metabolism) superfamily. Other 
members are the microsomal glutathione-S-transferases (MGST) 1-3 and PGE2 synthase 
[148, 149]. LTC4S exists as an 18 kDa protein in homodimers, and Mg
2+ enhances the 
catalytic activity [144]. 
 
2.4.4. Cyclooxygenases 
Cyclooxygenases (COX) enzymes comprise two isoforms; COX-1 that is mainly 
connected to physiological functions and COX-2, which is mainly involved in 
pathological processes. In addition, a splice variant of COX-1 was described in dogs, 
termed COX-3. The two genes are located on chromosomes 9 and 1, respectively [150], 
and encode for proteins of rather similar features regarding molecular mass (67 and 72 
kDa, respectively), intracellular localisation (nuclear or ER membranes [151]), and 
enzymatic function. COX-1 is expressed in many tissues, but COX-2 expression is 
apparently restricted to cells related to inflammation, such as macrophages, fibroblasts, or 
endothelial cells [151]. Platelets were long assumed to contain COX-1 only, since de novo 
(inducible) expression in these denucleated cells is not possible. Recent evidence however 
suggests, that in the precursor cells, megakaryocytes, COX-2 mRNA is formed, allowing Introduction 26 
the synthesis of functional COX-2 enzymes in platelets [152, 153]. A causal relation to 
aspirin resistance in some patients is currently under debate [150]. 
Concerning catalytic activity, COX bears a cyclooxygenase active site, where the 
hydroperoxy endoperoxide prostaglandin (PG)G2 is formed from AA, and a heme with 
peroxidase activity that converts PGG2 to PGH2. Besides PGH2, COX also generates 12-
hydroxyheptadecatrienoic acid (12-HHT) from AA. Under inflammatory conditions, 
PGH2 synthesis exceeds 12-HHT, but presence of reducing agents (GSH, 1 mM) shifts the 
ratio towards 12-HHT generation [154]. PGH2 serves as precursor for various prostanoids, 
including thromboxane (Tx)A2, PGD2, E2, F2α, and prostacyclin (PGI2). Prostanoids are 
pivotal mediators of fever, pain, and inflammation, and also play roles in the regulation of 
the gastrointestinal tract, reproduction, and the cardiovascular system [155]. Remarkably, 
prostanoids do not possess uniform properties. For instance, prostacyclin and TxA2 are 
mutual antagonists, the latter acting as pro-thrombotic and pro-aggregatory 
vasoconstrictor, while PGI2 mediates opposite effects [150]. Due to their central role in the 
progression of many diseases, COX-targeting non-steroidal anti-inflammatory drugs 
(NSAIDs, e.g. aspirin) are long since established on the drug market. 
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Figure 4: Derivatisation cascade of arachidonic acid 
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2.5.  Biological functions of eicosanoids 
2.5.1. Leukotrienes 
Leukotrienes are short-lived ‘local hormones’ with potent pro-inflammatory properties. 
Upon intracellular formation at nuclear membranes of leukocytes (neutrophils, 
eosinophils, mast cells, macrophages), they diffuse into the extracellular space and 
activate specific GPCRs on target cells or are further metabolised. LTB4, the primary LT 
derived from neutrophils, acts on BLT-1 and -2 receptors, which are expressed in several 
cell types including leukocytes (mainly BLT-1), smooth muscle cells, and endothelial cells 
([156] and overview in table 1). The affinity of LTB4 to BLT-1 is about 20-fold higher 
than for the more ubiquitously expressed BLT-2. Furthermore, BLT-1 binds LTB4 more 
specifically as compared to BLT-2 that also accepts 12(S)-HPETE or 15(S)-HETE as 
ligands. Thus, BLT-1 is regarded as the primary, most sensitive LTB4 receptor that 
governs LTB4 effects in inflamed tissues [157, 158]. Receptor activation results in 
enhanced activation of granulocytes, chemotaxis, rolling and adhesion to vessel walls, as 
well as stimulation of ROS release and lysosomal enzyme secretion [159]. Ca
2+ appears to 
be a key mediator in BLT signalling, as LTB4 induces intracellular Ca
2+ mobilisation, and 
neutrophils from BLT1-knock-out mice have impaired Ca
2+ signalling and chemotaxis 
[160, 161]. LTB4 is further assumed to promote the development of atherosclerosis and 
cell survival [162]. 
CysLTs are synthesised during anaphylactic reactions, are potent bronchoconstrictors by 
causing smooth muscle contraction, enhance endothelial permeability in post-capillary 
venules, and promote eosinophil recruitment. Thus, involvement of CysLTs in 
inflammation is evident. As stated above (section 2.4.3.), only some cell types 
(eosinophils, mast cells, etc.) are able to generate and release CysLTs. Transcellular 
metabolism is an important source for precursors of CysLTs [156]. CysLTs specifically 
activate two known GPCRs, of which CysLT1 receptor is expressed in leukocytes, mast 
cells, endothelium, lung, and nasal mucosa [163], and CysLT2 receptor is found in 
immunity-relevant tissues (liver, spleen, lymph nodes), as well as in heart, adrenal gland, 
and peripheral blood leukocytes [164]. Both CysLT receptors are activated by all CysLTs 
in different rank order of potency. Based on the potent pro-inflammatory activities of 
CysLTs, the pharmaceutical industry has sought to develop blockers of LT synthesis and 
LT receptors. Remarkably, only CysLT1 receptor antagonists have successfully entered 
the markets (zafirlukast, montelukast, pranlukast) [156]. 
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2.5.2.  5- and 12-H(P)ETE 
H(P)ETEs are hydro(pero)xy derivatives of AA with biological activities. Compared to 
LTs, their effects are less well characterised, although there is substantial formation by 
LOs upon activation of the AA cascade. 5(S)-HETE is a growth-inducing agent, has 
chemokine properties, and acts via a putative GPCR in leukocytes [165], thereby inducing 
ERK and Akt activation [166]. The 5-HETE receptor, which in contrast to BLT and 
CysLT receptors has not been cloned yet, is suggested to be involved in eosinophil 
recruitment to sites of allergic reactivity, mitosis, and nerve impulse transmission. 
Moreover, a role of 5-HETE in tumour progression can be appreciated, since it is 
constitutively produced in prostate cancer cells, and cells undergo apoptosis when the 
synthesis of 5(S)-HETE is blocked [167, 168]. 
5(S)-HETE can be converted by specific dehydrogenases in human PMNL, monocytes, 
and lymphocytes into 5-oxo-ETE, a compound that has been investigated in more detail. 
Intriguingly, 5-oxo-ETE is the most active chemoattractant for human eosinophils, 
promoting the transmigration through basement membranes. It is further involved in the 
recruitment of inflammatory cells in allergy and asthma. On the cellular level in 
neutrophils, 5-oxo-ETE causes Ca
2+ mobilisation, degranulation, actin remodelling, and 
adherence by induced surface expression of integrins [169]. These effects are presumably 
transduced through a specific 5-oxo-ETE GPCR [170, 171]. 
12(S)-HETE is a bioactive mediator promoting cell proliferation in cancer cells [172], cell 
motility [173], and angiogenesis [174]. It acts as a renal vasoconstrictor, and 12(S)-HETE 
levels are increased in diabetes and hypertension, whereas vasodilatory properties were 
reported in coronary and cerebral vasculatures [175]. Exposure of 12-HPETE to platelets 
results in inhibition of main platelet functions, probably mediated by enhanced cGMP 
levels and suppressed Ca
2+ mobilisation [176]. A receptor for 12-HETE as part of a larger 
receptor complex was identified in lung carcinoma cells, and a nuclear binding site for 12-
HETE has been suggested as well ([177] and table 1). On the protein level, 12-HETE 
activates a signalling network including PLC, PLD, PKCα, ERKs and Src family kinases 
[178, 179].  
 
2.5.3.  15-HETE, oxo-ETEs, lipoxins, hepoxilins, and EETs 
Controversial effects have been reported for 15-HETE. Although it is the major eicosanoid 
in some inflammatory diseases (proctocolitis) and serves as a quantitative marker for the 
accompanying inflammatory process in cancer patients [137, 180], several anti-
inflammatory implications of 15-HETE have been demonstrated. For instance, it inhibits Introduction 29 
superoxide formation, exocytosis, and migration in stimulated human PMNL, and was 
found to block the synthesis and biological effects of LTB4. Additionally, it was reported 
to induce apoptosis [131]. However, in some settings, masking of 15-HETE effects by 
other 15-LO products could not be excluded, such as 12-/15-diHETEs, 5-oxo-15-HETE, 
the trihydroxy derivatives lipoxin (LX)A4 and LXB4, and hepoxilins [137]. Consistently, 
lipoxins are currently regarded as lipid mediators with primary anti-inflammatory 
properties [181]. Their synthesis requires intercellular ‘collaboration’ of different LOs (5-
/12-/15-LO) as well as COX for the aspirin-triggered lipoxins (ATLs). A lipoxin-specific 
GPCR (designated ALX) in PMNL and macrophages has been identified and cloned 
[182]. Downstream effectors of ALX are modulated in cell type-specific fashion. 
Functionally, lipoxin actions terminate neutrophil infiltration and initiate the resolution of 
inflammatory processes via macrophage activation [183]. Hepoxilins, in contrast, are 
PMNL-activating hydroxyepoxide derivatives of 12-HPETE, with hepoxilin A3 (HxA3) 
being the most prominent representative [184, 185]. Platelets can form HxA3 and thereby 
cause neutrophil chemotaxis and promote migration across intestinal epithelia. This effect 
may be mediated by mobilisation of intracellular Ca
2+ in PMNL [186]. 
Finally, epoxyeicosatrienoic acids (EETs) are cytochrome P450 (CYP) epoxygenase-
derived products from AA with diverse biological functions. Primary epoxidation products 
of AA are 5,6-, 8,9-, 11,12-, and 14,15-EET. EETs are particularly involved in the 
regulation of normal and pathophysiological vascular function, predominantly exhibiting 
protective (anti-inflammatory) effects. These actions are mediated in part by NF-κB 
inhibition [187] but also via membrane receptor activation [188]. On the other hand, EETs 
stimulate endothelial cell proliferation and selectively (5,6-EET, 8,9-EET) cause 
angiogenesis [189]. Thus, central physiological and pathological functions in immunity 
and the cardiovascular system are governed by an amazingly complex network of AA 
derivatives, set off by LOs, COX, and CYPs. 
 
An overview of eicosanoid effects and receptors is given in table 1. Introduction 30 
 
agent biological  effects  receptor  reference 
LTB4  pro-inflammatory functions (neutrophil 
activation, chemotaxis) 
promotes atherosclerosis and survival  
of tumour cells 
BLT1, -2  [159, 162] 
LTC4/D4/E4  smooth muscle contraction (bronchi) ↑ 
vascular permeability ↑ 
eosinophil recruitment 
CysLT1, -2 [148] 
5(S)-HETE growth  induction 
eosinophil recruitment 
tumour promotion 
putative 5-HETE 
receptor 
[165, 167, 
168] 
5-oxo-ETE eosinophil  chemoattractant 
pro-inflammatory (chemoattractant) 
putative 5-oxo-
ETE receptor 
[170, 171] 
12(S)-HETE  cell proliferation, motility 
angiogenesis 
vasoconstriction/dilatation 
putative receptor 
complex 
[172-175] 
15(S)-HETE  inflammation marker in cancer 
anti-inflammatory functions (leukocyte 
ROS formation ↓, migration ↓) 
unknown [131,  137, 
180] 
lipoxins  anti-inflammatory functions (neutrophil 
infiltration ↓) 
macrophage activation 
ALX [181,  182] 
hepoxilins neutrophil  activation (chemoattraction, 
migration ↑) 
unknown [185,  186] 
EETs  regulation of vasculature (anti-
inflammatory, protective effects) 
endothelial cell proliferation 
angiogenesis 
putative 
membrane and 
intracellular 
receptors 
[188-190] 
 
Table 1: Selection of functional effects exerted by eicosanoids 
 
 
2.6. Boswellic  acids 
2.6.1.  Historical overview and sources 
The lipophilic fraction of the gum resin from Boswellia (B.) serrata, termed 
‘frankincense’, has been traditionally applied in Indian ayurvedic medicine for the topical 
treatment of joint diseases and various inflammatory disorders, in particular chronic 
illnesses. Initial scientific studies demonstrated analgesic and psychopharmacological 
effects of B. serrata gum resin in rats [191, 192], supporting a potential therapeutic value. 
Dried extracts of the gum resin (olibanum or ‘Salai guggal’), named Sallaki, were first 
marketed in India, and are nowadays approved in a part of Switzerland (sold as H15 Introduction 31 
Gufic). Besides B. serrata (mainly growing in India), other important sources for BAs 
exist, including B. sacra (Arabian peninsula), B. carterii, and B. frereana (both Eastern 
Africa)[193]. 
The pentacyclic triterpenes (PTs) boswellic acids (BAs) were identified as the major 
ingredients of the lipophilic fraction of olibanum (figure 5), as listed in table 2. BAs exist 
in an α (geminal methyl groups at C-20) or β (vicinal methyl groups at C-19/C-20) 
configuration. Various pharmacological studies indicate that the β-configurated 
derivatives possess superior efficacy over the respective α-isomers. Further structural 
variation is given by a carbonyl moiety at C-11, yielding the 11-keto-BAs, or an acetyl 
moiety at the C-3 oxygen yielding 3-O-acetyl-BAs. Both, 3-O-acetyl and 11-keto groups 
are today believed to constitute crucial pharmacophores of the molecule. α-Amyrin and 
ursolic acid, which are closely related BA analogues existing in significant quantities, lack 
several specific residues (e.g. the C4-COOH-group) of BAs (figure 5).  
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Figure 5: Structures of the four major β–configurated BAs. 
 
 
 
ingredient  content in % 
AKBA 3.7  % 
Aβ-BA  10.5 % 
KBA 6.1  % 
β-BA  18.2 % 
α-BA 
Aα-BA 
13.2 % 
3.3 % 
 
Table 2: Composition of the pentacyclic triterpenes in the dry extract of the gum resin 
from B. serrata (according to [194]) 
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2.6.2.  BAs in disease treatment 
To date, a number of animal studies and clinical trials with human subjects have been 
carried out. Isolated BAs or preparations of B. spec containing diverse BAs revealed 
pharmacological properties with potential therapeutic value for the treatment of 
inflammation (rheumatoid arthritis, osteoarthritis, autoimmune encephalomyelitis, ileitis, 
colitis, hepatitis), pain, cancer, hyperlipidemia and hypercholesterolemia, and allergy 
(anaphylaxis) in experimental animal models [195-202]. 
A prerequisite for a desired pharmacological effect in the human body of an administered 
bioactive compound is sufficient bioavailability. In one study, the plasma concentrations 
of BAs after oral administration of B. serrata extracts (4 × 786 mg extract/day for 10 
days) in a brain tumour patient were analysed. The levels of BAs in plasma were 10.1, 2.4, 
0.34, and 0.1 µM for β-BA, Aβ-BA, KBA and AKBA, respectively [203]. Focusing on the 
pharmacokinetics, food intake profoundly affects the kinetic profile of BA plasma levels, 
as high-fat meal strongly increases the plasma concentrations of various BAs as compared 
to the fasted state [194]. 
In fact, clinical studies on humans confirmed the therapeutic potential for the intervention 
with several disease types. Administration of B. spec extracts to patients with 
osteoarthritis showed beneficial effects, as expressed by reduced pain sensation and 
disability score, as well as increased knee flexion [204, 205]. No significant effects were 
however found in a trial of rheumatoid arthritis [206]. In a study of colitis ulcerosa 
patients, a B. serrata preparation was compared to sulfasalazine treatment and observed to 
be equally potent in the improvement of disease parameters (stool properties, blood 
parameters, histopathology) [207]. A similar approach was pursued to evaluate B. serrata 
effects in Crohn’s Disease, here the extract (H15) was compared to mesalazine. The B. 
serrata-treated patients displayed a remarkable improvement in the Crohn’s Disease 
Activity Index score, and the extract was clearly superior to mesalazine [208]. Only one 
study addressed the efficacy of B. spec extracts in bronchial asthma, a major leukotriene-
related disease. Again, a large fraction (70 %) of the gum resin extract-treated patients 
experienced an amelioration of the disease, indicating effectiveness of B. serrata treatment 
[209]. One of the most promising targets for B. serrata treatment yet appears to be cancer, 
particularly central nervous system (CNS) tumours. Two studies were carried out, one 
with 19 young people suffering from intracranial tumours, and another with 12 
glioblastoma and leukoencephalopathy patients. H15 was used as drug and applied for 
several months. The results show that in the first trial, no anti-proliferative effects of 
palliative H15 treatment were observed, nevertheless an improvement in health parameters Introduction 33 
and neurological symptoms in some patients was apparent [210]. Also in the second study, 
anti-neoplastic effects were absent, but tumour-associated progressive edema were 
reduced in a significant fraction of patients. Besides, all leukoencephalopathy patients 
improved clinically, indicating beneficial effects of H15 treatment in this disease form 
[211]. Accordingly, H15 is today approved for the clinical indication ‘peritumoral edema’, 
but only in a part of Switzerland. To conclude, the number of clinical studies is still far 
from sufficient to reasonably evaluate the potential therapeutic benefits of BA treatment. 
Good tolerance and some encouraging results should give reason to conduct further trials 
with BA preparations. 
 
2.6.3.  BAs in immunity and inflammation 
2.6.3.1. Modulation of the immune response 
Various ingredients of the extracts of B. spec. have been isolated, purified, and subjected 
to cellular and molecular studies, in order to identify the pharmacological principles and 
mechanisms of action of the gum resin. First reports indicated that B. spec extracts 
antagonise the host defence system by impairment of leukocyte infiltration and the 
complement system [212-214]. Other mechanisms that may contribute to the modulation 
of the immune response include anti-allergic/anaphylactic effects (inhibition of mast cell 
degranulation, suppression of macrophage NO production) and alteration of T helper (TH) 
cell signalling (TH1 cytokine inhibition, TH2 cytokine potentiation) [201, 202, 215]. 
 
2.6.3.2. Anti-inflammatory effects 
In order to explain the anti-inflammatory actions of BAs stated in several animal models 
(see above, 2.6.2.), 5-LO, the key enzyme in LT biosynthesis (section 2.4.2.), was 
suggested as a target for BAs (see below) [216, 217]. LTs have long been recognised as 
potent mediators of inflammation and allergy. Thus, the concept that suppression of LT 
formation by BAs is the underlying mechanism of the anti-inflammatory actions of BAs 
appeared reasonable. It was first observed that B. serrata extracts inhibited the generation 
of LTB4 in rat neutrophils [216]. Inhibition of LT biosynthesis by isolated BAs was later 
confirmed by other studies, and 3-O-acetyl-11-keto-BA (AKBA) was identified as the 
most efficient derivative with IC50 values in the range of 1.5-8 µM, depending on the 
experimental settings (e.g. animal/human, cell type, stimulus etc.) [197, 217-222]. Even 
though direct inhibition of 5-LO by AKBA was demonstrated [219], significant higher 
concentrations were required to directly suppress 5-LO activity in vitro as compared to 
intact cells, suggesting that potent inhibition of LT formation might be due to interference Introduction 34 
with cellular events required for activation of 5-LO (see below, section 2.6.4.). Moreover, 
for cellular 5-LO activity, up-regulatory effects of BAs were reported, since low 
concentrations of B. serrata extracts potentiated 5-LO product synthesis in stimulated 
PMNL [218]. Implications of isolated AKBA or KBA applied to PMNL, platelets, and 
monocytes were addressed in this thesis. 
Representing a major pro-inflammatory pathway, NF-κB signalling was found to be 
suppressed by 3-O-acetyl-BAs in human peripheral monocytes. This blockade caused 
inhibition of LPS-stimulated TNFα expression, apparently by direct interference with 
‘inhibitor of NF-κB-kinases’ (IKKs) [223]. NF-κB downregulation might also explain 
altered effector levels observed in a humane genome screen using TNFα-stimulated 
human microvascular cells [224]. The results of this screen substantiate anti-inflammatory 
effects of BAs. Thus, the expression of pro-inflammatory effectors (matrix 
metalloproteinases (MMPs), reported as targets before [225] and adhesion receptors 
(VCAM-1, ICAM-1)) was inhibited. Consistently, a recent report using a semi-synthetic 
form of AKBA revealed the inhibition of P-selectin upregulation and leukocyte-platelet 
adherence in induced colitis in mice [199]. Taken together, BAs exert contrasting effects 
on various cell types implicated in immunity. Discrepancies also remain between the 
observed anti-inflammatory actions of either crude B. spec. extracts or purified BAs that 
also evoke a number of stimulatory and activating effects. Therefore, a straightforward 
explanation capable to relate cell-type specific effects of BAs to physiological 
observations made with preparations of B. spec. can not yet be provided. 
 
2.6.4.  Molecular targets 
2.6.4.1. 5-Lipoxygenase 
In 1991, AKBA was claimed as a novel specific nonredox-type inhibitor of 5-LO, the IC50 
value was determined at 1.5 µM [217]. Other BAs were weaker inhibitors (IC50 up to 8 
µM). These conclusions were however drawn from experiments assessing 5-LO inhibition 
in intact rat PMNL, but no data were provided using crude human 5-LO enzyme in cell-
free assays. Nonetheless, a direct molecular interaction of AKBA with (rat) 5-LO was 
shown later (IC50 ≈ 8 µM in rat PMNL cytosolic fractions, and 16 µM on affinity-purified 
5-LO from human PMNL) [219]. Deviating from these findings, in our group the IC50 of 
AKBA was determined around 50 µM, using the cytosolic fractions of differentiated 
(human) HL-60 and monocytic Mono Mac 6 cells [221, 222]. The discrepancies in the 
potency of AKBA may be due to different cell types and distinct species (rat, human) as 
well as varying experimental conditions.  Introduction 35 
Binding of AKBA was suggested to occur at a selective site for PTs that is different from 
the AA-binding site of 5-LO [219]. Non-active BAs (β-BA) as well as related PTs 
(amyrine) antagonised AKBA-mediated 5-LO inhibition, and it was concluded that the PT 
ring system is crucial for binding to the selective effector site, whereas functional groups 
(i.e. the 11-keto and C4-carboxylic moiety) are essential for molecular inhibition of 5-LO 
[220].  
In a smart approach using a photoaffinity analogue of AKBA, modified at the 3-O-acetyl 
position, the existence of a second, regulatory binding site for PTs and AA on 5-LO 
(distinct from the primary substrate binding site) was verified. Binding of AKBA and AA 
was shown to be competitive and Ca
2+-dependent [226]. Since the C2-like domain of 5-
LO binds Ca
2+ [227], and this domain also interacts with other hydrophobic molecules 
such as phospholipids [228] or glycerides [63], a common binding site for hydrophobic 
molecules such as BAs can be appreciated. Interference of BAs with other AA-
metabolising enzymes (12-LO, COX) has once been ruled out [217], but been revised in 
this thesis, and is presented below. 
 
protein/ 
enzyme 
source/ 
setting 
most potent 
BA 
(a)ctivating/ 
(i)nhibiting 
EC50/IC50 reference 
5-LO rat/human 
PMNL 
AKBA  i  16/50 µM   [219, 221] 
HLE  human  AKBA  i  15 µM   [229] 
CYP 
2C8/2C9/3A4 
human, 
recombinant 
β-BA>KBA 
>AKBA 
i  5-10 µM   [230] 
topoisomerase I  human  AαBA>AβBA
>AKBA 
i  3-30 µM   [231] 
topoisomerase IIa  human  AαBA>AβBA
>AKBA 
i  1-30 µM   [231] 
IKKα/β human, 
recombinant 
AαBA, 
AKBA 
i  1-10 µM   [223] 
IKKα/β PC-3  cells  AKBA> 
AβBA 
i  3-10 µM   [232] 
 
Table 3: Molecular targets of BAs 
 
 
2.6.4.2. Other molecular targets 
Within the last decade, several targets capable to interact with BAs have been suggested 
(table 3). Besides 5-LO, human leukocyte elastase (HLE) was identified as target for BAs 
[229, 233]. Purified HLE is inhibited in a competitive manner in the low micromolar Introduction 36 
range (IC50 = 4-6 µM) by ursolic acid and derivatives thereof, which are structurally 
related to BAs [233]. Other serine proteases (pancreatic elastase, α-chymotrypsin, trypsin) 
were also inhibited, but less efficiently [233]. HLE inhibition by ursolic acid (IC50 = 0.9-
2.4 µM) was later confirmed and expanded to BAs, that blocked HLE with IC50 values of 
about 15 µM (AKBA) [229]. Since HLE release is increased upon PMNL activation in a 
variety of inflammatory and hypersensitivity-based diseases, inhibition of HLE by BAs 
may indeed contribute to the antiphlogistic properties of BAs.  
Recently, B. spec. extracts as well as purified BAs were accounted as potent and non-
selective inhibitors of the drug-metabolising CYP enzyme family [230]. In a setup using a 
mixture of recombinant CYP enzymes, β-BA, KBA and AKBA inhibited CYP 2C8/2C9 
and 3A4 activity in the range of 5 to 10 µM. Although the physiological significance of 
CYP inhibition by BAs is still unknown, one should nonetheless consider an influence on 
the pharmacokinetics of other drugs administered in conjunction with B. spec. extracts.  
In contrast to the classical approach of target identification, that was directed from 
phenomenological descriptions via identification of signalling networks involved toward 
elucidation of single target molecules, powerful analytical methods nowadays allow a 
reverse approach. This includes identification of targets e.g. by genome screening [224] or 
selective protein fishing (presented in this work) without initial knowledge about the 
physiological and functional relevance of the obtained interaction. Obviously, verification 
of found molecular target should follow in vitro and in vivo. 
Note that more molecular targets of BAs (topoisomerases, IKK) are discussed in a later 
section (2.6.6.). 
 
2.6.5. Modulation  of  intracellular signalling networks 
BAs interfere with multiple cellular signalling routes within as well as between cells. Key 
players of intracellular signalling networks are protein kinases (PKs) such as PKA, 
PKB/Akt, PKC and MAP kinases (MEK/ERK, p38, JNKs). Most of the PKs are activated 
by phosphorylation events, terminated by dephosphorylation via corresponding 
phosphatases. There are so far no descriptions of BA effects on phosphatases, but there is 
substantial evidence for a modulation of diverse kinase activities.  
The first detailed investigation on cellular activation in this context was performed with 
two tetracyclic triterpenes extracted from B. serrata resin, namely 3-oxo-tirucallic acid (3-
oxo-TA) and 3-acetoxy-TA [234]. Both compounds (10 µM) enhanced LT formation in 
stimulated PMNL in a Ca
2+- and MEK/ERK-dependent fashion, accompanied by Introduction 37 
increased nuclear 5-LO translocation. However, at higher concentrations, inhibitory 
properties became apparent.  
Interestingly, also AKBA induced p38 MAPK and ERK1/2 activation in PMNL, and in 
parallel, AKBA caused a marked elevation of [Ca
2+]i [235]. Since both Ca
2+ and MAPKs 
are necessary for liberation of AA [65], we investigated in this work whether AKBA 
induced the release of AA from PMNL, presumably connected to formation of pro-
inflammatory LTs (see paper I). This investigation was expanded to human platelets, and 
strong effects of BAs were found (see papers II and III). In that regard, AKBA 
antagonised TNFα-induced phosphorylation of Akt and p38 MAPK in human myeloid 
KBM-7 cells without interference of ERK activation [236]. In contrast, AKBA (IC50 = 15 
µM) even prevented ERK1/2 phosphorylation and cell motility in PDGF-stimulated 
meningioma cells [237]. Since the Ras-ERK route transmits survival signals in 
tumorigenic cells [238], ERK inhibition could (at least partly) explain the antiproliferative 
effects of AKBA observed in that study [237]. Putative antagonistic effects of AKBA on 
MAPK activation and Ca
2+ signalling in monocytic cells were further investigated in this 
thesis (see paper V). 
In summary, BA-mediated modulation of signalling cascades follows no unique pattern 
and obviously strongly depends on the cell type and the experimental conditions. 
Accordingly, further elucidation of the complex network of BA effects on the level of 
cellular signalling cascades is reasonably required. 
 
2.6.6.  Effects of BAs on cell proliferation, differentiation, and death 
Shortly after the first descriptions of BA-mediated immunosuppression, anti-proliferative 
and cytotoxic effects of B. spec. preparations and BAs were reported. Studies revealed 
growth inhibition of human leukemic HL-60 cells (IC50 for AKBA ≈ 30 µM) [239, 240], 
accompanied by inhibition of DNA, RNA and protein synthesis (IC50 AKBA from 0.5 to 
7.1 µM) [241, 242]. Likewise, B. serrata extracts arrested growth of certain tumours [200, 
242]. 
Inhibited proliferation often goes hand in hand with enhanced differentiation. 
Accordingly, B. carterii extracts induced differentiation of HL-60 cells [239], and BC-4, a 
1:1 mixture of α- and β-ABA, promoted differentiation of HL-60, U937, ML-1, and 
B16F10 mouse melanoma cells [225, 243]. 
Cell differentiation was often accompanied by the incidence of cytotoxicity, and when 
examined in more detail, revealed signs and attributes of apoptotic cell death. Indeed, 
BAs, foremost AKBA, induced apoptosis in several glioblastoma cell lines with effective Introduction 38 
concentrations at 20 µM [244]. Apoptosis due to BAs was further reported in HL-60 cells 
[240, 243, 245, 246], several other human leukaemia and brain tumour cell lines [245], 
and various cancer cell lines of different tissues [225, 232, 247].  
It was once suggested that the occurrence of apoptosis in otherwise highly proliferative 
cells might be a consequence of topoisomerase inhibition [248, 249]. In relation to that, B. 
carterii ingredients were reported to inhibit murine topoisomerase II already in 1991 
[250], and purified AKBA (but not amyrin) potently inhibited topoisomerase I from calf 
thymus and induced apoptosis in topoisomerase I-expressing HL-60 cells at 
concentrations of ≥30 µM [240]. Direct binding of acetyl-BAs to purified human 
topoisomerases I and IIa was shown later with comparabale IC50 values found for AβBA 
(IC50 = 10-30 µM) and AKBA (IC50 = 30-50 µM) [231]. The inhibitory mechanism relies 
on competition of BAs with DNA for topoisomerase binding. Interestingly, AαBA was the 
most potent analogue (IC50 = 1-3 µM), indicating different structural requirements for 
target binding as compared to 5-LO (section 2.6.4.). Thus, 5-LO inhibition as major cause 
for apoptosis induction was clearly ruled out [231]. Since also another report documented 
inhibition of murine topoisomerase II by BC-4 from B. carterii [225], it is conclusive that 
topoisomerase inhibition may contribute to BA-evoked apoptosis. 
Tackling the mechanisms of BA-induced apoptosis induction, the initiator caspase-8 was 
identified as a central mediator [246, 247, 251]. Caspase-8, in turn, activates the ‘executer’ 
caspase 3. Although caspase-8 is typically activated in response to ligation/activation of 
upstream death receptors such as Fas, the apoptotic effect of BAs is mediated via a 
pathway independent of Fas/FasL interaction [236, 247]. Controversial results were 
obtained regarding the induction of apoptosis mediators. Pro-apoptotic (Bax) and anti-
apoptotic (Bcl-2, Bcl-XL) protein levels were unchanged in human myeloid leukaemia cell 
lines treated with BC-4 [246], whereas in PC3 cells, Bcl-2, Bcl-XL, and the cell cycle 
protein cyclin D1 were downregulated after AKBA and ABA (10 µM, each) treatment, in 
conjunction with loss of mitochondrial cytochrome c [232]. Interestingly, non-transformed 
human fibroblasts were resistant toward apoptosis in parallel experiments, implying 
selective cytotoxicity of AKBA in transformed cancer cells [232]. 
As a molecular mechanism of BA-mediated apoptosis, the same group suggested direct 
inhibition of constitutive IKK activity by AKBA, leading to suppression of the pro-
survival transcription factor NF-κB [232]. In a recent study using human myeloid KBM-5 
cells, a blockade of the anti-apoptotic kinase “Akt” was instead suggested as responsible 
mechanism resulting in reduced NF-κB signalling and low expression levels of Bcl-2 and Introduction 39 
Bcl-XL as well as the Fas receptor. Direct inhibition of IKK activity was ruled out in that 
study [236]. 
Collectively, the recruitment of pro-apoptotic mediators and downstream effector caspases 
by BAs is unequivocal, and typical apoptotic markers such as DNA laddering and poly 
(ADP-ribose) polymerase (PARP) cleavage support apoptotic cell death signalling [232, 
236, 246]. However, the primary target protein(s) initialising apoptotic signals are still not 
clearly defined. 
 
2.7.  Aim of this work 
Frankincense preparations containing bioactive BAs have proven to be effective in the 
treatment of chronic inflammatory diseases for centuries in the Indian ayurvedic medicine. 
In the course of an upcoming awareness for natural (plant-derived) compounds as safe and 
well-tolerable drugs during the last decades in our society, the scientific community is 
increasingly turning the focus to the elucidation of the mechanism by which these 
remedies act on the molecular and cellular level. This interest is substantiated by recent 
clinical trials demonstrating beneficial effects of B. spec preparations in several disease 
forms such as inflammatory bowel diseases and some cancer forms (see sections above). 
However, the utilised extracts consist of a plethora of different compounds. Although BAs 
represent the largest fraction and are considered as primary pharmacological principles, 
application of this mixture in cellular experiments in order to identify molecular targets is 
not feasible, due to the heterogeneity of the extract and the diversity of ingredients. Thus, 
investigations on the cellular level should start with the purified compounds, namely BAs. 
That has been done since about 15 years, and has yielded a number of relevant target 
proteins, including 5-LO [252]. AKBA was discerned as the most potent BA. 
Subsequently, modulation of LT formation, which are key mediators of inflammation with 
additional implications in carcinogenesis, was described by a series of studies. Also other 
targets, related to cell proliferation and apoptosis, were identified [223, 236]. None of 
these findings, though, can presently provide a satisfying explanation for the anti-
inflammatory effects of the extracts observed in clinical settings and the traditional folk 
medicine. Hence, this thesis was designed to further elucidate the actions of BAs on 
cellular physiology and intracellular signalling networks. Haematopoietic cells 
(leukocytes, platelets) were used as a model system, as they are primary governors of 
inflammatory processes and wounding. 
Investigations on the cellular and molecular effects of BAs were started in this group by 
Oliver Werz [222], and a first thesis work focusing on the effects of BAs on neutrophils Introduction 40 
was performed by Anja Altmann. Based on these initial findings [235], studies were 
continued and expanded toward other related cell types (monocytic cells, platelets). The 
results are presented in this thesis. 
First, we examined a putative correlation of intracellular Ca
2+ mobilisation and ERK1/2 
activation by 11-keto-BAs [235] to the generation of ROS, release of AA and formation of 
LTs (paper I). Second, the effects of BAs on Ca
2+ mobilisation, MAPK activation, and 
functional responses in human platelets were investigated (paper II). The work with 
human platelets further revealed interactions of BAs with platelet-type 12-LO, and the 
implications on the formation of p12-LO products were described (paper III). In this 
publication, an artificial construct of immobilised BAs was utilised to identify putative 
target molecules. The synthesis of this construct was documented in paper IV. Lastly, 
turning focus towards monocytes, which are the pivotal leukocytes in chronic 
inflammation, the actions of BAs on cellular physiology as compared to PMNL were 
investigated and surprising effects were attained (published in paper V). Methods 41 
3 Methods 
 
Method   Paper 
 
Isolation of human PMNL  I, II 
Isolation of human platelets II,  III 
Isolation of human monocytes  V 
Cell culture of human suspension cells  I, V 
5-/12-LO activity assay  I, III 
COX product evaluation assay  III 
AA release assay  I–III 
SDS-gel electrophoresis and Western Blot  I, II, V 
Spectrofluorimetric Ca
2+ imaging  I, II, V 
Immobilisation of BAs  IV 
Measurement of cellular peroxide formation  I 
Determination of superoxide formation  I 
Cell viability assessment  II 
PLC activity assay  V 
Selective protein precipitation (target fishing)  III 
Platelet shape change and aggregation  II 
Thrombin generation assay (ETP)  II 
FACS analysis of adhesion receptor expression  II 
 
 
 
Primary cells: 
PMNL, freshly isolated from human leukocyte concentrates (buffy-coats)  I 
Human platelets, freshly isolated from buffy-coats or whole blood  II, III 
Monocytes, isolated from buffy-coats  V 
 
Cell lines: 
HL-60 cells (human acute myeloid leukaemia cells)  I 
MonoMac 6 cells (monocytes/macrophages)  I, V Results and Discussion  42 
4  Results and Discussion 
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4.1. Paper  I:  Coupling of boswellic acid-induced Ca
2+ mobilisation and MAPK 
activation to lipid metabolism and peroxide formation in human leucocytes 
 
Background and aims: 
BAs, the active principles from Frankincense, have proved their beneficial action in the 
traditional treatment of various inflammatory diseases. Recent clinical studies supported 
an anti-inflammatory and anti-cancerogenic potential of BAs or B. spec extracts. However, 
little is known about the molecular mechanisms and cellular effects of BA action. Initial 
studies postulated 5-LO inhibition as pivotal mode of action, conferring anti-inflammatory 
effects via suppression of LT formation [217]. Due to the high concentrations of AKBA 
(50 µM) required to directly inhibit purified 5-LO [221, 222], other molecular effects of 
AKBA or of related BAs probably contribute to the observed pharmacological influence 
of  B. spec preparations. In a first study devoted to enlighten in vitro BA actions on 
isolated inflammatory cells, the related tetracyclic triterpene 3-oxo-TA promoted ERK 
activation and moderate Ca
2+ mobilisation in human PMNL [234]. In our group, AKBA 
was shown to cause substantial Ca
2+ elevation in human PMNL, comparable to the 
chemotactic agonist fMLP, as well as phosphorylation of the MAPK members ERK2 and 
p38 [235]. These stimulatory effects were surprising, suggesting apparent pro-
inflammatory action of AKBA. In order to elucidate whether these agonistic effects have 
relevant implications for cellular physiology, we determined functional responses 
including generation of ROS, liberation of AA, and biosynthesis of LTs in PMNL that 
were exposed to AKBA. 
 
Results: 
PMNL belong to the group of phagocytes that can respond to exogenous stimuli with an 
oxidative burst. Here, the release of ROS by PMNL upon stimulation with AKBA was 
evaluated by two separate methods. First, the peroxide-sensitive dye DCF-DA 
(dichlorofluorescein diacetate) was applied in a spectrofluorimetric assay to detect all 
forms of ROS. Second, lucigenin was used to specifically detect superoxide anions, the 
product of NADPH oxidase. We found that the 11-keto-BAs (AKBA, KBA; 30 µM each) 
caused robust formation of ROS and superoxide anions, even exceeding the potency of 
Ca
2+ ionophore A23187 and of fMLP. Only the potent activator of the PKC-NADPH 
oxidase pathway, PMA (0.1 µM), was slightly superior to AKBA (30 µM). The prominent 
ROS formation could be blocked by application of the NADPH oxidase inhibitor DPI 
(diphenyleneiodonium chloride), indicating involvement of this enzyme, and Ca
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depletion by the chelators BAPTA/AM and EDTA, showing Ca
2+-dependency of AKBA 
action. Furthermore, inhibitors of PI-3 K (wortmannin, LY-294002) and ERK (U0126) 
imply participation of these kinases, whereas no role was evident for PKC (RO-318425). 
Ca
2+ and MAPK activation are determinants for cPLA2 activation, leading to AA 
liberation from endogenous phospholipids. In an AA release assay using radiolabeled AA 
(incorporated into cellular membranes), we recorded an increase in free AA by PMNL 
after exposure to BAs. The rank order of potency was AKBA>KBA>β-BA>Aβ-BA. High 
concentrations of BAs (≥ 30 µM) were necessary to provoke measurable AA release. 
Inhibitor studies point toward an involvement of Ca
2+ and ERKs in the signalling route 
leading to cPLA2 activation. Enhanced AA release could lead to formation of LTs. Thus, 
5-LO products of BA-stimulated PMNL were analysed by HPLC. BAs (foremost AKBA, 
30 µM), added simultaneously with AA (20 µM), increased 5-LO product formation 3.8- 
and 1.9-fold in the absence and presence of 1 mM Ca
2+, respectively. Other BAs were less 
potent. When the AKBA concentration was increased to 100 µM, no 5-LO products were 
detectable, possibly due to direct inhibitory effects on the 5-LO enzyme. Inhibitor 
experiments excluded a role for MAPK in the induction of 5-LO product formation. 
Since AKBA was identified as potent activator of ROS generation and Ca
2+ mobilisation, 
and sustained exposure of these determinants to 5-LO inactivates the enzyme [91], we 
speculated whether a prolonged preincubation (30 min) with AKBA would still lead to 
enhanced LT formation. Interestingly, no significant upregulation could be observed; 
instead, AKBA concentration-dependently inhibited 5-LO product accumulation. This 
effect was more pronounced in the presence of Ca
2+ (IC50 = 8 µM) rather than in its 
absence (IC50 = 50 µM). 
It had been speculated that AKBA might act via a not yet identified GPCR to induce 
cellular signalling pathways. Involvement of a putative Gαi protein was therefore 
evaluated by means of pertussis toxin (PTx). We observed that PTx attenuated the AKBA-
induced stimulatory effects regarding Ca
2+ mobilisation (~70 % inhibition), ERK 
activation (~60 % inhibition), ROS formation (~20 % inhibition), and 5-LO activation (~8 
% inhibition). The efficacy of PTx was verified in control experiments using Gαi-
dependent stimuli such as fMLP. 
Finally, we determined the effects of AKBA in related cells of the haematopoietic lineage, 
i.e. monocytic Mono Mac 6 cells, B-lymphocytic BL-41-E-95-A cells and granulocytic 
HL-60 cells. No Ca
2+ mobilisation, MAPK activation, or ROS formation induced by 
AKBA was observed in monocytic and B-lymphocytic cells. In contrast, HL-60 cells Results and Discussion  45 
showed Ca
2+ elevations, MAPK (ERK2, p38) activation, and ROS generation in analogy 
to PMNL exposed to AKBA (30 µM). 
Personal contributions: Lucigenin assay, parts of ROS generation assay, PTx 
experiments, parts of 5-LO product formation measurements, preparation of text and 
figures for the manuscript (~40 % of total work). 
 
Discussion: 
In this study, we could demonstrate that BAs, particularly those bearing a 11-keto moiety, 
exert potent stimulatory effects on human PMNL. The induction of Ca
2+ mobilisation and 
MAPK phosphorylation is in line with the findings made with 3-oxo-TA in PMNL before 
[234]. Since Ca
2+ and MAPK may promote cPLA2 activation and subsequent LT 
formation, it is conclusive that AKBA also induces the release of AA and the biosynthesis 
of LTs by 5-LO. Moreover, Ca
2+ promotes NADPH oxidase activation, and consequently, 
AKBA strongly stimulates ROS formation. Thus, we show that 11-keto-BAs (but hardly 
those BAs lacking an 11-keto-moiety) indeed activate functional responses in leukocytes, 
i.e. PMNL and granulocytic HL-60 cells. The physiological meaning of this agonism is 
unknown, especially since the concentrations required to elicit agonistic effects of AKBA 
(10-30 µM) are not achieved in the blood plasma after standard dosage of B. spec extracts. 
However, due to their lipophilic structure, BAs might accumulate in local intracellular 
membrane compartments, thereby possibly occurring in concentrations related to those in 
our experiments. Hence, investigation of signalling molecules evoked by AKBA is 
reasonable. 
Similarities in kinetics and utilisation of signalling molecules (MAPK) by AKBA and 
common chemotactic ligands such as fMLP, PAF, or LTB4, might justify the hypothesis 
that AKBA transduces signals in a similar way to these GPCR agonists. That issue was 
investigated using the Gαi protein inhibitor PTx. Our results indicate that a heterotrimeric 
G protein mediates the effects of AKBA in PMNL, especially the Ca
2+ mobilisation and 
ERK activation. In contrast, other mediators than Gαi proteins are potential transducers of 
the AKBA-induced p38 MAPK and 5-LO activation. In conclusion, the participation of a 
G protein in signal transduction pathways initialised by AKBA can be appreciated, but 
whether interference of AKBA with the signalling cascades occurs at the stage of a GPCR, 
G proteins, or at regulators of G protein signalling (RGS), is still unclear. 
Downstream of the initial AKBA target, various kinases appear to play a central role in 
further signal transduction. Comparable differential inhibitory effects as for PTx were 
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involvement of PI-3 K in AKBA signalling, depending on the functional response that was 
assayed. PI-3 K converts PIP2 into PIP3, thus altering the abundance of 
phosphatidylinositides in cellular membranes with impact on the membrane binding 
capacity of proteins bearing PH (pleckstrin homology) domains. A precise relation of PI-3 
K to the 5-LO pathway has not been established so far. Nevertheless, PI-3 K, which can be 
targeted by G protein subunits (e.g. Giβγ), may influence the activity of PLC isoforms that 
rely on a supply of PIP2, and also modulate downstream MAPK activation. Via soluble 
tyrosine kinases from the Src family, PI-3 K activates the Ras-Raf-MEK-ERK cascade; 
therefore, it is conclusive that the inhibitory effects of PI-3 K and MEK/ERK inhibitors 
(wortmannin and U0126, respectively) in this work often correlate with each other. One 
example is the induction of ROS formation by AKBA. ROS, predominantly superoxide 
anions, are part of the unspecific host defence against pathogens. The main source for 
ROS is the NADPH oxidase, which can be activated via Ca
2+ and PKC. In our control 
experiments, we demonstrated the absolute requirement for PKC and a partial contribution 
of ERK in PMA-induced ROS generation. Contrasting these findings, the AKBA-induced 
ROS formation was not dependent on PKC but rather on PI-3 K and partly on ERK. In 
either case, Ca
2+ was a prerequisite for ROS generation.  
The release of AA was likewise dependent on Ca
2+ and ERK activity. Thus, it appears 
reasonable that cPLA2 activation occurs downstream of Ca
2+ mobilisation and ERK 
activation. However, we found a substantial increase in 5-LO product formation also in 
the absence of Ca
2+, and furthermore, this increase was not dependent on MAPK (ERK 
and p38). Notably, the enhancement (fold increase) of LT formation was most pronounced 
when Ca
2+ was chelated (3.8 fold) as compared to the presence of Ca
2+ (1.9 fold), clearly 
indicating that additional signalling routes govern AKBA-induced LT formation. Taken 
together, these data indicate that BAs (foremost AKBA) are potent activators of pro-
inflammatory responses in PMNL, and that Ca
2+, PI-3 K and ERK are major determinants 
of AKBA-induced signal transduction. The respective molecular target(s) for AKBA has 
not yet been solved, although regulation at the level of G proteins or GPCRs is 
conceivable. Despite these potent activating effects on inflammatory cells, pre-exposure to 
AKBA may reveal anti-inflammatory actions of the compound. Our experiments 
performed with cells incubated with AKBA for 20-30 min prior stimulation with pro-
inflammatory agonists (such as AA) indicate that the capacity of cells to form LTs is 
remarkably reduced. This may be due to suicide inactivation of the enzyme [91], a 
consequence of elevated Ca
2+ and ROS levels caused by AKBA. Thus, sustained exposure 
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ingestion of B. spec medicine, may eventually lead to decreased levels of pro-
inflammatory LTs. 
In conclusion, elucidation of the signalling molecules involved in the agonistic action of 
AKBA in inflammatory cells as well as knowledge of the functional responses elicited by 
AKBA may help to better understand the molecular and cellular effects of AKBA, but 
identification of precise molecular targets is missing. Moreover, the causal relation with 
the observed anti-inflammatory action of B. spec extracts in disease treatment still has to 
be established. 
 
 
4.2. Paper  II:  Induction of central signalling pathways and select functional effects in 
human platelets by β-boswellic acid 
 
Background and aims: 
Platelets are relevant cells in the onset of an inflammatory response, particularly after 
tissue injury or vessel wounding (section 2.2.3). Thus, there was reason to assess the 
influence of BAs on platelet signalling, in order to evaluate whether platelet physiology is 
modified by BAs. Previous studies using several types of leukocytes had revealed that 
BAs evoke differential effects, depending on the cell type ([235] and Paper I). We 
observed that 11-keto-BAs were most potent in the activation of intracellular signalling 
cascades involving Ca
2+ mobilisation, PI-3 K and ERK activation, as well as cPLA2 
activation, in human PMNL. Other related cells such as B-lymphocytic and monocytic 
cells could not be activated by BAs (paper I). The cellular effects in PMNL resulted in 
enhanced formation of ROS and LT, which are generally regarded as factors that promote 
an inflammatory response in phagocytes. How these findings relate to the anti-
inflammatory action of BAs in disease models is unknown, but we reasoned that other 
cells (relevant in inflammation) might contribute to the physiological effects of BAs. 
Therefore, we decided to investigate the response of human platelets upon exposure of 
BAs. 
Interestingly, our previous studies revealed that AKBA and KBA, rather than BAs lacking 
the 11-keto moiety (11-methylene-BAs), are the most effective BA members regarding 
modulation of cellular physiology. Only in HL-60 cells, Aβ-BA and β-BA also exerted 
agonistic effects. Nonetheless, reports in the literature in some selected cases also 
identified 11-methylene-BAs as the responsible BA isoforms for the observed effect [231, Results and Discussion  48 
244]. We therefore devoted particular attention to the structure-activity relationship of the 
four major β-configurated BAs regarding platelet functional responses. 
 
Results: 
In comparison to PMNL, platelets were more sensitive towards BA-induced intracellular 
Ca
2+ mobilisation. Furthermore, platelets showed an inverse structure-activity relationship 
for BA agonism. 11-Methylene-BAs evoked substantial Ca
2+ mobilisation already at 10 
µM (increase of ~400 nM [Ca
2+]i), with β-BA being the most potent analogue. This 
response was transient, equally potent to the strong platelet agonist thrombin (0.5 U/ml), 
and further increased up to 100 µM β-BA. In contrast, 11-keto-BAs displayed a non-
significant Ca
2+ mobilisation at 10 µM and required higher concentrations (30-100 µM) to 
evoke a notable but delayed response (compared to thrombin or β-BA). Experiments in the 
absence of extracellular Ca
2+ also revealed that the Ca
2+ elevation by β-BA consisted of an 
intracellular (~37 %) and an extracellular component, presumably via SOCE mechanisms. 
Inhibitor studies demonstrated that the β-BA- and thrombin-evoked Ca
2+ signals were 
essentially dependent on PLC (inhibition by U-73122 and 2-aminoethoxyphenylborate (2-
APB)) and Src family kinases (inhibition by PP2 and SU6656). Despite the similarities 
between thrombin and β-BA, the putative receptor for β-BA is still unknown. Thus, 
several receptor antagonists were employed for their ability to interfere with β-BA 
signalling. Neither purinergic P2X1 and P2Y1,12 receptor antagonists (NF-449/MRS-2179) 
nor PAF receptor (WEB 2086) and thrombin antagonists (argatroban) significantly 
attenuated the β-BA-induced Ca
2+ response, excluding these receptors as targets for β-BA. 
Further studies will have to identify the molecular target transducing β-BA signalling. 
Besides elevation of intracellular Ca
2+ levels, 11-methylene-BAs induced p38 MAPK and 
ERK phosphorylation. p38 MAPK was also activated by 11-keto-BAs. The fast and potent 
effect of β-BA on ERK phosphorylation (EC50 = 10-30 µM, maximal after 1 min) was also 
found in a slightly attenuated fashion in Ca
2+-depleted cells with similar kinetics, implying 
the existence of a Ca
2+-independent activation pathway. Moreover, β-BA but not AKBA 
induced Akt activation with a maximum after 5 min in a PI-3 K-(inhibitor: wortmannin) 
and PLC-dependent (inhibitor: U-73122) manner. Chelation of Ca
2+ (BAPTA/EDTA) 
abolished the β-BA effect on Akt phosphorylation, indicating that this event is located 
downstream of Ca
2+ mobilisation in the signalling cascade. 
A cell viability assay demonstrated no immediate cytotoxicity of β-BA and AKBA (30 
µM, each, incubation for 15 min). BAs were then evaluated regarding functional responses 
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is a marker of platelet activation due to subsequent generation of bioactive eicosanoids. 
However, β-BA only slowly and weakly induced platelet aggregation in calcified buffer, 
displaying no endogenous (Ca
2+-independent) pro-aggregatory action. AKBA was totally 
ineffective. In that regard, BAs strongly differed from the potent agonists collagen and 
ADP that immediately cause aggregation. Likewise, β-BA did not induce the 
externalisation of the platelet activation markers PAC-1 and CD62, whereas thrombin 
receptor-activated peptide (TRAP, used as positive control) did. 
Another parameter that displays platelet activation is the capacity of agonists to evoke 
thrombin generation. β-BA (but not AKBA) strongly induced the endogenous thrombin 
potential (ETP), almost comparably potent to collagen. In the absence of Ca
2+, there was 
only a slight activation by β-BA but none of collagen. 
Personal contributions: All experimental work except for parts of platelet functional 
assays. Functional assays were performed together with Lars Tausch. Major contributions 
to the preparation of the manuscript (~90 % of total work). 
 
Discussion: 
Our experiments with human platelets revealed a striking difference in the structure-
activity relationship of BAs concerning cell activation as compared to PMNL and HL-60 
cells. We found that 11-methylene-BAs (β-BA) were superior to 11-keto-BAs (e.g. 
AKBA) with respect to the induction of several functional effects in platelets, and that 11-
methylene-BAs were often similarly potent as strong platelet agonists such as thrombin or 
collagen. Nevertheless, the pattern of β-BA-induced platelet activation is unique and 
differs in some aspects to that of thrombin or collagen, indicating that distinct signalling 
routes are operative. For example, intracellular Ca
2+ mobilisation induced by β-BA is 
significantly delayed as compared to thrombin (peaking ~25 s after application in contrast 
to ~3-5 s for thrombin), allowing the conclusion that β-BA does not directly target the (G 
protein-)PLC-IP3 route but might instead activate an upstream member of an as yet 
unidentified signalling cascade. The receptors for ADP, PAF, and thrombin were ruled out 
as potential signal transducers for β-BA, but Src family kinases and PLC were identified 
as indispensable mediators of β-BA signalling. Presumably, Src family kinases might be 
activated as direct or secondary targets of β-BA, transducing the signal to U-73122-
sensitive PLC-γ isoforms (which are known targets of Src family kinases, see [53]), 
resulting in IP3-mediated Ca
2+ mobilisation. Whether an endogenous mediator is first 
generated upon exposure of platelets to β-BA, or β-BA targets an adhesion receptor linked 
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An involvement of a signalling cascade involving PLC/Ca
2+ and PI-3 K can be 
appreciated in the activation of Akt, an anti-apoptotic protein kinase with multiple cellular 
functions. Akt activation by β-BA, as reported here, is yet in contrast to many reports in 
the literature stating general pro-apoptotic capacity of BAs in diverse cell lines such as 
human leukaemia cells (see for example [240, 245], and section 2.6.6.). Although this 
potential contradiction can not be explained by now, it has to be noted that most pro-
apoptotic effects of BAs were mediated by AKBA and less by 11-methylene-BAs, 
pointing out specific effects of BAs depending on the structure. Along these lines, when 
dissecting the AKBA effects from those of β-BA, we found that AKBA did not stimulate 
intracellular Ca
2+ mobilisation with similar potency, did not activate Akt, and was 
inefficient in the induction of functional responses such as aggregation, thrombin 
generation, or adhesion receptor externalisation. All BAs, though, induced p38 MAPK and 
ERK activation (concerning ERK, β-BA was most potent), whose functional implication is 
not readily apparent. The Ca
2+-independent effects of β-BA on ERK activation and 
thrombin generation indicate that additional signalling routes are initiated by β-BA that 
will have to be further defined. 
In several assays performed in this study, β-BA proved to be efficient already at 
concentrations of 3-10 µM. This is in the range of physiologically achievable plasma 
levels of β-BA (10 µM), determined after oral application of 4 x 786 mg B. serrata 
extract/day (H15
(R)) within 10 days [253], thus highlighting the pharmacological relevance 
of our results in vivo. In contrast, AKBA was much less concentrated in plasma (0.1 µM), 
probably due to deacetylation processes and a generally lower abundance in crude B. 
serrata extracts as compared to β-BA [194]. 
Despite the strong agonistic effects of β-BA in terms of Ca
2+ mobilisation, MAPK and Akt 
activation, AA release, and thrombin generation, there is a curious lack of activity 
regarding aggregation and externalisation of pro-coagulant adhesion receptors. On the 
basis of these findings, β-BA can not be considered as an equally potent platelet agonist 
like thrombin or collagen. Obviously, the failure of β-BA to cause rapid aggregation and 
induce adhesion receptor expression is more compatible with physiological evidence of 
anti-inflammatory or immunomodulatory properties of B. spec preparations observed in 
disease treatment. It may be speculated that β-BA has additional targets, putatively within 
pro-coagulation signalling routes in the platelet, that may counteract its agonistic activity 
on Ca
2+ homeostasis and other responses. Thus, the search for additional molecular targets 
for BAs is ongoing. 
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4.3.   Paper III: Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase 
activity in human platelets independent of Ca
2+ and differentially interact with 
platelet-type 12-lipoxygenase 
 
Background and aims: 
In the previous report (paper II), we demonstrated that β-BA activates selected functional 
effects in human platelets in a specific mode, including robust mobilisation of intracellular 
Ca
2+, activation of MAPK and Akt, and liberation of AA. Ca
2+ and MAPK are 
determinants of cPLA2 activation, eventually leading to enhanced activity of the enzyme 
[65]. Along these lines, we reported earlier that 11-keto-BAs promoted Ca
2+ elevations, 
MAPK activation, ROS formation, and AA release in human PMNL (paper I). The release 
of AA was essentially dependent on the presence of Ca
2+ and relied partially on ERK 
activity, suggesting a signalling pathway encompassing Ca
2+ elevations and ERK activity 
upstream of cPLA2 activation. Concomitant to cPLA2 induction, AKBA enhanced the 
formation of pro-inflammatory LTs by 5-LO. 
Regulation of cellular 5-LO activation is complex, involving peroxides, Ca
2+, 
phospholipids, and phosphorylation by MK-2 or ERK2 (for review, see [96]). Upon 
exposure to PMNL, AKBA indeed positively influenced most of these means, so 
subsequent activation of 5-LO in addition to cPLA2 was consistent. Nonetheless, AKBA 
had been reported as a selective 5-LO inhibitor before [217]. Although the molecular 
inhibition of the purified enzyme was later shown to require high AKBA concentrations 
(50 µM, [221, 222]), it may be that this inhibition partly compromised the stimulatory 
effects of AKBA on LT formation. 
Platelets do not express 5-LO, but contain the closely related platelet-type (p) 12-LO. 
There is little information about the regulation of p12-LO activation, at least Ca
2+ appears 
to play a role in facilitating membrane association [64] (also see section 2.4.2.2.). We 
previously observed that 11-methylene-BAs are potent inducers of platelet Ca
2+ 
mobilisation and AA release, and here we investigated the effects of β-BA on p12-LO 
product formation. Also the kinetics of 12-H(P)ETE accumulation were studied. On the 
basis of the known signalling molecules transducing β-BA effects in human platelets 
(paper II), we further attempted to determine the participation of these signalling routes in 
β-BA-induced lipid metabolism. 
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Results: 
First, the induction of PLA2 activity by BAs was investigated in more detail. Despite 
divergent effects of 11-methylene- and 11-keto BAs in other assays, in the presence of 
Ca
2+, β-BA and AKBA caused a similar concentration-dependent increase in AA release 
that was significant at concentrations ≥10 µM. At 30 µM, BAs were almost as potent as 
the strong agonists thrombin (2 U/ml) and Ca
2+-ionophore A23187 (5 µM). Potent AA 
liberation by BAs was also observed in Ca
2+-depleted platelets, indicating that Ca
2+-
independent signalling pathways are induced by BAs (see papers I and II). In the absence 
of Ca
2+, BAs were superior over thrombin and A23187. 
AA is the substrate for p12-LO, hence the formation of the p12-LO metabolite 12-
H(P)ETE was assayed. As expected, BAs promoted 12-H(P)ETE accumulation, but with 
rather different potency. β-BA evoked a concentration-dependent increase in p12-LO 
products, that (at 30 µM) was almost equally potent as thrombin (2 U/ml). In contrast, 
AKBA exerted only a weak effect on p12-LO product synthesis, and at concentrations >30 
µM, it was no longer active. Thus, regarding p12-LO activity, a remarkable difference 
between AKBA and β-BA became apparent that was not seen in the release of AA. 
Since we demonstrated Ca
2+-independent release of AA by BAs, it appeared possible that 
BAs also cause Ca
2+-independent accumulation of 12-H(P)ETE. In fact, we found 
enhanced 12-H(P)ETE synthesis in the absence of Ca
2+, again with much higher potency 
for β-BA as compared to AKBA. This was a unique finding as the potent platelet agonist 
thrombin was ineffective under these conditions. 
Detailed kinetic studies revealed that fundamentally different mechanisms apparently 
underlie the β-BA-induced p12-LO activation. In the presence of intracellular Ca
2+, 12-
H(P)ETE formation is rapid (half maximal product accumulation within 37 s), thus being 
equally fast as the direct conversion of p12-LO substrate AA, and considerably faster than 
that of thrombin. In the absence of Ca
2+, however, p12-LO product formation induced by 
β-BA was delayed for approximately 3 min until it started to continuously increase for up 
to 2 hours. No comparable effect was found for any other applied stimulus. 
Dissecting the signalling pathways that mediate the β-BA effects on lipid metabolism (AA 
release and 12-H(P)ETE formation), we identified Src family kinases and PI-3 K as 
important signalling molecules as long as Ca
2+ was present. No role for p38 MAPK or 
ERK was evident. However, when Ca
2+ was omitted, none of the examined signalling 
molecules (Src kinases, PI-3 K, ERK, p38 MAPK) apparently contributed, so other 
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The finding of Ca
2+-independent activation of p12-LO activity prompted us to investigate 
putative direct interaction of BAs with p12-LO. Accordingly, we incubated platelet 
supernatants (rich in soluble p12-LO) with β-BA and AKBA. Whereas β-BA was found to 
activate p12-LO approximately 2-fold at a threshold concentration of 10 µM in Ca
2+-free 
buffer, AKBA concentration-dependently inhibited p12-LO product formation in vitro. 
The IC50 for AKBA was determined at ~15 µM in the presence of Ca
2+ and at ~50 µM in 
the absence of Ca
2+, the difference in IC50s due to enhanced basal conversion by p12-LO 
in Ca
2+-containing buffer. Interaction of AKBA with p12-LO was then confirmed in a 
protein fishing assay using platelet homogenates as protein source and immobilised KBA 
(linked to sepharose beads) as bait. We selectively precipitated p12-LO as compared to 
control samples using pure sepharose beads, thus supporting the hypothesis of a direct 
interaction between AKBA and p12-LO. Along these lines, in vitro cPLA2 activation 
could not be measured, and cPLA2 was not precipitated in the protein fishing assay. 
Hence, we conclude that BAs interfere with lipid signalling primarily at the stage of p12-
LO. 
Personal contributions: All experimental work plus manuscript preparation. Parts of 
additional protein fishing and AA release measurements were conducted by Lars Tausch. 
Together ~90% of total work. 
 
Discussion: 
Several platelet stimuli (thrombin, PAF, thromboxane) cause a release of AA, leading to 
the formation of endogenous mediators via COX and p12-LO [254]. cPLA2 activation is 
promoted by Ca
2+ [255], MAPK phosphorylation [65], and PIP2 interaction [80]. In 
contrast, only Ca
2+ was described as a stimulating factor of p12-LO [64], whereas no other 
regulators have been clearly defined. We previously reported strong stimulating effects of 
11-methylene-BAs in terms of Ca
2+ mobilisation and MAPK activation in human platelets. 
Based on these findings, we expanded our investigations toward platelet lipid metabolism. 
Not surprisingly, β-BA induced the release of AA and its subsequent conversion into 12-
H(P)ETE, comparable to potent platelet agonists (thrombin, A23187). More surprisingly, 
β-BA also promoted cPLA2 activation and 12-LO product formation in the absence of 
Ca
2+. So far no agonists are known which are able to induce this cascade in a Ca
2+-
independent manner. The underlying mechanism appears to deviate from the one 
involving Ca
2+, since, in the first case, it took significantly longer to accumulate 
substantial amounts of 12-H(P)ETE, whereas in the second case, none of the known 
signalling molecules mediating β-BA effects regarding Ca
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in the presence of Ca
2+ apparently contributed when cells were depleted of Ca
2+. In vitro 
experiments with soluble p12-LO revealed that the capacity of β-BA to activate p12-LO at 
least in part relies on direct stimulation of the enzyme. No activation of cPLA2 was found 
until now. Nevertheless, additional unknown factors seem to transduce the activation of 
cPLA2 by β-BA when Ca
2+ is missing. On the other hand, when Ca
2+ is present, cPLA2 
and 12-LO activities are probably located downstream of the major activating events 
induced by β-BA (Ca
2+ mobilisation, PI-3 K and MAPK activation), which were described 
in the previous publication (paper II).  
AKBA paralleled the effects of β-BA in respect to AA release, both in the presence or 
absence of Ca
2+. However, striking differences were apparent regarding p12-LO 
activation, where AKBA caused only a minor (and slow) enhancement of 12-H(P)ETE 
synthesis, accompanied by total inefficacy at 100 µM. This discrepancy can be attributed 
to direct inhibition of p12-LO, an effect that was verified in a protein fishing approach 
yielding p12-LO as selective binding partner for immobilised KBA. Thus, despite robust 
release of AA, further conversion to 12-H(P)ETE is blocked by direct inhibition of p12-
LO. These results disprove the traditional paradigm that AKBA is a selective inhibitor of 
5-LO without affecting p12-LO and COX enzymes [217]. Comparing IC50 values, p12-LO 
(IC50 approx. 15 µM) is even more susceptible to AKBA inhibition than human 5-LO 
(IC50 approx. 50 µM) under similar experimental conditions. 
The pharmacological implications of our results for platelets in vivo are speculative. 
Enhanced 12-H(P)ETE formation upon exposure to β-BA might promote or maintain pro-
inflammatory processes, including leukocyte chemotaxis and motility, angiogenesis, and 
tumour metastasis [172-174]. Even so, 12-HPETE might also be involved in an autocrine 
loop, eventually causing platelet silencing by inhibition of main platelet functions [176]. 
That scenario, although hypothetic, would better match the beneficial effects of B. spec 
preparations observed in the treatment of inflammatory diseases. Certainly, the validity of 
this model will have to be verified in further experiments. 
 
 
4.4.   Paper IV: Immobilisation of Boswellic acids at EAH Sepharose
TM for “target 
fishing” 
 
Background and aims: 
This publication describes the chemical synthesis of the immobilised KBA construct that 
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To date, two publications have appeared that utilised modified BAs to determine the 
molecular interaction with different target molecules. In the first report [226], AKBA was 
derivatised at its 3-O-acetyl group with radio-labelled 4-azido-5-
125iodo-salicyloyl-β-
alanine to yield azido-
125I-KBA. This molecule was structurally similar to AKBA with 
exception for a more bulky alanyl ester as compared to the original acetyl group. The 
synthesis of this construct was not stated. Azido-
125I-KBA inhibited 5-LO in intact PMNL 
as potently as AKBA. Furthermore, amyrin modulated 5-LO inhibition by the novel 
construct in a similar way as with AKBA. The aim of that study was to identify and 
characterise the binding site of AKBA at 5-LO. Accordingly, azido-
125I-KBA specifically 
labelled 5-LO in a Ca
2+-dependent manner when irradiated with UV light (254 nm), and 
binding was competitively antagonised by the presence of other related PTs including 
AKBA as well as AA. In contrast, competitive 5-LO inhibitors (ZM-230,487) did not 
interfere with photolabelling. The authors concluded that AKBA binds to 5-LO at a 
regulatory site (that also binds AA) distinct of the substrate binding site [226]. 
A second study used Aα-BA as template for an immobilisation to surface plasmon 
resonance (SPR) sensor chips [231]. In a first step, Aα-BA was deacetylated and coupled 
to 6-aminocaproic acid anhydride to yield 3-O-(6-aminocaproyl-)-α-BA. In a second step, 
this molecule was biotinylated, resulting in a construct termed 3-O-(N-(+)-biotinyl-6-
aminocaproyl)-α-BA. The conjugate was bound to neutravidin and then immobilised on 
the SPR surface. In biological tests, the soluble conjugate was able to inhibit human 
topoisomerase activity in relaxation assays in the same way as natural Aα-BA (IC50 = 12 
and 2 µM for topoisomerases I and IIα, respectively). The immobilised compound 
specifically and potently interacted with human topoisomerases through high-affinity 
binding sites in a DNA-competitive mode [231]. 
Thus, since modified BAs proved to be valuable without remarkable loss of efficiency in 
at least two different reports, we attempted to create a novel construct using the 3-OH 
moiety of KBA as starting point for chemical modification. In parallel, this synthesis was 
carried out with β-BA. It was our aim to couple the BAs to an insoluble biocompatible 
resin via a linker molecule. With this construct, we attempt to selectively precipitate 
binding partners of KBA (β-BA) present in cellular samples. 
 
Results: 
As insoluble resin we chose EAH Sepharose 4B
TM, which is a frequently applied and 
rather inert resin in biochemical assays. Glutaric anhydride was applied as reactant for 
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termed glutaroyl-KBA (glutaroyl-β-BA). The remaining carboxyl group of the glutaroyl 
moiety reacted with the amino group of EAH Sepharose 4B
TM to give immobilised 
glutaroyl-KBA (glutaroyl-β-BA), designated KBA-sepharose (β-BA-sepharose). 
Experimentally, glutaroyl-BAs were prepared using 4-pyrrolidino-pyridine as catalyst and 
pyridine as solvent. The product was crystallised and subjected to X-ray spectroscopy, 
enabling the calculation of a three dimensional model. Due to poor solubility of glutaroyl-
BAs in water, the coupling to EAH Sepharose 4B
TM had to be conducted under 
heterogeneous conditions in a water/dioxane 50/50 (v/v) mixture. The success of the 
coupling reaction was determined by recovering the calculated excess of glutaroyl-BA. 
For detailed technical parameters of the synthesis reaction as well as particular 
experimental handicaps please refer to the original publication (paper IV). 
Personal contributions: Idea and selection of reaction educts, biochemical application 
(~10%). 
 
Discussion: 
Immobilised BAs are considered as a valuable tool for the selective precipitation of 
potential target molecules from protein pools. In ongoing biochemical studies, we will 
attempt to pull down proteins that specifically bind to the immobilised β-BA or KBA. 
Naturally, this approach does not enable all existing (but not yet identified) BA targets to 
be retrieved, because masking of the 3-O-acetyl group will exclude all those proteins that 
specifically interact with this portion of BAs. From a chemical point of view, this was 
however the only readily accessible functional residue of the BA molecule for chemical 
modification, and was therefore chosen as starting point for the immobilisation. Glutaric 
acid was selected as a linker of suitable length, on the one hand providing sufficient space 
between the sepharose matrix and the KBA molecule to allow interaction with bulky 
binding partners, on the other hand being short enough to prevent self-cyclisation via the 
two carboxyl groups. 
Technically, protein pull-downs are separated by gel electrophoresis and after comparison 
with pull-downs utilising crude EAH sepharose beads (lacking BAs as bait, negative 
control), the respective proteins are selected and identified by MALDI mass spectrometry 
or, as performed in paper III, by western blotting and visualisation via specific antibodies. 
In paper III, we applied KBA-sepharose in a protein pull-down assay to precipitate 
potential target molecules from platelet lysates. Whereas p12-LO was successfully and 
selectively extracted by KBA-sepharose from the protein mixture, no specific interaction 
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as for KBA-sepharose and 5-LO from human PMNL lysates (paper III). Thus, although 5-
LO was once shown to be a molecular target for AKBA [226], this interacting could not 
be verified. Two reasons can explain this finding. Either, the molecular interaction of 
KBA to 5-LO is too weak to yield significant binding, or the 3-O-acetyl moiety in its 
unmasked form is a critical determinant of the KBA-5-LO binding. 
After the successful application of this construct in p12-LO precipitation, experiments to 
retrieve additional as yet unrecognised binding partners for KBA-sepharose and β-BA-
sepharose have started. Presumably, systematic analysis of fished proteins via 1-D or 2-D 
gel electrophoresis followed by Coomassie staining and MALDI-based protein 
identification will yield a variety of novel binding partners for BAs, whose physiological 
relevance will be evaluated in subsequent studies. 
 
 
4.5.   Paper V: 3-O-Acetyl-11-keto-boswellic acid decreases basal intracellular Ca
2+ 
levels and inhibits agonist-induced Ca
2+ mobilisation and MAP kinase activation in 
human monocytic cells 
 
Background and aims: 
In the previous publications, multifaceted aspects of BA action on haematopoietic cells 
have been described. Moreover, the literature provides a large number of clinical and 
molecular/cellular studies devoted to elucidate the effects of B. spec preparations or 
isolated BAs, and results have been almost as diverse as the number of studies themselves 
(for review, see [252]). Thus, it becomes increasingly clear that the actions of BAs are 
very selective, depending on the cell type as well as on the structure of the BA analogue. 
In our papers discussed above, we demonstrated opposite structure-activity relationships 
of 11-keto-BAs (AKBA) and 11-methylene-BAs (β-BA) in human PMNL and human 
platelets, respectively. In PMNL, AKBA was found to be the most potent BA analogue, 
capable to induce cellular activation as well as functional responses. On the other hand, 
platelets were most strongly activated by β-BA. 11-keto-BAs acted more weakly and by 
different mechanisms, partly mediated by direct inhibitory effects on p12-LO. Taken 
together, in these studies cell-activating effects of BAs were evident, leading to functional 
responses with mainly pro-inflammatory characteristics. Which processes are eventually 
responsible for the anti-inflammatory action of B. spec extracts or BAs in disease models, 
remains to be answered. A growing number of researchers attempt to reveal the basis of 
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[231] and/or IκB kinases (IKK) [223] have been suggested as responsible mechanisms. 
Still, convincing evidence capable to fully explain B. spec actions on a cellular and 
molecular level is lacking. 
Platelets play an important role in tissue repair and wounding, whereas leukocytes have 
additional tasks in host defence mechanisms. At sites of infection, PMNL govern the acute 
inflammatory response, until they are gradually replaced by macrophages, derived from 
monocytes [2, 3]. Hence, in chronic inflammation macrophages play a dominant role. On 
this account, in the following study we addressed the issue whether monocyte/macrophage 
physiology (represented by the monocyte-macrophage cell line Mono Mac (MM) 6) is 
affected by BA treatment. 
 
Results: 
When resting MM6 cells were exposed to BAs, they responded with a sudden decrease of 
intracellular Ca
2+ levels. This response was most pronounced for AKBA, with a 
significant drop of [Ca
2+]i already at 1 µM, followed by KBA, Aβ-BA, and β-BA. The 11-
methylene analogues did not significantly reduce resting [Ca
2+]i levels even at a 
concentration of 30 µM, indicating that the 11-keto moiety is of crucial importance for this 
effect. A similar drop in [Ca
2+]i as seen for AKBA (30 µM ; from approx. 160 to 80 nM) 
was determined after application of the PLC inhibitor U-73122 (3 µM; from approx. 160 
to 90 nM). Since U-73122 and AKBA gave no additive effects, we initially suspected 
AKBA to act via PLC inhibition (see below). 
Next, we investigated whether AKBA also antagonises [Ca
2+]i elevations evoked by 
physiological (fMLP, PAF) and non-physiological (thapsigargin (TG), the PLC activator 
m-3M3FBS, and ionomycin) agonists. AKBA added 50 s after PAF (0.1 µM) immediately 
caused a drop of the increases in intracellular Ca
2+ level, attaining almost equally low 
[Ca
2+]i levels as after addition to resting cells. This effect was again mimicked by U-73122 
in a concentration-dependent fashion. Likewise, pre-exposure of MM6 cells to AKBA (30 
µM, 20 s or 20 min) significantly attenuated the subsequent [Ca
2+]i elevation elicited by 
PAF, fMLP, and m-3M3FBS. Notably, no attenuation of Ca
2+ mobilisation was observed 
when agonists that circumvent the PLC/IP3 route, namely TG and ionomycin, were 
utilised. Evaluating the influence of different pre-incubation periods (20 s vs. 20 min) with 
AKBA and U-73122 on Ca
2+ homeostasis, we found that AKBA but not U-73122 caused 
sustained depression of [Ca
2+]i levels. The suppressive effects of AKBA on Ca
2+ 
elevations induced by PAF were confirmed in primary human monocytes isolated from 
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Ca
2+ mobilisation induced by receptor agonists (PAF, fMLP) as well as by m-3M3FBS 
and the SERCA inhibitor TG consists of an intracellular release from internal storage sites 
(endoplasmatic reticulum, ER), and influx from the extracellular milieu via SOCE 
mechanisms [256]. Thus, we asked whether AKBA also compromises the intracellular 
portion of agonist-induced Ca
2+ mobilisation. Indeed, AKBA attenuated Ca
2+ mobilisation 
from intracellular stores with slightly reduced potency, when added to MM6 cells 20 s 
before the agonist. As AKBA also affected the Ca
2+ release by TG, which does not signal 
via PLC and IP3, inhibition of PLC was excluded as sole mechanism mediating the effects 
of AKBA on Ca
2+ homeostasis. 
In contrast, when a putative interaction of AKBA with PLC was tested in an assay 
quantifying the amount of IP3 generated by PLC in intact MM6 cells, we only found 
minor (non-significant) attenuation of m-3M3FBS-induced PLC activity by AKBA (30 
µM) but strong inhibition, as expected, by the PLC inhibitor U-73122 (5 µM). 
Intriguingly, Aβ-BA was superior as compared to AKBA regarding PLC inhibition. The 
weak effect of AKBA was accompanied by the finding that AKBA concomitantly caused 
a significant increase on PIP2 turnover in resting (unstimulated) MM6 cells. Thus, AKBA 
appears to stimulate PLC activity rather than inhibiting it, ruling out PLC inhibition as 
primary mechanism of AKBA-induced [Ca
2+]i drops. 
The potential mode of action exerted by AKBA was investigated using pharmacological 
inhibitors of various Ca
2+-regulating systems of the plasma membrane. We observed that 
inhibitors of non-selective cation channels (LOE908, SKF96365) and SOCE channels (2-
APB, SKF96365), but not inhibitors of voltage-gated Ca
2+ channels or the Na
+-Ca
2+ 
exchanger, mimicked the effect of AKBA. 
Finally, we expanded this antagonism study to another read-out system, namely the 
activation of members of the MAPK family (ERKs, p38). AKBA antagonised both resting 
ERK activity and agonist (fMLP)-elevated ERK and p38 MAPK phosphorylation when 
MM6 cells were pre-exposed to AKBA for 5 min. Similar effects were recorded for U-
73122, whereas Aβ-BA was inactive. Collectively, AKBA is the most potent BA 
analogue, causing interference with primary signalling routes in human monocytic cells, 
visualised by reduced or suppressed Ca
2+ elevations as well as impaired MAPK activation 
elicited by pro-inflammatory stimuli. 
Personal contributions: All experimental work except for parts of Western Blotting 
experiments and Ca
2+ measurements, manuscript and figure preparation (~95% of total 
work). 
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Discussion: 
The activation of monocytes by pro-inflammatory stimuli occurs frequently at sites of 
infections or tissue injury. The bacterial tripeptide fMLP represents an exogenous agonist 
that acts on specific fMLP receptors on leukocytes, thereby causing cell activation 
connected to the synthesis of pro-inflammatory mediators as well as pathogen-directed 
ROS [10, 257]. However, in chronic inflammation, persistent presence of macrophages at 
inflamed sites may eventually result in destruction of surrounding healthy tissue, therefore 
pharmacological intervention of macrophage activation is reasonable. B. spec preparations 
have proved to be effective in the traditional treatment of chronic inflammatory disorders 
for centuries [258], but the molecular mechanism of BA action has not been resolved yet. 
Thus, this study was designed to address the effects of BAs on monocyte/macrophage 
physiology. The situation at a site of (chronic) inflammation experienced by monocytes 
was mimicked by the application of natural chemokines like fMLP and PAF. 
Our data show that AKBA rather than any other BA was effective in attenuating agonist-
induced Ca
2+ elevations as well as reducing basal [Ca
2+]i levels in resting MM6 cells. At 
the same time, AKBA interfered with MAPK activation, causing a reduction of activated 
(phosphorylated) ERK and p38 MAPK under pro-inflammatory conditions (stimulation 
with fMLP). Hence, pharmacological intervention with B. spec extracts targeting chronic 
inflammatory diseases might indeed (partly) rely on reduced monocyte activation, 
conferred by AKBA. Other potential mechanisms explaining the anti-inflammatory action 
of BAs have also been suggested. For instance, BAs were reported to down-regulate 
expression of the pro-inflammatory cytokine TNFα in activated human monocytes via 
inhibition of IKK [223]. Moreover, AKBA was shown to reduce expression of the 
transcription factor NF-κB in stimulated tumour cells, abrogating the expression of pro-
inflammatory and anti-apoptotic gene products [236]. All these studies add pieces of 
evidence that may ultimately allow to explain the anti-inflammatory effects of B. spec 
extracts in vivo. 
In our study, we also investigated the molecular basis of the antagonistic effects observed 
after AKBA treatment. Although initial results pointed toward PLC as principal target for 
AKBA, subsequent experiments excluded a central role for PLC in the mediation of 
AKBA effects. AKBA exerted a much more sustained attenuation of agonist-induced Ca
2+ 
mobilisation than U-73122, indicating different modulation of cellular physiology. It also 
antagonised the intracellular Ca
2+ release elicited by the SERCA inhibitor TG, which does 
not act via PLC. Lastly, by analysis of cellular IP3 levels in response to AKBA and/or U-
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turnover. Thus, we conclude that AKBA and U-73122 target different structures involved 
in the regulation of Ca
2+ homeostasis and MAPK activation. 
In attempts to elucidate the molecular mechanism of the AKBA-induced Ca
2+ depression, 
we applied various inhibitors of the machinery controlling cellular Ca
2+ homeostasis. In 
principle, enhanced Ca
2+ export or intracellular storage via Ca
2+-ATPases are possible 
mechanisms, otherwise attenuated influx via Ca
2+- or unspecific cation channels could be 
responsible for the observed effects [259, 260]. Our results indicate non-selective cation 
channels and/or SOCE channels probably modulated by AKBA in a direct or indirect 
fashion. We propose that AKBA might reduce the open probability of these channels, 
meanwhile Ca
2+ extrusion via ATPases is ongoing, leading in sum to a net export of Ca
2+ 
that was observed in our experiments. Evidently, more detailed studies will have to 
address this issue in the future. Summary 62 
5 Summary 
 
Traditional ayurvedic medicine in India, but also folk medicine in China and Africa has 
long included BAs in the therapy of inflammatory diseases. Besides phenomenological 
descriptions of the beneficial effects conferred by application of B. spec extracts 
(frankincense) in arthritis or joint diseases, clinical studies have addressed the question of 
efficacy of B. spec preparations in selected disease types. Today, only one approved 
medicine derived from B. serrata gum resin is available on the market (H15® Gufic), and 
the distribution is restricted to India and a part of Switzerland. Regardless of the restricted 
availability of B. spec medicine, there is growing demand for natural, well tolerable 
products with beneficial implications in certain inflammatory disorders. Consequently, 
medical researchers continue to evaluate the efficacy of various B. spec preparations (most 
trials are carried out using H15® Gufic) in animal studies or clinical trials. On the other 
hand, basic scientists are trying to identify the molecular mechanisms by which the effects 
of BAs, the main ingredients of B. spec extracts, are transduced. 
Promising results came from some clinical studies that demonstrated efficiency of B. spec 
preparations in the treatment of asthma, osteoarthritis, colitis ulcerosa and inflammatory 
bowel diseases. Apart from several inflammation-related disorders, a potential future 
indication for B. spec treatments are brain tumours, as implied by two approaches 
demonstrating efficacy in clinical trials. Up to now, clinical research has been carried out 
using B. spec extracts or mixtures of the main ingredients, the BAs. Molecular research, in 
contrast, is increasingly focusing on the effects of solitary BAs, thereby simplifying the 
experimental setup and allowing to draw verifiable conclusions regarding BA actions. 
Based on the hypothesis that BAs are the main active principles of B. spec extracts 
responsible for the pharmacological efficacy, the aim of these studies is to specify the 
mode of BA action on a molecular and cellular level. Eventually, elucidation of the 
mechanisms should help to better understand the phenomenological effects of B. spec 
preparations in vivo, and facilitate the development of novel drugs containing a defined 
composition of BA(s). 
Molecular targets for BAs have already been identified in several reports. Initially, 
abrogation of LT biosynthesis by neutrophils, presumably due to inhibition of the 
responsible enzyme 5-LO by AKBA, was suggested as responsible mechanism for the 
anti-inflammatory effects of B. spec. Although that hypothesis constituted an attractive 
model to explain B. spec actions, doubts could not be entirely smoothed out whether 5-LO 
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The scepticism was mainly due to high AKBA concentrations necessary to cause 
sufficient 5-LO inhibition in in vitro assays on the one hand, and to relatively low plasma 
levels determined for AKBA after ingestion of B. spec preparations on the other hand. 
Accordingly, researchers were prompted to search for additional mechanisms and targets 
that might provide more satisfying explanations concerning the mode of action of BAs. In 
fact, a number of additional molecular targets have been reported for BAs, such as 
topoisomerases, human leukocyte elastase, cytochrome p450 enzymes, or IκB kinase. 
Defining the interference of BAs with molecular targets in vitro is certainly important, but 
sole focusing on molecular interactions of BAs with putative binding partners ignores the 
fact that an interplay of several intra- and intercellular parameters in intact cells or tissues 
might form the basis of the eventual efficacy of BAs. Following this line, in the present 
work a more integrated approach using intact cells related to inflammation (PMNL, 
monocytes/macrophages, platelets) was pursued in order to evaluate the effects of BAs on 
the cellular physiology, including signalling pathways and functional cellular responses. 
Based on interesting findings made in this respect, we finally switched toward the 
characterisation of molecular interactions of BAs with some putative binding partners. 
Initial studies using AKBA and human PMNL in this group indeed revealed remarkable 
effects of AKBA on PMNL signalling events. Exposure of PMNL to BAs resulted in a 
prominent transient mobilisation of intracellular Ca
2+, comparable to that evoked by the 
chemotactic agent fMLP. Moreover, enhanced phosphorylation of the MAPK members 
p38 and ERK2 was stated, and signalling molecules involved in the activation pathway 
were defined (Ca
2+, PI-3 K). Structure-activity comparisons showed that AKBA was the 
most potent BA analogue, whereas 11-methylene-BAs were rather inactive. The finding of 
substantial activating properties exhibited by AKBA was however hardly compatible with 
the anti-inflammatory effects observed in disease treatment. Thus, the physiological 
significance of the reported results was unclear. 
This thesis was started with a project attempting to define the cellular effects of BAs on 
PMNL in more detail, and to relate the findings to cellular functional responses of PMNL. 
As demonstrated in paper I, we discovered a relation between the previously reported Ca
2+ 
mobilisation/MAPK activation and PMNL functional effects such as formation of ROS, 
release of AA, and biosynthesis of LTs. Upon exposure to AKBA, PMNL synthesised 
large amounts of ROS, which represent a pivotal unspecific host defence mechanism. 
Likewise, AKBA promoted the release of AA, a precursor for pro-inflammatory LTs as 
well as prostanoids. Elevated hydroperoxide levels, Ca
2+, and the availability of substrate 
(AA) generally determine 5-LO catalysis, resulting in the formation of LTs. Accordingly, Summary 64 
we observed that AKBA caused enhanced biosynthesis of 5-LO products. In conclusion, 
AKBA showed pro-inflammatory characteristics despite its anti-inflammatory effects in 
vivo that led to PMNL activation rather than inhibition. Comparable results were obtained 
with a granulocytic human leukaemia cell line (HL-60). In contrast, a B-lymphocytic and 
monocytic cell line did not respond to AKBA, emphasising specific cell type dependency 
of BA actions. 
Pharmacological inhibitors were employed to unravel critical determinants for the 
observed functional effects. We found that AKBA signals through a putative Gαi protein, 
Ca
2+ mobilisation, PI-3 K, and ERKs. Thus, we gained insight into the intracellular 
signalling machinery stimulated by AKBA, culminating in PMNL activation. 
Furthermore, we confirmed AKBA to be the most potent BA analogue, since BAs lacking 
the 11-keto group were virtually ineffective. 
PMNL are not the only type of leukocytes implicated in inflammatory processes, hence we 
switched to other haematopoietic cell types to assess the effects of BAs on cellular 
physiology. In papers II and III, we extensively examined how and by what means BAs 
affect signalling routes and functional responses of human platelets. This cell type was 
selected as a model system since platelets are involved in the onset of local inflammatory 
reactions after tissue injury and vessel wounding. Furthermore, platelets intimately interact 
with several leukocyte types, thereby modulating leukocyte activation via receptor-ligand 
interactions as well as via secretion of lipid mediators. The most striking discovery of our 
first platelet study was an inverse structure-activity relationship for 11-methylene-BAs and 
11-keto-BAs compared to previous results with PMNL. BAs lacking the 11-keto moiety 
(β-BA, Aβ-BA) were pronounced activators of platelets, displayed by robust transient 
Ca
2+ mobilisation, MAPK (p38, ERK) and Akt activation, AA release, thrombin 
generation and (moderate) aggregation. In this regard, the potency of β-BA (10-30 µM) 
often corresponded to that of the strong platelet agonists thrombin, collagen, and Ca
2+ 
ionophore A23187. 
β-BA also strongly stimulated the generation of the platelet-type 12-lipoxygenase (p12-
LO) product 12-H(P)ETE, a chemotactic factor for leukocytes. Notably, the 
concentrations for β-BA required to provoke these effects were in the range of achievable 
plasma levels in humans (10 µM), thus being of physiological relevance. 11-Keto-BAs 
were only weak activators of some platelet functions. The most intriguing difference 
between the 11-methylene-BA and 11-keto-BA effects was obvious in the modulation of 
p12-LO product formation. With increasing concentrations, 11-keto-BAs failed to 
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cause the release of AA. This effect, published in paper III, was due to direct inhibition of 
the p12-LO enzyme by AKBA. Two strategies confirmed this finding. First, in cell-free 
assays using cytosolic fractions of platelets as source for p12-LO, AKBA inhibited the 
substrate conversion by the enzyme. Second, in a protein pull-down assay using 
immobilised AKBA as bait, we selectively precipitated p12-LO from platelet lysates. The 
synthesis of immobilised BAs is documented in paper IV. 
It is of interest that the remarkable stimulation of platelet lipid signalling by β-BA was 
also found at conditions where virtually no other known agonist was active, that is, when 
Ca
2+ was missing. Along these lines, we state that all BAs cause the release of substantial 
amounts of AA, and β-BA induces slow but continuous p12-LO product accumulation in 
the absence of Ca
2+. Thus, with β-BA we identified a novel agonist for platelet lipid 
metabolism that acts independently of Ca
2+. 
In line with previous studies, we also focused on the elucidation of intracellular signalling 
events transducing the activating BA effects in human platelets. Under normal conditions 
where Ca
2+ was present, the observed effects clearly involved Src family kinases as 
putative signal transducers toward PLCγ, as well as PI-3 K and ERKs. None of these 
proteins however participated in the transduction of Ca
2+-independent β-BA effects. Thus, 
platelet activation by BAs is manifold, diverse, and characterised by the utilisation of 
several signalling routes. Nevertheless, our platelet studies summarise remarkable 
agonistic effects of BAs, especially of 11-methylene-BAs, on platelet physiology, whose 
consequences in physiological settings will have to be investigated in upcoming studies. 
The fact that BAs induced only selected functional responses in platelets, accompanied by 
the inhibition of p12-LO by AKBA, might indicate that exposure of platelets to BAs does 
not simply cause irreversible platelet activation. Rather, induction of specific effects may 
cause a kind of fine-tuning of the involved cells in the onset of an inflammatory response, 
presumably connected to the anti-inflammatory functionality of BAs by an as yet 
unrecognised mechanism. 
Turning focus to human monocytes, anti-inflammatory implications of BAs were 
apparent. In clinical trials and folk medicine, B. spec preparations were demonstrated to be 
efficient in chronic inflammatory disorders rather than in acute states of inflammation. 
Since monocytes (that differentiate into macrophages) are the primary type of leukocytes 
implicated in the maintenance of chronic inflammation, the necessity to address BA 
effects on monocyte/macrophage physiology was evident. 
The human monocytic cell line MM6 was chosen as experimental model because the 
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Nevertheless, the most important findings attained with MM6 cells were later confirmed 
with primary monocytes. In the course of that study (paper V), it became apparent that 
monocytes respond in a very distinct manner to BA treatment compared to PMNL or 
platelets. As reported before with PMNL, in MM6 cells AKBA was the most potent BA 
analogue, consistent with the fact that both cell types are leukocytes. However, Ca
2+ 
homeostasis of MM6 cells was downregulated after application of AKBA, visualised by 
depressed intracellular Ca
2+ levels of resting and agonist-treated cells as well as by 
attenuation of agonist-induced Ca
2+ transients after pre-exposure to AKBA. The 
suppressive effect on Ca
2+ mobilisation by AKBA was long-lasting, and BAs lacking the 
11-keto-moiety were virtually ineffective. Similar attenuating effects were found when 
MAPK phosphorylation levels were assessed after stimulation with the chemotactic 
agonist fMLP. 
In that study, also the molecular basis of the antagonistic effects of AKBA was 
investigated. In contrast to initial assumptions, PLC inhibition was not the responsible 
mechanism, since AKBA even enhanced PIP2 turnover. The responses to AKBA were 
always compared to those of the PLC inhibitor U-73122, and U-73122 strongly 
suppressed PLC activity although both agents (AKBA, U-73122) showed comparable 
effects on intracellular Ca
2+ levels. Based on inhibitor experiments, several regulators of 
cellular ion homeostasis were assayed for a putative role in the transduction of AKBA 
effects. We identified two regulators of Ca
2+ influx, non-selective cation channels as well 
as the SOCE channel system, as likely targets for the action of AKBA. Partial inhibition of 
these channels would then result in a net efflux of intracellular Ca
2+ due to continuous 
activity of extrusion pumps. 
Collectively, we report that AKBA exerts a form of ‘silencing’ effect on monocyte 
physiology, resulting in attenuation of cellular activation elicited by pro-inflammatory 
external stimuli. This interference occurs at the stage of crucial signalling parameters 
within the cell, namely Ca
2+ mobilisation and MAPK activation. As a consequence, 
monocyte activation might be impaired when these cells are exposed to AKBA under 
physiological conditions in the plasma and tissues; hence, the effects described in this 
paper might provide a mechanistic basis underlying the well-known anti-inflammatory 
features of AKBA. 
 
In conclusion, the work included in this thesis yielded substantial additional information to 
the growing knowledge of the cellular effects exerted by BAs, with particular focus on 
three cell types involved in inflammation and injury (PMNL, monocytes, platelets). Now, Summary 67 
we have gained a more differentiated perception of the intracellular signalling events as 
well as the functional responses activated in leukocytes and platelets, the pivotal 
regulators of inflammation. It has to be noted that the physiological significance of the 
reported findings is not always evident, but at least in case of the platelet and the 
monocyte studies, results were obtained at BA concentrations that can be accomplished in 
vivo. Besides description of cellular effects, target identification for BAs was an intended 
aim of the investigations. In the course of this thesis, p12-LO was discovered as novel 
target for 11-keto-BAs, but certainly more targets will be identified in future studies. A 
useful tool for selective fishing of binding partners will be the immobilised BA construct 
described in paper IV. Broad scientific interest for BAs and B. spec effects has grown 
within the recent years, as reflected by the increasing number of scientific studies in 
renowned journals, so exciting novel insights into molecular, cellular and clinical BA 
effects are likely to come up in the near future. Zusammenfassung 68 
6 Zusammenfassung 
 
Die traditionelle ayurvedische Medizin in Indien, aber auch die Naturmedizin in China 
und Afrika stützt sich hinsichtlich der Behandlung entzündlicher Erkrankungen seit langer 
Zeit auf Boswelliasäuren (BAs). Neben empirischen Beschreibungen der positiven 
Effekte, die durch Anwendung von B. spec-Extrakten (Weihrauch) bei Arthritis oder 
Gelenkerkrankungen erhalten werden konnten, wurden auch in klinischen Studien die 
Wirksamkeit von B. spec-Präparationen auf verschiedene Krankheitsformen untersucht. 
Heutzutage ist jedoch nur ein (regional) zugelassenes Präparat auf dem Markt erhältlich 
(H15® Gufic), welches aus B. serrata-Rohharz hergestellt wird. Der Vertrieb beschränkt 
sich auf Indien und einen Teil der Schweiz. Ungeachtet der geringen Verfügbarkeit von 
Weihrauchprodukten gibt es jedoch eine wachsende Nachfrage nach pflanzlichen, gut 
verträglichen Medikamenten zur Behandlung entzündlicher Krankheiten. Um die 
Wirksamkeit von BAs zu belegen, werden weiterhin verschiedenste 
Weihrauchpräparationen (im Regelfall H15® Gufic) in Tierexperimenten oder klinischen 
Studien getestet. Parallel dazu arbeiten Grundlagenforscher an der Aufklärung der 
molekularen Mechanismen, welche den Wirkungen von BAs, den Hauptinhaltsstoffen von 
Weihrauchextrakten, zugrunde liegen. 
Vielversprechende Ergebnisse lieferten einige klinische Studien, welche die Wirksamkeit 
von  B. spec-Präparationen in der Behandlung von Asthma, Osteoarthritis, Colitis 
Ulcerosa, und entzündlichen Darmerkrankungen untersuchten. Neben 
Entzündungsprozessen stellen Gehirntumore eine potentielle Indikation für die 
Behandlung mit Boswelliaextrakten dar. Dies wird durch zwei klinische Studien nahe 
gelegt. Bis heute wurden solche klinischen Untersuchungen hauptsächlich mit 
Weihrauchextrakten oder Mischungen aus den Hauptinhaltsstoffen, den BAs, 
durchgeführt. Die molekulare Forschung konzentriert sich hingegen auf die Analyse der 
Effekte von reinen BAs, wodurch experimentelle Ansätze vereinfacht und nachprüfbare 
Schlussfolgerungen ermöglicht werden. Auf Grundlage der Hypothese, dass BAs die 
pharmakologisch relevanten Inhaltsstoffe von Weihrauchextrakten sind, haben 
wissenschaftliche Studien die Ermittlung des Wirkmechanismus von BAs auf molekularer 
und zellulärer Ebene zum Ziel. Auf lange Sicht sollte die Aufklärung der zugrunde 
liegenden Mechanismen das Verständnis für die nutzbringenden Effekte von 
Weihrauchpräparaten  in vivo erleichtern und die Entwicklung neuer Medikamente mit 
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In einigen Publikationen wurden bereits molekulare Targets von BAs beschrieben. 
Ursprünglich war die Hemmung der LT-Biosynthese in Neutrophilen, vermutlich über 
eine AKBA-vermittelte Inhibition des verantwortlichen Enzyms (5-LO), als 
verantwortlicher Mechanismus für die anti-entzündlichen Effekte von Weihrauch 
vorgeschlagen worden. Damit war ein attraktives Modell geschaffen worden, das die 
Effekte von B. spec erklären konnte. Allerdings kamen bald Zweifel auf, ob die 
beobachteten Effekte allein durch eine 5-LO-Hemmung begründet werden können. Die 
Zweifel basierten unter anderem auf den hohen AKBA-Konzentrationen, die in in vitro-
Studien notwendig waren, um ausreichende 5-LO-Hemmung zu erzielen, sowie den relativ 
niedrigen gemessenen Plasmakonzentrationen für AKBA nach Einnahme von 
Weihrauchmedikation. Aus diesem Grund haben Forscher kontinuierlich nach weiteren 
Mechanismen und Targets gesucht, welche die Wirkungen von BAs hinreichender 
erklären können. Infolgedessen wurde eine Anzahl zusätzlicher molekularer Targets für 
BAs identifiziert, darunter Topoisomerasen, humane Leukozyten-Elastase, CYP-Enzyme, 
oder die IκB Kinase. 
Die Charakterisierung der Wechselwirkung von BAs mit molekularen Zielstrukturen in in 
vitro-Ansätzen ist zweifellos wichtig, jedoch lässt die Beschränkung auf molekulare 
Interaktionen von BAs mit potenziellen Bindungspartnern die Tatsache außer Acht, dass 
das Wechselspiel vielerlei intra- und interzellulärer Parameter in intakten Zellen und 
Geweben wesentlich zum Wirkmechanismus von BAs beitragen könnte. Basierend auf 
dieser Hypothese wurde in der vorliegenden Arbeit ein eher „ganzheitlicher“ Ansatz 
verfolgt und intakte Zellen als Modellsystem benutzt, die in Enzündungsprozessen 
beteiligt sind (PMNL, Monozyten/Makrophagen, Thrombozyten), und die Effekte von 
BAs auf die zelluläre Physiologie inklusive Signalkaskaden und funktionellen Antworten 
hin untersucht. Auf der Grundlage der erhaltenen Ergebnisse wurde im letzten Teil dieser 
Arbeit die Charakterisierung molekularer Wechselwirkungen von BAs mit einigen 
möglichen Bindungspartnern eingehender beleuchtet. 
Anfängliche Studien mit AKBA und humanen PMNL in dieser Arbeitsgruppe zeigten in 
der Tat bemerkenswerte Auswirkungen von AKBA auf die Signalwege in PMNL. Die 
Zugabe von AKBA verursachte unter anderem eine prominente transiente Mobilisierung 
von intrazellulärem Ca
2+, vergleichbar mit der Wirkung des chemotaktischen Liganden 
fMLP. Weiterhin konnte eine verstärkte Phosphorylierung der MAPK p38 und ERK2 
festgestellt werden, und eine Definierung der beteiligten Signalwegsmoleküle (Ca
2+, PI-3 
K) wurde versucht. Struktur-Wirkungs-Beziehungen ergaben, dass AKBA die potenteste 
BA darstellte, wohingegen 11-Methylen-BAs eher inaktiv waren. Die Entdeckung Zusammenfassung 70 
substanzieller aktivierender Eigenschaften durch AKBA stand jedoch im Widerspruch zu 
den beoachteten anti-entzündlichen Wirkungen in der Behandlung von Krankheiten, und 
die physiologische Bedeutung der berichteten Ergebnisse blieb zunächst unklar. 
Die vorliegende Arbeit wurde daher mit einem Projekt begonnen, welches die zellulären 
Effekte von BAs in PMNL im Detail analysieren sowie einen Bezug zu funktionellen 
Antworten von PMNL herstellen sollte. Wie in Paper I gezeigt wird, konnte eine 
Verbindung zwischen den zuvor berichteten Effekten bezüglich Ca
2+-
Mobilisierung/MAPK-Aktivierung und funktionellen Antworten wie ROS-Bildung, 
Arachidonsäure (AA)-Freisetzung, und LT-Biosynthese hergestellt werden. Nach Zugabe 
von AKBA bildeten PMNL große Mengen an Sauerstoffradikalen, welche einen primären 
Abwehrmechanismus der unspezifischen Immunabwehr darstellen. In gleichem Maße 
bewirkte AKBA eine Freisetzung von AA, den Vorläufer entzündungsfördernder LT 
sowie Prostanoide. Erhöhte Hydroperoxid-Konzentrationen, Ca
2+, und die Verfügbarkeit 
von Substrat (AA) stimulieren allgemein die 5-LO-Katalyse mit dem Ergebnis der 
Bildung von LT. Dementsprechend konnte eine verstärkte Biosynthese von 5-LO-
Produkten beobachtet werden. Insgesamt zeigte AKBA trotz seiner 
entzündungshemmenden Effekte in der Medizin hier pro-entzündliche Eigenschaften, 
welche eher eine PMNL-Aktivierung als eine Hemmung bewirkten. Vergleichbare 
Ergebnisse wurden bei Verwendung der granulozytären humanen Leukämie-Zelllinie HL-
60 erhalten. Im Gegensatz dazu reagierten eine B-lymphozytäre und eine monozytäre 
Zelllinie nicht auf AKBA, was die spezifischen zelltyp-abhängigen Effekte von BAs 
verdeutlicht. 
Mit Hilfe von pharmakologischen Inhibitoren wurden beteiligte Signalmoleküle der 
beobachteten Zellantworten ermittelt. Es zeigte sich, dass in der durch AKBA 
eingeleiteten Signaltransduktion ein putatives Gαi Protein, Ca
2+-Mobilisierung, PI-3 K und 
in den meisten Fällen auch ERKs beteiligt sind. Auf diesem Wege erhielten wir Einblicke 
in das intrazelluläre Signaltransduktions-Netzwerk, welches durch AKBA stimuliert wird. 
Weiterhin wurde AKBA als potenteste BA bestätigt, da BAs ohne 11-Keto-Gruppe 
praktisch inaktiv waren. 
In Entzündungsprozessen spielen nicht nur PMNL eine wichtige Rolle, daher befassten 
wir uns ebenso mit anderen hämatopoetischen Zelltypen, um die Einflüsse von BAs auf 
die zelluläre Physiologie zu beleuchten. Die Publikationen II und III enthalten eine 
umfassende Untersuchung über die Art und Weise, wie BAs die Signalwege und 
funktionellen Zellantworten in humanen Thrombozyten beeinflussen. Dieser Zelltyp 
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entzündlichen Reaktion nach Verletzung von Gewebe oder Blutgefäßen eine wichtige 
Rolle spielen. Darüberhinaus interagieren Plättchen sehr eng mit mehreren 
Leukozytenarten und modulieren die Leukozytenaktivierung über Rezeptor-Ligand-
Wechselwirkungen sowie anhand der Sekretion von Lipidmediatoren. Das 
bemerkenswerteste Ergebnis unserer ersten Thrombozytenstudie war die umgekehrte 
Struktur-Wirkungs-Beziehung für 11-Keto-BAs und 11-Methylen-BAs im Vergleich zu 
früheren Berichten. BAs ohne 11-Keto-Gruppe (β-BA, Aβ-BA) waren ausgeprägte 
Aktivatoren der Plättchenphysiologie, erkennbar an einer starken Ca
2+-Mobilisierung, 
MAPK (p38, ERK) und Akt-Aktivierung, AA-Freisetzung, Thrombin-Generierung und 
(moderaten) Aggregation. In dieser Hinsicht entsprach die Wirksamkeit von β-BA (10-30 
µM) zumeist der Potenz der starken Plättchen-Stimuli Thrombin, Kollagen und Ca
2+-
Ionophor A23187. 
β-BA stimulierte außerdem die Bildung des p12-LO-Produkts 12-H(P)ETE, eines 
chemotaktischen Faktors für Leukozyten. Interessanterweise waren Konzentrationen um 
10 µM, die im Bereich der physiologisch erreichbaren Plasmaspiegel im Menschen liegen, 
bereits ausreichend, um die beschriebenen Effekte von β-BA auszulösen. 11-Keto-BAs 
stellten sich im Unterschied zu PMNL als nur schwache Aktivatoren einiger zellulärer 
Funktionen dar. Der auffälligste Unterschied zwischen 11-Methylen- und 11-Keto-BAs 
wurde in Bezug auf die p12-LO-Produktspiegel deutlich. Mit zunehmenden BA-
Konzentrationen stimulierten 11-Keto-BAs die p12-LO nur bis zu einer gewissen Grenze, 
obwohl sie gleichzeitig zu einer verstärkten AA-Freisetzung führen. Dieser Effekt 
(veröffentlicht in Paper III) wird auf die direkte Hemmung des p12-LO-Enzyms durch 
AKBA zurückgeführt. Zwei Strategien konnten dieses Ergebnis belegen. Erstens, im 
zellfreien System, unter Verwendung von zytosolischen Fraktionen aus Blutplättchen als 
p12-LO-Quelle, hemmte AKBA die Substratumwandlung durch das Enzym. Zweitens 
konnte p12-LO in einem Pulldown-Verfahren, welches immobilisierte KBA als Anker 
nutzte, selektiv aus Plättchen-Lysaten präzipitiert werden. Die Synthese der 
immobilisierten BAs ist in Paper IV beschrieben. 
Hervorzuheben ist, dass der bemerkenswerte Agonismus von β-BA auf das Lipid-
Signalling in Plättchen auch unter Bedingungen gefunden wurde, bei denen kein anderer 
bekannter Stimulus wirksam ist, nämlich dann, wenn Ca
2+ fehlt. Unter diesen 
Messbedingungen wurde die Freisetzung beträchtlicher Mengen an AA durch alle BAs 
registriert, und β-BA induzierte zudem eine langsame, aber kontinuierliche Bildung von 
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Lipidmetabolismus in Blutplättchen identifiziert wurde, welcher unabhängig von Ca
2+ 
wirkt. 
In Analogie zu vorhergehenden Studien wurden auch in Plättchen die intrazellulären 
Signaltransduktions-Ereignisse untersucht, welche den aktivierenden Effekten von BAs 
zugrunde liegen. Unter normalen Bedingungen, wenn Ca
2+ zugegen ist, sind Src Kinasen, 
PI-3 K und ERKs an der PLCγ-Aktivierung beteiligt. Keines dieser Proteine war indessen 
in die Vermittlung der Ca
2+-unabhängigen Effekte von β-BA involviert. Somit kann die 
Thrombozyten-Aktivierung durch BAs als vielfältig beschrieben und durch die 
Verwendung mehrerer Signalwege gut charakterisiert werden. Weiterhin fasst unsere 
Studie auffällige agonistische Effekte von BAs, speziell von 11-Methylen-BAs, auf die 
Plättchenphysiologie zusammen, deren Konsequenzen im physiologischen System im 
Rahmen von zukünftigen Studien erforscht werden sollen. Die Tatsache, dass BAs nur 
bestimmte funktionelle Antworten in Plättchen induzieren (unter Berücksichtigung der 
p12-LO-Hemmung durch AKBA), deutet darauf hin, dass Zugabe von BAs zu 
Thrombozyten nicht nur schlicht eine irreversible Aktivierung der Zellen bewirkt. Im 
Gegenteil, die Induktion selektiver Effekte könnte eine Art Feinregulierung der beteiligten 
Zellen zu Beginn einer Entzündungsreaktion verursachen, die mit der anti-entzündlichen 
Funktionalität der BAs über noch ungeklärte Mechanismen in Zusammenhang stehen 
könnte. 
In Experimenten mit Monozyten waren mögliche entzündungshemmende Wirkungen von 
BAs leichter einsichtig. In klinischen Studien und der Naturmedizin hatten B. spec-
Präparationen ihre Wirksamkeit eher in chronischen als in akuten entzündlichen 
Zuständen gezeigt. Da Monozyten (die zu Makrophagen differenzieren können) die 
primäre Leukozytenart in der Aufrechterhaltung chronisch entzündlicher Zustände ist, 
liegt die Notwendigkeit einer Auseinandersetzung mit den BA-Effekten auf die 
Monozyten/Makrophagen-Physiologie auf der Hand. 
Die humane Monozyten-Zelllinie MM6 wurde als experimentelles Modellsystem 
ausgewählt, da die Aufreinigung von primären Monozyten aus Blutproben aufwendig und 
schwierig ist. Dennoch wurden primäre Monozyten später zur Bestätigung der wichtigsten 
Erkenntnisse eingesetzt. Im Zuge dieser Studie (Paper V) wurde offenbar, dass 
Monozyten, verglichen mit PMNL oder Thrombozyten, in sehr verschiedener Weise auf 
BA-Behandlung reagieren. Wie zuvor in PMNL stellte AKBA die potenteste BA dar, was 
damit in Einklang steht, dass beide Zellarten Leukozyten sind. Dennoch wurde die Ca
2+-
Homöostase in MM6 Zellen nach Behandlung mit AKBA herunterreguliert. Dies spiegelte 
sich in erniedrigten [Ca
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durch die Abschwächung agonist-induzierter Ca
2+-Erhöhungen nach vorheriger AKBA-
Zugabe wider. Der unterdrückende Effekt auf die Ca
2+-Mobilisierung durch AKBA war 
langanhaltend, und BAs ohne 11-Keto-Gruppe waren praktisch unwirksam. Ähnliche 
abschwächende Effekte wurden hinsichtlich der MAPK Phosphorylierungs-Spiegel nach 
Stimulation mit dem chemotaktischen Agonisten fMLP beobachtet. 
In dieser Studie wurde weiterhin die molekulare Basis der antagonistischen AKBA-
Effekte erkundet. Im Gegensatz zur anfänglichen Vermutung war eine Hemmung der PLC 
nicht der verantwortliche Mechanismus, da AKBA die PIP2-Umwandlung sogar erhöhte. 
Die zellulären Antworten auf AKBA wurden jeweils mit denen des PLC-Inhibitors U-
73122 verglichen, und U-73122 blockierte erwartungsgemäß die PLC-Aktivität, obwohl 
beide Agonisten (AKBA, U-73122) vergleichbare Effekte auf die intrazellulären Ca
2+-
Spiegel hatten. Mittels Inhibitorexperimenten wurden mehrere Schaltstellen der zellulären 
Ca
2+-Homöostase auf eine Mitwirkung an den durch AKBA ausgelösten Effekten hin 
untersucht. Wir konnten dabei zwei Regulatoren des Ca
2+-Einstroms als wahrscheinliche 
Targets für AKBA-Wirkungen identifizieren, nämlich sowohl nicht-selektive Kationen-
Kanäle als auch SOCE Kanäle. Eine teilweise Hemmung dieser Kanäle würde dann in 
einem Netto-Ausstrom von intrazellulärem Ca
2+ bei gleichzeitiger kontinuierlicher 
Aktivität der Extrusions-Pumpen resultieren. 
Zusammenfassend dokumentiert Paper V somit eine Anzahl ‚supprimierender’ Effekte 
von AKBA auf die Monozyten-Physiologie, die sich in einer Abschwächung der 
zellulären Aktivierung durch pro-entzündliche Stimuli ausdrückt. Diese Interferenz findet 
auf der Ebene wichtiger Signaltransduktionswege innerhalb der Zelle statt, der Regulation 
des Ca
2+-Spiegels sowie der MAPK-Aktivierung. Demzufolge wird die Monozyten-
Aktivierung verhindert, wenn die Zellen in Plasma oder Gewebe AKBA ausgesetzt waren. 
Damit können die hier vorgestellten Effekte eine Basis für die bekannten anti-
entzündlichen Eigenschaften von AKBA sein. 
 
Als Fazit kann festgestellt werden, dass die vorliegende Arbeit wesentliche neue 
Informationen zum wachsenden Kenntnisstand über die zellulären Effekte von BAs 
beiträgt, mit besonderem Augenmerk auf drei im Entzündungsgeschehen und bei 
Verletzungen beteiligte Zellarten (PMNL, Monozyten, Thrombozyten). Infolgedessen sind 
wir zu einer differenzierteren Wahrnehmung sowohl der Einflüsse auf intrazelluläre 
Signaltransduktionswege als auch der funktionellen Zellantworten von Leukozyten und 
Blutplättchen gelangt. Zwar ist die physiologische Bedeutung der vorgestellten Befunde 
nicht immer auf Anhieb offensichtlich, jedoch wurden unsere Ergebnisse zumindest im Zusammenfassung 74 
Falle der Thrombozyten- und Monozyten-Studien mit BA-Konzentrationen erzielt, die in 
vivo erreichbar sind. Neben der Beschreibung von zellulären Effekten stellte auch die 
Targetidentifizierung von BAs ein erklärtes Ziel der Untersuchungen dar. Im Zuge der 
Arbeit wurde daher p12-LO als neues Target von 11-Keto-BAs entdeckt. Sicherlich wird 
es zukünftig zur Identifikation weiterer Targets kommen, beispielsweise mittels 
selektivem „Fischen“ nach Bindungspartnern auf der Grundlage immobilisierter BAs 
(Konstrukt vorgestellt in Paper IV). 
Das breite wissenschaftliche Interesse an BAs und B. spec-Effekten hat innerhalb der 
letzten Jahre zugenommen, was sich in der steigenden Zahl wissenschaftlicher Studien in 
renommierten Fachzeitschriften widerspiegelt. So ist in absehbarer Zeit mit weiteren 
interessanten Einblicken in die molekularen, zellulären und klinischen Effekte von BAs zu 
rechnen. References 75 
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 Paper I Coupling of boswellic acid-induced Ca
2þ mobilisation and MAPK
activation to lipid metabolism and peroxide formation in human
leucocytes
1Anja Altmann,
1Daniel Poeckel,
1Lutz Fischer,
1Manfred Schubert-Zsilavecz,
1Dieter Steinhilber
&*
,1Oliver Werz
1Institute of Pharmaceutical Chemistry, University of Frankfurt, Marie-Curie Strasse 9, Frankfurt D-60439, Germany
1 We have previously shown that 11-keto boswellic acids (11-keto-BAs), the active principles of
Boswellia serrata gum resins, activate p38 MAPK and p42/44
MAPK and stimulate Ca
2þ mobilisation in
human polymorphonuclear leucocytes (PMNL).
2 In this study, we attempted to connect the activation of MAPK and mobilisation of Ca
2þ to
functional responses of PMNL, including the formation of reactive oxygen species (ROS), release of
arachidonic acid (AA), and leukotriene (LT) biosynthesis.
3 We found that, in PMNL, 11-keto-BAs stimulate the formation of ROS and cause release of AA as
well as its transformation to LTs via 5-lipoxygenase.
4 Based on inhibitor studies, 11-keto-BA-induced ROS formation is Ca
2þ-dependent and is
mediated by NADPH oxidase involving PI 3-K and p42/44
MAPK signalling pathways. Also, the release
of AA depends on Ca
2þ and p42/44
MAPK, whereas the pathways stimulating 5-LO are not readily
apparent.
5 Pertussis toxin, which inactivates Gi/0 protein subunits, prevents MAPK activation and Ca
2þ
mobilisation induced by 11-keto-BAs, implying the involvement of a Gi/0 protein in BA signalling.
6 Expanding studies on differentiated haematopoietic cell lines (HL60, Mono Mac 6, BL41-E-95-A)
demonstrate that the ability of BAs to activate MAPK and to mobilise Ca
2þ may depend on the cell
type or the differentiation status.
7 In summary, we conclude that BAs act via Gi/0 protein(s) stimulating signalling pathways that
control functional leucocyte responses, in a similar way as chemoattractants, that is, N-formyl-
methionyl-leucyl-phenylalanine or platelet-activating factor.
British Journal of Pharmacology (2004) 141, 223–232. doi:10.1038/sj.bjp.0705604
Keywords: Boswellic acids; leucocytes; MAPK; Ca
2þ; reactive oxygen species; lipoxygenase; arachidonic acid
Abbreviations: AA, arachidonic acid; AB, antibody; A-b-BA, 3-O-acetyl-b-boswellic acid; AKBA, 3-O-acetyl-11-keto-b-
boswellic acid; b-BA, b-boswellic acid; cPLA2, cytosolic phospholipase A2; DCF-DA, 20,70-dichlorofluorescein
diacetate; DPI, diphenyleneiodonium chloride; fMLP, N-formyl-methionyl-leucyl-phenylalanine; GPCR, G
protein-coupled receptor; KBA, 11-keto-b-boswellic acid; 5-LO, 5-lipoxygenase; LT, leukotriene; MAPK,
mitogen-activated protein kinase; PAF, platelet-activating factor; PBS, phosphate-buffered saline; PG buffer, PBS
pH 7.4containing 1mgml
 1 glucose; PGC buffer, PBS containing 1mgml
 1 glucose and 1mM CaCl2; PI 3-K,
phosphatidylinositol 3-kinase; PKC, protein kinase C; PMA, phorbol myristate acetate; PMNL, polymorpho-
nuclear leucocytes; PTX, pertussis toxin; ROS, reactive oxygen species; SDS-b, 2 SDS–PAGE sample-loading
buffer; TGFb, transforming growth factor b; WB, Western blotting
Introduction
Extracts of Boswellia serrata gum resins have been tradition-
ally used as folk medicine to cure inflammatory and arthritic
diseases (Safayhi & Sailer, 1997). It was found that B. serrata
extracts suppress the formation of proinflammatory leuko-
trienes (LTs), and boswellic acids (BAs) were identified as the
active principles targeting 5-lipoxygenase (5-LO), the key
enzyme in LT biosynthesis (Safayhi et al., 1992; 1995). In
addition, human leucocyte elastase was found to be a target for
BAs (Safayhi et al., 1997). Aside of these anti-inflammatory
implications, BAs have been reported to influence the growth
and differentiation of tumour cells. Thus, B. serrata extracts or
isolated BAs induce the apoptosis of brain tumour cell lines
(Glaser et al., 1999), meningioma cells (Park et al., 2002), rat
gliomas (Winking et al., 2000), liver and colon cancer cell lines
(Liu et al., 2002a), and also of leukaemic cells (Hoernlein et al.,
1999). Caspase-8 (Liu et al., 2002a), topoisomerases (Hoern-
lein et al., 1999), and the p42/44
MAPK pathway (Park et al.,
2002) have been suggested as signalling molecules mediating
the apoptotic effects of BAs.
With respect to inhibition of 5-LO, 3-acetyl-11-keto-BA
(AKBA) was the most potent BA, whereas BAs lacking an 11-
keto-group were weak 5-LO inhibitors (Safayhi et al., 1992).
*Author for correspondence;
E-mail: o.werz@pharmchem.uni-frankfurt.de
Advance online publication: 22 December 2003
British Journal of Pharmacology (2004) 141, 223–232 & 2004 Nature Publishing Group All rights reserved 0007–1188/04 $25.00
www.nature.com/bjpThe IC50 values of AKBA for inhibition of 5-LO differ
between different groups and appear to depend also on the cell
type. Thus, the IC50 values were determined in the range of
1.5mM for 5-LO in rat neutrophils (Safayhi et al., 1992) and
12–15mM in differentiated HL60 and MM6 cells, respectively
(Werz et al., 1997). In cell-free systems, the IC50 values of
AKBA for 5-LO inhibition were around 50mM, implying that,
in intact cells, cellular components or mechanisms improve the
efficacy of AKBA (Werz et al., 1997). Finally, low concentra-
tions of ethanolic extracts of B. serrata potentiated 5-LO
product formation in PMNL induced by ionophore (Safayhi
et al., 2000), and 3-oxo-tirucallic acid, isolated from B. serrata
extracts, stimulated 5-LO product synthesis in resting and
agonist-challenged PMNL (Boden et al., 2001). Therefore,
until today, inhibition of 5-LO as the main principle for the
anti-inflammatory effects of B. serrata extracts, determined in
several in vivo models (Gupta et al., 1992; Krieglstein et al.,
2001) and pilot clinical studies (Gerhardt et al., 2001; Gupta
et al., 2001), remains a matter of debate.
Chemotactic agonists, such as platelet-activating factor
(PAF), N-formyl-methionyl-leucyl-phenylalanine (fMLP), or
LTB4, bind to their specific G protein-coupled receptors
(GPCR), leading to the activation of MAPK and the
mobilisation of Ca
2þ, which are pivotal signalling molecules
that regulate a number of functional processes of PMNL,
including chemotaxis, degranulation, formation of reactive
oxygen species (ROS), release of arachidonic acid (AA), and
LT biosynthesis (Herlaar & Brown, 1999; Belcheva & Coscia,
2002; Johnson & Druey, 2002). Recently, we showed that 11-
keto-BAs (AKBA, KBA, in the range of 10–30mM) are potent
activators of p42
MAPK and p38 MAPK, and stimulate Ca
2þ
mobilisation in PMNL (Altmann et al., 2002). Comparison of
these actions of BAs with those of chemotactic agonists led us
to conclude that BAs may possibly function as ligands of a
certain GPCR. In this study, we investigated if BAs are able to
induce the functional cellular responses in PMNL and if a Gi/0-
coupled heterotrimeric G protein mediates BA-induced
MAPK/Ca
2þ signalling. Finally, we demonstrate that BAs
induce signalling responses depending on the cell type.
Methods
Materials
A-b-BA, b-BA, AKBA, and KBA were purchased from
ChromaDex (Laguna Hills, CA, U.S.A.). Nycoprep was from
PAA Laboratories (Linz, Austria); diphenyleneiodonium
chloride (DPI), phorbol 12-myristate 13-acetate (PMA),
Ca
2þ-ionophore A23187, and fMLP were from Sigma
Chemical Co. (Deisenhofen, Germany); BAPTA/AM, LY-
294002, SB203580, U0126, and Fura-2/AM were from
Calbiochem (Bad Soden, Germany); RO-31-8425 was from
Alexis (Gru ¨ nberg, Germany); 20,70-dichlorofluorescein diace-
tate (DCF-DA) and lucigenin were from Molecular Probes
European BV (Leiden, Netherlands); and wortmannin from
Biotrend (Colonia, Germany). RPMI-1640 medium was from
Gibco-BRL (Grand Island, NY, U.S.A.), and fetal calf serum
was obtained from Boehringer Mannheim (Mannheim,
Germany). Human TGF-b1 was purified from outdated
platelets, as described (Werz et al., 1996). Calcitriol was kindly
provided by Dr H. Wiesinger (Schering AG). [
3H]AA was from
Biotrend (Colonia, Germany); and high-performance liquid
chromatography (HPLC) solvents were from Merck (Darm-
stadt, Germany).
Cells
Human PMNL were freshly isolated from leucocyte concen-
trates obtained at St Markus Hospital (Frankfurt, Germany).
In brief, venous blood was taken from healthy adult donors
and subjected to centrifugation for the preparation of
leucocyte concentrates. PMNL were immediately isolated by
dextran sedimentation, centrifugation on Nycoprep cushions,
and hypotonic lysis of erythrocytes, as described (Werz et al.,
2002a). PMNL were finally resuspended in PBS plus 1mgml
 1
glucose (PG buffer), or alternatively in PBS plus 1mgml
 1
glucose and 1mM CaCl2 (PGC buffer), as indicated.
HL60 cells were maintained in RPMI 1640 medium
supplemented with 10% fetal calf serum, 100mgml
 1 strepto-
mycin, and 100Uml
 1 penicillin. For differentiation towards
granulocytic cells, cells were seeded at a density of 2 10
5
cellsml
 1 and cultured in the presence of 1.5% (vv
 1)
dimethylsulphoxide, 500pM calcitriol, and 2ngml
 1 TGFb
for 4days.
Mono Mac (MM) 6 cells were cultured and differentiated
with TGFb and calcitriol, as described (Werz et al., 1996).
Determination of release of [
3H]-labelled AA from
PMNL
Freshly isolated PMNL were resuspended at 2 10
6 in 1ml
RPMI 1640 medium containing 4.8nM[
3H]AA (corresponding
to 0.25mCiml
 1, specific activity 200Cimmol
 1) and incu-
bated for 120min at 371Ci n5 %C O 2 atmosphere. Thereafter,
the cells were collected by centrifugation, washed once with
PBS and twice with PBS containing 2mgml
 1 fatty acid-free
albumin, to remove unincorporated [
3H]AA. Labelled PMNL
(5 10
6) were resuspended in 1ml PGC buffer containing
2mgml
 1 fatty acid-free albumin. The reaction was started by
addition of the indicated stimuli. After 5min at 371C, the
samples were placed on ice for 2min and cells were centrifuged
at 400 g for 5min at RT. Aliquots (100ml) of the super-
natants were measured in a beta-counter (Micro Beta Trilux,
Perkin Elmer, Foster City, CA, U.S.A.) to detect the amounts
of [
3H]-labelled AA released into the medium.
Determination of cellular peroxide formation
Measurement of peroxides was conducted using the peroxide-
sensitive fluorescence dye DCF-DA. Freshly isolated PMNL
(1 10
7), HL 60 cells (1 10
7), or MM6 cells (5 10
6) were
resuspended in 1ml PGC buffer and preincubated with DCF-
DA (1mgml
 1 for PMNL and MM6; 10mgml
 1 for HL 60
cells) for 2min at 371C in a thermally controlled (371C)
fluorimeter cuvette in a spectrofluorometer (Aminco-Bowman
series 2, Thermo Spectronic, Rochester, NY, U.S.A.) with
continuous stirring. The fluorescence emission at 530nm was
measured after excitation at 485nm. The mean fluorescence
data measured 5min after stimulus addition are given as
arbitrary units.
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Freshly isolated PMNL (2 10
5) were resuspended in 200mlo f
100mM NaCl, 5mM KCl, 25mM NaHCO3,2 0 m M HEPES,
pH 7.4, and transferred to a 96-well plate. Lucigenin (25mM,
final concentration) and 1mM CaCl2 were added and cells were
stimulated with the indicated stimuli. After stirring, samples
were measured in duplicates at 371C. The chemiluminescence
(CL) was recorded using a Micro Luminat Plus LB 96V
(Berthold, Bad Wildbad, Germany) at intervals of 6s (two
cycles) in a total detection time of 3min. The detected CL was
summarised over two intervals and plotted versus blank values.
Measurement of intracellular Ca
2þ levels
The determination of intracellular Ca
2þ levels was performed
as described previously (Werz, 2002a). In brief, freshly isolated
PMNL (1 10
7), HL 60 cells (1 10
7 buffer), or MM6 cells
(3 10
6) were resuspended in 1ml PGC buffer and incubated
with 2mM Fura-2/AM for 30min at 371C. After washing, cells
were finally resuspended in 1ml PGC buffer and transferred
into a thermally controlled (371C) fluorimeter cuvette in a
spectrofluorometer (Aminco-Bowman series 2, Thermo Spec-
tronic, Rochester, NY, U.S.A.) with continuous stirring. The
fluorescence emission at 510nm was measured after excitation
at 340 and 380nm, respectively. Intracellular Ca
2þ levels were
calculated according to the method of Grynkiewicz et al.
(1985), whereas Fmax (maximal fluorescence) was obtained by
lysing the cells with 0.5% Triton-X 100 and Fmin by chelating
Ca
2þ with 10mM EDTA.
Determination of MAPK activation by SDS–PAGE and
Western blotting
Freshly isolated PMNL, HL60, or MM6 cells (5 10
6 each)
were resuspended in PGC buffer; the final volume was 100ml.
After addition of the indicated stimuli, samples were incubated
at 371C and the reaction was stopped by addition of 100mlo f
ice-cold 2  sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS–PAGE) sample-loading buffer (SDS-b;
20mM Tris/HCl, pH 8, 2mM EDTA, 5% SDS (wv
 1), 10%
b-mercaptoethanol), vortexed and heated for 6min at 951C.
Total cell lysates (20ml) were mixed with 4ml of glycerol/0.1%
bromophenolblue (1:1, vv
 1) and analysed by SDS–PAGE
using a Mini Protean system (Bio-Rad, Hercules, CA, U.S.A.)
on a 10% gel. After electroblot to nitrocellulose membrane
(Amersham Pharmacia, Little Chalfont, U.K.), membranes
were blocked with 5% nonfat dry milk in 50mM Tris/HCl, pH
7.4, and 100mM NaCl (Tris-buffered saline (TBS)) plus 0.1%
Tween 20 for 1h at RT. Membranes were washed and then
incubated with primary antibody (AB) overnight at 41C.
Phospho-specific ABs recognising p44/42
MAPK (Thr202/
Tyr204) and p38 MAPK (Thr180/Tyr182) were obtained from
New England Biolabs (Beverly, MA, U.S.A.), and used as
1:2000 dilution. The membranes were washed and incubated
with 1:1000 dilution of alkaline phosphatase-conjugated
immunoglobulin G (Sigma Chemical Co.) for 2h at RT. After
washing with TBS and TBS plus 0.1% NP-40, proteins were
visualised with nitro blue tetrazolium and 5-bromo-4-chloro-3-
indolylphosphate (Sigma Chemical Co.) in detection buffer
(100mM Tris/HCl, pH 9.5, 100mM NaCl, 5mM MgCl2).
Determination of 5-LO product formation in PMNL
To determine 5-LO product formation in intact cells, 1 10
7
freshly isolated PMNL were finally resuspended in 1ml PG
buffer. When 5-LO product formation was assayed in the
absence of Ca
2þ, PMNL were finally resuspended in 1ml PG
buffer and 1mM EDTA and 30mM BAPTA/AM were added.
The reaction was started by simultaneous addition of
exogenous AA with the indicated BAs. After 10min at 371C,
the reaction was stopped with 1ml of methanol, and 30mlo f
1 N HCl, and 200ng prostaglandin B1 and 500ml of PBS were
added. Formed AA metabolites were extracted using C-18
solid-phase extraction columns and analysed by HPLC as
described (Werz et al., 1997). 5-LO product formation is
expressed as ng of 5-LO products per 10
6 cells, which includes
LTB4 and its all-trans isomers, 5(S),12(S)-di-hydroxy-6,10-
trans-8,14-cis-eicosatetraenoic acid (5(S),12(S)-DiHETE),
5(S)-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-
HETE), and 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosate-
traenoic acid (5-HPETE). 5-HETE and 5-HPETE coelute as
one major peak; integration of this peak represents both
eicosanoids. Cysteinyl LTs (LTC4,D 4, and E4) were not
detected and oxidation products of LTB4 were not determined.
Statistics
The results are presented as mean7s.e. The program
‘GraphPad PRISM 3.0’ was used for statistical comparisons.
Statistical evaluation of the data was performed using Student´s
t-test for unpaired observations. A P-value of o0.05 was
considered significant.
Results
11-Keto-BAs stimulate the release of superoxide anion
and ROS in PMNL
In order to explore the effects of BAs on PMNL, we sought to
determine whether BAs are capable of eliciting functional
processes connected to Ca
2þ mobilisation and MAPK
activation. Phagocytes undergo an oxidative burst in response
to different agonists, resulting in the release of ROS via the
NADPH oxidase. PMNL, preloaded with the ROS-sensitive
dye DCF-DA, were stimulated with BAs (30mM, each) and for
comparison with 1mM fMLP, 2.5mM ionophore A23187, and
100nM PMA. After 5min, ROS formation was determined by
analysing the fluorescence of the oxidised dye. In agreement
with the literature (Roos et al., 1976; Simchowitz & Spilberg,
1979), fMLP, ionophore A23187, or PMA caused a rapid
formation of ROS in PMNL (Figure 1). AKBA and KBA
strongly upregulated the formation of ROS, whereas b-BA and
A-b-BA had only moderate effects (Figure 1). Notably, the
magnitude of AKBA- (or KBA-) induced ROS formation was
much more pronounced as compared to fMLP, being in a close
range of the efficacy of ionophore and PMA. Similar results
were obtained when the formation of superoxide anion (O2
 )
was determined by measuring the chemiluminescence of the
metabolised lucigenin. Thus, stimulation of PMNL with 30mM
AKBA resulted in a 12-fold increase in O2
  formation
compared to unstimulated cells, whereas fMLP (1mM) and
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AKBA-induced ROS formation involves NADPH
oxidase, PI 3-K, and p42/44
MAPK, and requires Ca
2þ
To further dissect the signalling pathways leading to ROS
formation, pharmacological inhibitors of potential signalling
molecules were examined using the DCF-DA fluorescence
assay. PMA, used as a control, binds to PKC isoenzymes,
stimulating NADPH oxidase by multiple phosphorylations of
p47
phox (Heyworth & Badwey, 1990). DPI, a direct inhibitor of
NADPH oxidase (Hancock & Jones, 1987), almost completely
abolished PMA- as well as AKBA-induced ROS formation
(Figure 2a). Also, chelation of Ca
2þ by 30mM BAPTA/AM
and 1mM EDTA clearly reduced AKBA- or PMA-induced
ROS formation (Figure 2a). As shown in Figure 2b, PMA-
induced ROS formation was only slightly affected by
wortmannin (50nM) or LY-294002 (30mM), inhibitors of
phosphatidylinositol 3-kinase (PI 3-K), or by the p38 MAPK
inhibitor SB203580 (10mM). However, U0126 (3mM) that
blocks the activation of p42/44
MAPK partially reduced ROS
generation and the PKC inhibitor RO-318425 (1mM) totally
abolished the effects of PMA. In contrast, AKBA-induced
ROS formation was not at all affected by PKC inhibition (RO-
318425), but was clearly reduced by wortmannin or LY-
294002, and by U0126, implying an involvement of PI 3-K and
p42/44
MAPK, respectively (Figure 2b). Also, for AKBA-
induced ROS formation, a role for p38 MAPK is not
apparent.
11-Keto-boswellic acids cause the release of [
3H]AA from
PMNL
In PMNL, AA is released from phospholipids upon cell
stimulation by the cytosolic PLA2 (cPLA2). Since cPLA2 is
activated by phosphorylation at serine residues by members of
the MAPK family and/or elevation of the intracellular Ca
2þ
levels (Gijon & Leslie, 1999), BAs were tested for their ability
to elevate the liberation of AA from PMNL. AKBA and KBA
considerably enhanced the release of [
3H]-labelled AA, whereas
b-BA and A-b-BA showed only weak effects (Figure 3). Also,
under these experimental settings, AKBA and KBA caused
even more pronounced responses as compared to 1mM fMLP.
The fMLP- as well as the AKBA-induced AA release was
completely abolished when Ca
2þ was removed by chelation
using EDTA and BAPTA/AM (not shown). Experiments
using SB203580 (10mM) and U0126 (3mM), in order to inhibit
p38 MAPK and p42/44
MAPK activities, respectively, were
performed to estimate the importance of these MAPK for
AA liberation. The effect of AKBA was partially suppressed
by U0126 (5374.6%), but was unaffected by SB203580 (not
shown), implying that p42/44
MAPK, but apparently not p38
MAPK, may contribute to the AKBA-induced AA release.
Effects of 11-keto-boswellic acids on cellular 5-LO
product formation in PMNL
In intact cells, 5-LO can be activated upon elevation of the
intracellular Ca
2þ levels and/or phosphorylation by p38
MAPK-regulated MAPKAPKs and p42/44
MAPK (Werz et al.,
2000; 2002a,b). Although 11-keto BAs are direct inhibitors of
5-LO (Safayhi et al., 1992; 1995), we speculated that, due to
their potential to mobilise Ca
2þ and to activate MAPK, BAs
could also stimulate 5-LO in intact cells. As shown in
Figure 1 11-Keto-BAs induce the generation of ROS in PMNL.
Freshly isolated PMNL (5 10
6 in 1ml PGC buffer) were
preincubated with DCF-DA (1mgml
 1) for 2min at 371C, prior
addition of the indicated stimuli. The generation of peroxides was
measured as described. Data determined 5min after addition of
stimuli are expressed as the mean of the fluorescence given in
arbitrary units 7s.e., n¼4. Student’s t-test; **Po0.01.
Figure 2 AKBA-induced ROS formation involves NADPH oxi-
dase, PI 3-K, and p42/44
MAPK, and requires Ca
2þ. PMNL (5 10
6 in
1ml PGC buffer) were preincubated with the indicated compounds
for 20min at RT, prior addition of DCF-DA (1mgml
 1). After
another 2min, AKBA (30mM) or PMA (100nM) were added and the
generation of peroxides was measured as described above. (a) Effects
of DPI and Ca
2þ depletion. Data determined 5min after addition of
stimuli are expressed as the mean of the fluorescence given in
arbitrary units7s.e., n¼3. Student’s t-test; **Po0.01. (b) Effects of
pharmacological protein kinase inhibitors. Data were determined
5min after addition of stimuli and expressed as the percentage of the
mean fluorescence7s.e., n¼4, of control. Student’s t-test; *Po0.05,
**Po0.01. The control values (100%) in the absence of inhibitors
for cells stimulated with AKBA were 425757, and for PMA
6757103 arbitrary fluorescence units.
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with 20mM AA, AKBA and KBA (30mM each) caused 3.8- and
2.4-fold increases in 5-LO product formation versus control
cells that had been stimulated with AA alone, whereas no
upregulatory effects were observed for b-BA and A-b-BA.
Notably, such upregulatory effects of the 11-keto-BAs were
most prominent when Ca
2þ was chelated by EDTA and
BAPTA/AM, whereas, in the presence of Ca
2þ, AKBA
increased 5-LO product formation only by 1.9-fold. Expand-
ing the preincubation period with BAs prior addition of AA
(41min) strongly reduced the effects of BAs (not shown). The
dose–response curve shown in Figure 4b reveals that, at higher
concentrations (100mM), AKBA fails to stimulate 5-LO,
possibly due to direct inhibitory enzyme interaction. In order
to determine if p38 MAPK and/or p42/44
MAPK are required for
AKBA-induced 5-LO activation, PMNL were preincubated
with 3mM U0126 and/or 10mM SB203580 prior stimulation.
Upregulation of 5-LO product formation by AKBA (in the
absence of Ca
2þ) was not significantly suppressed by these
inhibitors (not shown), suggesting that MAPK are not
determinants for AKBA-induced 5-LO activation.
Prolonged exposure of 5-LO to elevated Ca
2þ or oxidants
such as ROS leads to a rapid inactivation of 5-LO (Ford-
Hutchinson et al., 1994). Hence, it appeared possible, that the
potent 5-LO inhibition by AKBA in intact cells after longer
preincubation periods (30min) prior cell stimulation is related
to the prominent Ca
2þ mobilisation and the accompanied
Figure 3 11-Keto-BAs elicit the liberation of AA in PMNL.
Freshly isolated PMNL (2 10
6 in 1ml RPMI 1640 medium) were
prelabelled with 0.25mCiml
 1 [
3H]AA for 120min at 371C and 5%
CO2. After unincorporated [
3H]AA was removed, cells (5 10
6 in
1ml PGC buffer, containing 2mgml
 1 fatty acid-free albumin) were
treated with the indicated additives and incubated for 5min at 371C.
Free (nonesterified) [
3H]AA was determined as described in
Methods. Results are given as mean7s.e. (n¼4). Student’s t-test;
*Po0.05; **Po0.01.
Figure 4 Effects of 11-keto-BAs on the formation of 5-LO
metabolites. (a) Freshly isolated PMNL (5 10
6) were resuspended
in 1ml PG buffer containing 1mM EDTA and preincubated with
30mM BAPTA/AM for 15min. Then, cells were stimulated with
20mM AA alone or together with the indicated BAs (30mM, each).
After 10min at 371C, 5-LO products were determined by HPLC.
Results are given as meanþs.e., n¼4–6. Student’s t-test; **Po0.01.
(b) Dose–response curve of AKBA. PMNL (5 10
6) were resus-
pended in 1ml PG buffer containing 1mM EDTA and preincubated
with 30mM BAPTA/AM for 15min. Then, cells were stimulated with
20mM AA alone or together with the indicated amounts of AKBA.
After 10min at 371C, 5-LO products were determined. Results are
given as meanþs.e., n¼4–5. (c) Inhibition of 5-LO. PMNL
(5 10
6) were resuspended in either 1ml PGC buffer or PG buffer
containing 1mM EDTA and 30mM BAPTA/AM. After 15min at
371C, AKBA was added, and cells were incubated for another
30min at 371C. Then, CaCl2 was adjusted to 1mM in all incubations
and cells were immediately stimulated with 2.5mM ionophore and
40mM AA. After 10min, 5-LO products were determined. Results
are given as meanþs.e., n¼3.
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AKBA in the presence of Ca
2þ, which results in Ca
2þ
mobilisation and ROS formation. Alternatively, Ca
2þ was
removed by 1mM EDTA and 30mM BAPTA/AM during this
preincubation period, conditions where ROS release does not
occur. Subsequently, after preincubation, all samples were
adjusted to 1mM Ca
2þ and cells were immediately stimulated
with ionophore and AA to induce 5-LO product formation in
intact cells. As can be seen from Figure 4c, the efficacy of
AKBA to inhibit 5-LO product formation was strongly
impaired when cells were preincubated in the absence of
Ca
2þ (IC50 approx. 50mM), as compared to conditions when
Ca
2þ was present (IC50 approx. 8mM). Thus, potent 5-LO
inhibitory effects of AKBA in intact cells by may require
Ca
2þ-mediated processes, such as ROS formation.
Pertussis toxin (PTX) attenuates boswellic acid-induced
mobilisation of Ca
2þ and MAPK activation in PMNL
The proximal signalling pathways involved, as well as the
kinetics for Ca
2þ mobilisation and MAPK activation,
resembled those of chemotactic factors, such as fMLP, that
act via G protein-coupled receptors (GPCR). In order to
determine a possible role of Gi or G0 proteins in the AKBA-
induced Ca
2þ release and MAPK activation, the effects of
PTX, an irreversible inhibitor of Gai/0 subunits of hetero-
trimeric G proteins, were assessed in human isolated PMNL.
As shown in Figure 5a, PTX (2mgml
 1) suppressed the Ca
2þ
response induced by 30mM AKBA in a similar fashion as
compared to fMLP stimulation. Similarly, PTX clearly
reduced the activation of p42
MAPK in PMNL, stimulated with
AKBA or KBA, whereas activation of p38 MAPK was only
moderately reduced (Figure 5b). In control experiments
(Table1 and Figure 5b), PTX also partially decreased the
fMLP-induced activation of MAPK and Ca
2þ mobilisation,
whereas MAPK activation (not shown) and Ca
2þ mobilisation
(Table 1) induced by ionomycin (that circumvents G protein
signalling) were not suppressed by PTX.
Moreover, PTX (2mgml
 1) partially inhibited AKBA-
induced ROS formation (21.177.6%), but did not at all affect
ROS production in PMNL stimulated by PMA. On the other
hand, PTX caused only marginal suppression (8.374.1%) of
AKBA-induced 5-LO activity in PMNL.
Cell type-dependent induction of MAPK activation, Ca
2þ
mobilisation and ROS generation by BAs
The effects of BAs on the mobilisation of Ca
2þ, activation of
MAPK and formation of ROS were further investigated in
various haematopoietic cell lines. For monocytic MM6 cells
differentiated with calcitriol and TGFb, none of the four
different BAs (up to 100mM) induced Ca
2þ mobilisation or
activation of MAPK, and also no significant induction of ROS
formation was observed (not shown). In control experiments,
PAF, LTB4 or fMLP caused pronounced elevation of
intracellular Ca
2þ, demonstrating that G protein-coupled
Ca
2þ mobilisation is operative in these cells. Similarly, BAs
also failed to activate the B-lymphocytic cell line BL41-E-95-A
in this respect (not shown).
In contrast, the effects of BAs in differentiated granulocytic
HL60 cells resembled those observed in PMNL from human
blood. Thus, AKBA considerably induced mobilisation of
Ca
2þ, stimulated activation of p38 MAPK and p42
MAPK, and
upregulated the formation of ROS (Figure 6). Interestingly,
KBA was less effective, whereas b-BA and A-b-BA also
stimulated HL60 cells for MAPK activation and release of
ROS. Nevertheless, b-BA and A-b-BA failed to substantially
mobilise Ca
2þ in differentiated HL60 cells. It should be noted
Figure 5 PTX suppresses Ca
2þ mobilisation and activation of
MAPK in PMNL induced by boswellic acids. (a) Ca
2þ mobilisation.
Freshly isolated PMNL (1710
7ml
 1 PGC buffer) were loaded with
2mM Fura-2 for 30min at 371C. Then, cells were preincubated with
or without 2mgml
 1 PTX for 60min at 371C. After addition of
30mM AKBA, the fluorescence was measured and intracellular free
Ca
2þ was calculated as described. The monitored curves show one
typical experiment out of four. (b) MAPK activation. Freshly
isolated PMNL (5 10
6 in 100ml PGC buffer) were preincubated
with or without 2mgml
 1 PTX for 60min at 371C and then
stimulated with 30mM AKBA, 30mM KBA, 1mM fMLP, or left
untreated. After 1.5min at 371C, incubations were terminated by
addition of the same volume of ice-cold SDS-b. Samples were
electrophoresed and analysed for dually phosphorylated p38 MAPK
or p44/42
MAPK by Western blotting.
Table 1 Effects of PTX on Ca
2+ mobilisation
Stimulus Ca
2+ mobilisation (percentage of control)
Ionomycin (2.5mM) 94.178.3
fMLP (100nM) 39.679.7
AKBA (30mM) 43.8716.8
Freshly isolated PMNL (1 10
7ml
 1 PGC buffer) were
loaded with 2mM Fura-2 for 30min at 371C. Then, cells were
preincubated with or without 2mgml
 1 PTX for 60min at
371C. After addition of the indicated stimuli, the fluorescence
was measured and intracellular free Ca
2+ was calculated as
described. Values (mean7s.e., n¼4) are given as the
percentage of Ca
2+ mobilisation of PTX-treated cells versus
control cells that received no PTX.
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nor to the other BAs (not shown), implying that a certain
signalling component(s), induced during differentiation, is
required to transduce the effects of BAs.
Discussion
We have recently reported that 11-keto-BAs potently stimulate
the elevation of intracellular Ca
2þ levels and activate p38
MAPK as well as p42
MAPK (Altmann et al., 2002), which are
pivotal signalling events that regulate numerous effectors of
PMNL. In the present study, we show that 11-keto-BAs in fact
elicit functional responses of PMNL or granulocytic HL60
cells such as ROS generation, increased liberation of AA, and
its subsequent metabolism by 5-LO. Investigation of the
signalling molecules involved and comparison of the kinetics
with those of chemotactic ligands for leukocytes, that is,
fMLP, PAF or LTB4, led us to conclude that 11-keto-BAs may
transduce their signals in a common way as chemotactic
ligands that involve GPCR signalling (see Altmann et al.
(2002) and references therein). Since elevated levels of AA and
ROS are critical inducers of caspase-mediated apoptosis
(Hampton et al., 1998; Taketo & Sonoshita, 2002), our
findings may also provide a molecular basis for the 11-keto-
BA-induced caspase activation (Liu et al., 2002a,b) and the
apoptotic effects observed in various cancer cell lines (Shao
et al., 1998; Glaser et al., 1999; Hoernlein et al., 1999; Jing
et al., 1999; Liu et al., 2002a,b).
O2
  is the precursor of ROS, which are essential for the host
defence against microorganisms. The NADPH oxidase of
leucocytes is the major source of O2
  released upon agonist
challenge (Chanock et al., 1994). Activation of NADPH
oxidase requires the presence of Ca
2þ and multiple phospho-
rylations of the subunit p47
phox by certain PKC isoenzymes or
other kinases (Heyworth & Badwey, 1990; Chanock et al.,
1994; Dewas et al., 2000). We demonstrate that, according to
their ability to stimulate Ca
2þ mobilisation and MAPK
activation (compare Altmann et al., 2002), 11-keto-BAs, but
not BAs lacking the 11-keto group, induced a rapid and robust
formation of O2
  and of ROS in PMNL, as determined by
lucigenin chemiluminescence and the oxidation of DCF-DA,
respectively. Since the NADPH oxidase inhibitor DPI (Han-
cock & Jones, 1987) abolished ROS formation, ROS derived
from the NADPH oxidase system may indeed be responsible.
Pharmacological targeting of the proximal signalling pathways
revealed that AKBA-induced ROS formation seemingly
depends on PI 3-K and on the p42/44
MAPK pathway, but does
not require p38 MAPK or PKC. In this context, it is interesting
that the fMLP-induced phosphorylation of the p47
phox
component in neutrophils was suppressed by inhibition of
p42
MAPK (Dewas et al., 2000) and PI 3-K (Ding et al., 1995),
but not when p38 MAPK was blocked by SB203580 (Dewas
et al., 2000). In contrast, our control experiments utilising PMA
as a direct activator of PKC confirm the findings by others,
showing that PKC, and to a minor extent also p42
MAPK,a r e
required for NADPH oxidase-dependent ROS formation (Cox
et al., 1985; Heyworth & Badwey, 1990; Dewas et al., 2000),
whereas a role of PI 3-K or p38 MAPK is not readily apparent.
Notably, Ca
2þ signalling pathways are determinants for ROS
formation, since chelation of Ca
2þ strongly suppressed the
signals induced by AKBA and also by PMA. Together, 11-keto
BAs may stimulate ROS formation by mobilisation of Ca
2þ
and by activation of p42/44
MAPK, apparently involving PI 3-K.
The release of free AA by leukocytes is an important step in
the onset of inflammatory reactions and the cPLA2, which is
regulated by Ca
2þ and phosphorylation by MAPK, appears to
play a major role for AA liberation in PMNL (Gijon & Leslie,
1999). 11-keto BAs, but not b-BA and A-b-BA, induced the
release of considerable amounts of AA, with a similar efficacy
as fMLP. The doses of the respective BAs were somewhat
higher than those needed for the formation of ROS, which
might be due to the fact that cPLA2 favours a sustained Ca
2þ
influx (Qiu et al., 1998), which in turn requires higher
Figure 6 Effects of BAs on Ca
2þ release, MAPK activation, and
ROS production in granulocytic HL60 cells. HL60 cells were
differentiated towards granulocytic cells in the presence of 1.5%
DMSO, 2ngml
 1 TGFb, and 500pM calcitriol for 4days. (a)
Mobilisation of Ca
2þ. Cells (10
7ml
 1 PGC buffer) were loaded with
2mM Fura-2 for 30min at 371C. After addition of BAs (50mM, each)
or 1mM fMLP, the fluorescence was measured and intracellular free
Ca
2þ was calculated as described. The monitored curves show one
typical experiment out of 4–5, respectively. (b) MAPK activation.
Cells (5 106/100ml PGC buffer) were stimulated with 30mM of
BAs, 1mM fMLP, or left untreated. After 1.5min at 371C,
incubations were terminated by addition of the same volume of
ice-cold SDS-b. Samples were electrophoresed and analysed for
dually phosphorylated p38 MAPK or p44/42
MAPK by Western
blotting. (c) ROS formation. Cells (5 10
7ml
 1 PGC buffer) were
preincubated with DCF-DA (10mgml
 1) for 2min at 371C prior
addition of the indicated stimuli. The generation of peroxides was
measured as described. Data determined 5min after addition of
stimuli are expressed as the mean of the fluorescence given in
arbitrary units7s.e., n¼4. Student’s t-test; *Po0.05; **Po0.01.
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In agreement with findings reported for ligands acting via
GPCR (Qiu et al., 1998), AKBA-induced AA liberation also
depended on Ca
2þ and p42/44
MAPK.
Although BAs have been initially reported as direct-type
inhibitors of the 5-LO enzyme, without reducing or iron-
chelating properties (Safayhi et al., 1992; 1995), we demon-
strate that AKBA can paradoxically stimulate cellular 5-LO,
when added to PMNL concomitantly with AA. Also, it was
reported that low concentrations of B. serrata extracts
enhanced ionophore-stimulated 5-LO product synthesis in
PMNL (Safayhi et al., 2000), and 3-oxo-tirucallic acid, that
acts as a direct 5-LO inhibitor in cell-free systems, induced and
upregulated 5-LO activity in human neutrophils (Boden et al.,
2001). In intact cells, mobilisation of Ca
2þ, and also
phosphorylation by MAPKAPKs and by p42/44
MAPK, acti-
vates 5-LO for product formation (Werz et al., 2000; 2002a,b).
Interestingly, AKBA-induced 5-LO activation was most
prominent in the absence of Ca
2þ, and was not sensitive to
MAPK inhibitors and hardly sensitive to PTX. Thus,
additional unknown factors or pathways induced by AKBA
seem operative, which still remain to be determined.
A discrepancy in the efficacy of AKBA is evident for
suppression of 5-LO in intact cells (IC50E2–5mM) and cell-free
systems (IC50E15–50mM) (Safayhi et al., 1995; Werz et al.,
1997; 1998). Thus, in intact cells, additional factors are
operative for the suppression of 5-LO. Since prolonged
exposure to elevated Ca
2þ or oxidants rapidly inactivates
5-LO (Ford-Hutchinson et al., 1994), it appeared possible that
the potent 5-LO inhibition by AKBA in intact cells is related
to the prominent ROS release occurring during preincubation
periods (15–30min) prior cell stimulation. In fact, Ca
2þ
depletion, that prevents ROS formation, impaired the efficacy
of AKBA in intact cells (Figure 4c), and the respective IC50
value fits well with those obtained in cell-free systems (Werz
et al., 1998). Intriguingly, the efficacy of AKBA for suppres-
sion of 5-LO in MM6 cells (IC50E15mM), that are unable to
mobilise Ca
2þ and to produce ROS in response to AKBA, is
significantly reduced as compared to PMNL (IC50E2–5mM).
Upon ligation of their specific GPCR, chemoattractants
elicit various functional responses of different leucocytes
involving Ca
2þ mobilisation and activation of MAPK
(Herlaar & Brown, 1999; Belcheva & Coscia, 2002). The
putative BA receptor, operative in PMNL and mature HL60
cells, seems to be induced during differentiation towards
granulocytic cells, since undifferentiated HL60 cells did not
respond to BAs with Ca
2þ mobilisation, MAPK activation or
ROS formation. Along these lines, it was found that, in HL60
cells, the G protein-coupled fMLP receptor is also first induced
after differentiation (Perez et al., 1992). Nevertheless, differ-
entiated monocytic MM6 cells apparently do not possess any
BA-inducible signalling pathways or BA receptor(s), although
these cells respond to diverse ligands of GPCR (fMLP, LTB4
or PAF), implying intact G protein signalling pathways in
differentiated MM6 cells. Intriguingly, differentiated MM6
cells also failed to mobilise Ca
2þ in response to 5(S)-HETE or
5-oxo-ETE, which on the other side caused significant Ca
2þ
mobilisation in PMNL (unpublished observations). Accord-
ingly, even the expression of the putative G protein coupled 5-
oxo-ETE receptor was found to be cell type-dependent
(O’Flaherty et al., 2000). Thus, we conclude that the expression
of the target (–receptor) of AKBA may be restricted to certain
cell types. Finally, it should be noted that, in contrast to
PMNL, in differentiated HL60 cells also b-BA and A-b-BA
caused cell stimulation (Figure 6a and b), suggesting that, at
least in HL60 cells, putative receptor subtypes (not present in
PMNL) may exist that accept BAs lacking the 11-keto group.
Our experiments using PTX suggest that a Gi/0-subunit of a
heterotrimeric G protein mediates the effects of 11-keto-BAs in
PMNL. Remarkably, the activation of p38 MAPK and of 5-
LO was less affected by PTX, implying that, for example,
PTX-insensitive Gq subunits, as in the case of the PAF
receptor (Shimizu et al., 1996), are involved. Also, the PI 3-K
inhibitor wortmannin differentially suppressed the activation
of p38 MAPK and p42
MAPK induced by AKBA (Altmann
et al., 2002). It is yet unclear whether 11-keto-BAs act via a
GPCR or alternatively interfere directly with a G protein.
Notably, modulation of G proteins by low molecular weight
compounds in the absence of a GPCR, both in a positive or a
negative way, has been described (see Breitweg-Lehmann et al.
(2002) and references therein).
The data presented here imply that BAs, at least in
concentrations X10mM, are potent immunocompetent agents
that might be regarded as proinflammatory stimuli. By
contrast, cellular and pilot clinical studies indicate the anti-
inflammatory effects of B. serrata extracts and BAs (Gupta
et al., 1992; 2001; Gerhardt et al., 2001; Krieglstein et al.,
2001). It is conceivable that, at low concentrations, BAs may
have antagonistic activity within certain signalling pathways
induced by a second stimulus. In fact, at low concentrations,
AKBA (2–8mM) inhibited the activation of p42/44
MAPK in
meningioma cells stimulated with platelet-derived growth
factor (Park et al., 2002), and, in our hands, BAs (0.3–1mM)
significantly suppressed the PAF-induced Ca
2þ mobilisation
in platelets (unpublished results). Further studies are required
to identify the receptor(s) of BAs and the defined mechanisms
leading to Ca
2þ and MAPK signalling, and to reveal if BAs
can act as partial agonists at receptors relevant for inflamma-
tory processes. Such knowledge may help to unravel the
molecular mechanisms of the anti-inflammatory actions of
BAs, and may provide new concepts for the pharmacological
intervention with inflammatory diseases.
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 Paper II Induction of central signalling pathways and select functional
effects in human platelets by b-boswellic acid
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1 We have recently shown that in polymorphonuclear leukocytes, 11-keto boswellic acids (KBAs)
induce Ca
2þ mobilisation and activation of mitogen-activated protein kinases (MAPK). Here we
addressed the effects of BAs on central signalling pathways in human platelets and on various platelet
functions.
2 We found that b-BA (10mM), the 11-methylene analogue of KBA, caused a pronounced
mobilisation of Ca
2þ from internal stores and induced the phosphorylation of p38 MAPK,
extracellular signal-regulated kinase (ERK)2, and Akt. These effects of b-BA were concentration
dependent, and the magnitude of the responses was comparable to those obtained after platelet
stimulation with thrombin or collagen.
3 Based on inhibitor studies, b-BA triggers Ca
2þ mobilisation via the phospholipase (PL)C/inositol-
1,4,5-trisphosphate pathway, and involves Src family kinase signalling.
4 Investigation of platelet functions revealed that b-BA (X10mM) strongly stimulates the platelet-
induced generation of thrombin in an ex-vivo in-vitro model, the liberation of arachidonic acid (AA),
and induces platelet aggregation in a Ca
2þ-dependent manner.
5 In contrast to b-BA, the 11-keto-BAs (KBA or AKBA) evoke only moderate Ca
2þ mobilisation
and activate p38 MAPK, but fail to induce phosphorylation of ERK2 or Akt, and do not cause
aggregation or significant generation of thrombin.
6 In summary, b-BA potently induces Ca
2þ mobilisation as well as the activation of pivotal protein
kinases, and elicits functional platelet responses such as thrombin generation, liberation of AA, and
aggregation.
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Keywords: Boswellic acids; platelets; calcium; mitogen-activated protein kinases; Akt; arachidonic acid; thrombin
Abbreviations: AA, arachidonic acid; Ab-BA, 3-O-acetyl-boswellic acid; ADP, adenosine diphosphate; AKBA, 3-O-acetyl-11-
keto-boswellic acid; 2-APB, 2-aminoethoxydiphenylborate; AUC, area under the curve; BA, boswellic acid;
cPLA2, cytosolic phospholipase A2; DAG, diacylglycerol; ER, endoplasmatic reticulum; ERK, extracellular
signal-regulated kinase; ETP, endogenous thrombin potential; GPCR, G protein-coupled receptor; IP3, inositol-
1,4,5-trisphosphate; KBA, 11-keto-boswellic acid; LO, lipoxygenase; MAPK, mitogen-activated protein kinase;
MFI, mean fluorescence intensity; PAF, platelet-activating factor; PG buffer, PBS plus 1mgml
 1 glucose; PGC
buffer, PBS containing 1mgml
 1 glucose and 1mM CaCl2; PI 3-K, phosphatidylinositol 3-kinase; PLC,
phospholipase C; PMNL, polymorphonuclear leukocytes; PRP, platelet rich plasma; RFU, relative fluorescence
units; SDS-b, 2 sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample loading buffer; TG,
thapsigargin; TRAP, thrombin receptor-activating peptide; TXA2, thromboxane A2
Introduction
Platelets play critical roles in vascular thrombosis and
inflammation. Activation of platelets may lead to secretion
of granular contents and release of arachidonic acid (AA),
shape change, adhesion, and aggregation (Holmsen, 1994).
Agonists of platelets can be subdivided into strong activators,
such as thrombin or collagen, and weak agonists including
platelet-activating factor (PAF), adenosine diphosphate
(ADP), serotonin, or thromboxane (TX)A2 that require
autocrine stimulation for the entire platelet response
(Holmsen, 1994). Furthermore, platelets are partially activated
when brought in close contact with surfaces, for example by
adhesion to leukocytes or by aggregation.
Soluble platelet agonists, such as thrombin, ADP, PAF, or
TXA2, typically bind to specific G protein-coupled receptors
(GPCRs), leading to the activation of phospholipase (PL)C
(Ruggeri, 2002). PLC isoenzymes in turn, produce diacylgly-
cerols (DAGs) and inositol-1,4,5-trisphosphate (IP3), the latter
releases Ca
2þ via IP3 receptors from the endoplasmatic
reticulum (ER) (Rhee, 2001). GPCR stimulation may also
lead to activation of phosphatidylinositol 3-kinase (PI 3-K)
*Author for correspondence;
E-mail: o.werz@pharmchem.uni-frankfurt.de
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www.nature.com/bjpisoforms, resulting in Akt phosphorylation. Moreover, mito-
gen-activated protein kinase (MAPK) cascades, signalling
pathways distal of G proteins, are activated upon platelet
stimulation (Papkoff et al., 1994; Kramer et al., 1995).
Altogether, Ca
2þ, MAPKs, and PI 3-K/Akt regulate impor-
tant platelet functions, for example, activation of cytosolic
phospholipase (cPL)A2 that liberates AA from phospholipids.
In fact, agonist-stimulated platelets generate abundant AA
(Kroll & Schafer, 1989), that is mainly metabolised to
biologically active prostanoids, including TXA2, and to
12(S)-hydro(pero)xyeicosatetraenoic acid (Yoshimoto &
Takahashi, 2002).
The pentacyclic triterpenes boswellic acids (BAs, Figure 1)
are thought to be responsible for the pharmacological actions
of Boswellia serrata (BS) extracts, observed in several models
of inflammation (Safayhi & Sailer, 1997). 5-lipoxygenase
(5-LO) (Safayhi et al., 1992), leukocyte elastase (Safayhi
et al., 1997), IkB kinases (Syrovets et al., 2005), and
topoisomerases (Syrovets et al., 2000) are molecular targets
of BAs. The anti-inflammatory properties of BAs have
been attributed to inhibition of 5-LO (Safayhi & Sailer,
1997) but also to suppressed lipopolysaccharide-mediated
TNF-a induction in monocytes (Syrovets et al., 2005). More-
over, BAs induce apoptosis of tumor cells (Glaser et al., 1999;
Liu et al., 2002), accompanied by decreased ERK phosphor-
ylation (Park et al., 2002) and enhanced caspase activity
(Liu et al., 2002).
The functional properties and the potencies of the BAs
depend on their structure, in particular on the absence or
presence of the 11-keto group (Safayhi et al., 1992; Altmann
et al., 2002; Liu et al., 2002). Thus, 11-keto-BA (KBA)
and 3-O-acetyl-11-keto-BA (AKBA, Figure 1), but not the
11-methylene (11-me) analogues b-BA and Ab-BA, potently
inhibit 5-LO (Safayhi et al., 1992), induce caspase activation
(Liu et al., 2002), Ca
2þ mobilisation, and MAPK activation
in polymorphonuclear leukocytes (PMNL) (Altmann et al.,
2002), whereas 11-me-BAs were more efficient in inhibition of
topoisomerases (Syrovets et al., 2000) and induction of
apoptosis (Glaser et al., 1999).
Recently, we demonstrated that 11-keto-BAs can activate
PMNL by mobilisation of Ca
2þ and stimulation of MAPKs
(Altmann et al., 2002), coupled to functional PMNL responses
(Altmann et al., 2004). In the present study we identified b-BA
as an agonist for platelets inducing essential signal transduc-
tion pathways as well as functional platelet responses, for
example release of endogenous AA, thrombin generation, and
Ca
2þ-dependent aggregation.
Methods
Materials
BAs were kindly provided by Dr J. Jauch (Saarbruecken,
Germany). Argatroban was a gift from Mitsubishi Pharma
(Tokio, Japan) and WEB 2086 was a gift from Boehringer
Ingelheim (Ingelheim, Germany). Collagen was from
Nykomed Pharma (Unterschleiheim, Germany). U-73122,
Calbiochem (Bad Soden, Germany); BAPTA/AM, Fura-2/
AM, and forskolin, Alexis (Gru ¨ nberg, Germany); NF-449 and
wortmannin, Biotrend (Ko ¨ ln, Germany); thrombin receptor-
activating peptide (TRAP), Bachem (Weil am Rhein,
Germany); MRS-2179 and all other chemicals were obtained
from Sigma (Deisenhofen, Germany).
Cells
Platelets were freshly isolated from human venous blood
of healthy adult donors (St Markus Hospital, Frankfurt,
Germany) as described (Albert et al., 2002). Washed platelets
were finally resuspended in PBS pH 7.4 and 1mgml
 1 glucose
(PG buffer) or in PBS pH 7.4 and 1mgml
 1 glucose plus
1mM CaCl2 (PGC buffer). For incubations with solubilised
compounds, ethanol or DMSO was used as vehicle, never
exceeding 1% (vol by vol). For functional platelet test (AA
release, thrombin generation, aggregation, flow-cytometry of
platelet activation markers) platelet-rich plasma (PRP) was
prepared from freshly drawn blood (in 3.13% citrate,
designated ‘citrate-chelated PRP’) from healthy adult donors
by centrifugation for 7min at 750 g. Depending on the
experimental setup, PRP was recalcified to obtain a final
[Ca
2þ] of 1.5mM, or diluted (14%, vol by vol) in a buffer
containing 20m M HEPES, 140m M NaCl, 10m M glucose,
5mM KCl, 1mM MgCl2,1m M CaCl2. Alternatively, platelets
were isolated from PRP to yield washed platelets. Some flow-
cytometry experiments were also carried out using whole blood
(in 3.13% citrate).
Viability assessment
Washed platelets (B3 10
8ml
 1 PG buffer) were prewarmed
for 15min at 371C. Then, CaCl2 (1mM) and any agent
(DMSO, b-BA, AKBA, thrombin, or Ca
2þ ionophore
A23187) were added, and samples were incubated for another
15min at 371C. The particle distribution pattern in each
sample was then determined using a Sysmex Cell Counter
(Norderstedt, Germany) and compared to the DMSO sample
(negative control, viable cells) and the A23187 sample (cell
fragmentation and lysis due to ionophore action).
Measurement of intracellular Ca
2þ levels
Platelets (6 10
8ml
 1 PG buffer) were incubated with 2mM
Fura-2/AM for 30min at 371C. After washing, 10
8cellsml
 1
PG buffer were incubated in a thermally controlled (371C)
fluorimeter cuvette in a spectrofluorometer (Aminco-Bowman
series 2, Thermo Spectronic, Rochester, NY, U.S.A.) with
continuous stirring. At 2min prior stimulation, 1mM CaCl2 or
1mM EDTA was added. The fluorescence was measured and
[Ca
2þ]i was calculated according to Grynkiewicz et al. (1985).
Figure 1 Chemical structures of b-BA and AKBA. AKBA lacking
the 11-acetyl group yields KBA; 3-O-acetylation of b-BA yields
Ab-BA.
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electrophoresis (SDS–PAGE) and Western blotting
Platelets (10
9ml
 1 PG buffer containing 1mM CaCl2 or 1mM
EDTA plus 30mM BAPTA/AM, respectively) were incubated
with the indicated stimuli at 371C. The reaction was stopped
by addition of the same volume of ice-cold 2 SDS–PAGE
sample loading buffer (SDS-b). Samples for SDS–PAGE
(aliquots corresponding to 10
6 cells in 20ml volume) were
prepared, and proteins were separated as described (Werz
et al., 2002). Correct loading of the gel and transfer of proteins
to the nitrocellulose membrane was confirmed by Ponceau
staining. Western blotting using phospho-specific antibodies
(New England Biolabs (Beverly, MA, U.S.A.), 1:1000
dilution, each) against pERK1/2 (Thr202/Tyr204), pp38
MAPK (Thr180/Tyr182), or pAkt (Ser473), was performed
as described (Werz et al., 2002).
Determination of release of [
3H]-labelled AA from intact
platelets
PRP was labelled with 19.2nM. [
3H]AA (1mCiml
 1, specific
activity 200Cimmol
 1) for 2h at 371C in the presence of
100mM aspirin. Then, cells were washed twice with PBS pH
5.9 plus 1mM MgCl2, 11.5mM NaHCO3,1 g l
 1 glucose,
and 1mgml
 1 fatty acid-free BSA, and finally resuspended in
PG buffer (10
8ml
 1). Preparation of cells at pH 5.9 is thought
to minimise temperature-induced activation (Maurer-Spurej
et al., 2001). After 15min at RT, 1mM CaCl2 was added
2.5min prior stimulation with the indicated agents at 371C.
After 5min, incubations were put on ice for 10min, followed
by centrifugation (5000 g, 15min). Aliquots (300ml) of the
supernatants were measured (Micro Beta Trilux, Perkin
Elmer) to detect the amounts of [
3H]-labelled AA released
into the medium.
Measurement of thrombin generation
Thrombin generation was assessed by using a fluorometric
assay, based on the cleavage of a thrombin-specific fluorogenic
substrate resulting from stimulation of recalcified or citrate-
chelated PRP, yielding the so-called endogenous thrombin
potential (ETP) (Hemker et al., 2000). In all, 80ml of PRP
and 20ml of buffer containing the thrombin generation trigger
were added to each well of a 96-well microtitre plate. The
Fluoroskan Ascent Type 374 plate fluorometer (Labsystems;
Finland) was used with excitation wavelength 390nm, emis-
sion wavelength 460nm, and a measurement integration time
per well of 20ms. The first derivative of the fluorescence–time
curve reflects the course of thrombin activity in the sample.
The parameter of interest in the samples using recalcified PRP
was the maximal generation rate which is the peak of the first
derivative (ETP peak velocity, relative fluorescence units
(RFU) min
 1) of the thrombin generation curve, or, due to
low peak values in Ca
2þ-free samples, the ETP–area under the
curve (AUC).
Measurement of platelet activation markers CD62
and PAC-1 by flow cytometry
Whole blood samples (containing 3.13% sodium citrate),
recalcified PRP, or washed platelets resuspended in PGC were
incubated with b-BA, AKBA, TRAP, or vehicle (DMSO,
control) for 2 or 15min at RT. To measure CD62 and PAC-1,
samples were diluted 1:1 in 20m M HEPES, 137mM NaCl,
2.7mM KCl, 1mM MgCl2, 5.6mM glucose, 1gl
 1 BSA, pH
7.4, and aliquots of 5ml were incubated with saturating
concentrations of CD41-PC7, CD62-PE, and PAC1-FITC
at RT for 15min in the dark. Samples were fixed with
formaldehyde 1% (in PBS), washed twice (CellWash,
Becton-Dickinson, Heidelberg, Germany), and resuspended
in 300ml PBS. Isotype-matched IgG and IgM antibodies were
used to correct for the nonspecific binding of the specific
antibodies. P-selectin (represented by CD62) and PAC-1
antigen expression were quantified using Cellquest software
(Becton-Dickinson). Three-color flow cytometric analysis was
used with logarithmic modes set for all channels. A gate was
set around the platelet population (CD41), and 5000 events
were acquired from each probe. The percentage of CD62-
positive cells (%) as well as their mean channel fluorescence
intensity (MFI) was determined at a level which yields a value
of 1% for mouse IgG1-PE labelled sample. A histogram
of PAC1-FITC against cell events was generated and MFI
of the total platelet population was recorded.
Acquisition of data was carried out using a FACSCalibur
flow cytometer with CELLQuestt (Becton-Dickinson). The
instrument calibration and compensation was assured daily
with calibration beads (CaliBRITEt Beads, Becton-Dickin-
son) and FACSCompt. Fluorescence-conjugated antibodies
CD41-PC7, CD62-PE, and PE-labelled isotype IgG1 control
were obtained from Beckman Coulter (Krefeld, Germany),
PAC1-FITC and FITC-isotype IgM were from Becton-
Dickinson.
Ex vivo platelet aggregation (turbidimetric)
Aggregation of platelets in pure or diluted PRP was
determined using a turbidimetric light-transmittance device.
For aggregation, the response to 30mM b-BA, 30mM AKBA,
or (as positive controls) 2Uml
 1 thrombin, or 1mgml
 1
collagen is given as per cent of the maximal light transmission
Amax.I nC a
2þ-containing samples, CaCl2 was added right
before the start of the measurement. Aggregation was recorded
for 15min.
Statistics
Statistical evaluation of the data was performed by one-way
ANOVAs for independent or correlated samples followed by
Tukey HSD post hoc tests. Where appropriate, Student’s t-test
for paired observations was applied. A P-value of o0.05 (*) or
o0.01 (**) was considered significant.
Results
BAs evoke Ca
2þ mobilisation in washed human platelets
In the presence of extracellular Ca
2þ (1mM), BAs lacking the
11-keto moiety (Ab-BA and b-BA, 10mM each, chemical
structure see Figure 1) induced a transient but robust elevation
of [Ca
2þ]i in washed platelets that peaked 18–30s following
exposure, whereas KBA was ineffective and AKBA caused
only a weak and rather slow Ca
2þ mobilisation (Figure 2a
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significant (Figure 2b). At 10mM, the maximum increase in
[Ca
2þ]i (381728nM) elicited was comparable to that obtained
by thrombin (0.5Uml
 1; 364734nM), and exceeded the signal
obtained by PAF (100nM;6 2 75nM, Figure 2c). However,
thrombin- and PAF-induced Ca
2þ mobilisation was more
rapid, peaking 5–10s after exposure and (for thrombin) was
more sustained. Collagen (8mgml
 1) caused a slow and only
moderate elevation of [Ca
2þ]i (7877n M, after 90s). 11-Keto
BAs caused significant Ca
2þ mobilisation at higher concentra-
tions (X20–30mM) (Figure 2b), which again was rather slow.
Thus, the potencies and the kinetics differ between 11-keto-
BAs and their 11-me analogues.
[Ca
2þ]i was also measured in the absence of extracellular
Ca
2þ. b-BA, Ab-BA (not shown), and AKBA as well as
thrombin evoked an internal Ca
2þ release with similar kinetics
observed for the total Ca
2þ response in the presence of
extracellular Ca
2þ, respectively (Figure 2D, compare
Figure 2a). Nevertheless, in the absence of extracellular
Ca
2þ, elevation of [Ca
2þ]i was reduced to about 37714%
for thrombin and 28717% for b-BA, as compared to the total
Ca
2þ response (Figure 2e).
b-BA-, but not AKBA-induced Ca
2þ mobilisation is PLC
dependent
U-73122 (3mM) and 2-aminoethoxydiphenylborate (2-APB,
50mM) were used to examine the participation of PLC in BA-
induced Ca
2þ mobilisation. Cells were stimulated with b-BA
or AKBA (10mM each), with thrombin (positive control), or
thapsigargin (TG, negative control). Thrombin evokes Ca
2þ
elevations via a GPCR/PLC-dependent pathway (Coughlin,
2000), whereas TG induces Ca
2þ mobilisation by inhibition of
the ER Ca
2þ-ATPase, thus circumventing PLC and GPCR
signalling (Gouy et al., 1990). Thrombin- and b-BA-induced
Ca
2þ elevation was strongly suppressed by U-73122
(Figure 3a), both, in the presence and in the absence of
extracellular Ca
2þ (Table 1). In contrast, Ca
2þ mobilisation
induced by TG was not suppressed by U-73122, and the
response to AKBA was even potentiated (Figure 3a, Table 1).
Generally, U-73122 preincubation already caused a slight
elevation of the resting Ca
2þ levels (Figure 3a). U-73343,
the inactive analogue of U-73122, had no effect (not shown).
2-APB (50mM) (Maruyama et al., 1997), an inhibitor of IP3-
mediated elevations in cytosolic [Ca
2þ], also suppressed Ca
2þ
Figure 2 BAs induce intracellular Ca
2þ mobilisation. To Fura-2-loaded platelets (10
8ml
 1 PG buffer), 1mM CaCl2 (a–c and e) or
1mM EDTA (d and e) was added 2min prior stimulation, and [Ca
2þ]i was determined. (a) Ca
2þ mobilisation in the presence of
extracellular Ca
2þ. BAs (10mM, each) were added 30s after the measurement was started. (b) Concentration–response curves of BAs
in the presence of extracellular Ca
2þ. The maximal increase in [Ca
2þ]i obtained within 100s of measurement is given. (c) Ca
2þ
mobilisation induced by various agonists. The following agonists were used: b-BA (10mM), thrombin (0.5Uml
 1), collagen
(8mgml
 1), and PAF (100nM). (d) Ca
2þ mobilisation in the absence of extracellular Ca
2þ. BAs (10mM, each) or thrombin
(0.5Uml
 1) were added 30s after the measurement was started. (e) Comparison of Ca
2þ mobilisation in the presence (black bars)
or absence (white bars) of 1mM of extracellular Ca
2þ. The maximal increase in [Ca
2þ]i after stimulation with thrombin (0.5Uml
 1)
or BAs (10mM, each) was determined within 100s of measurement. Values are given as meanþs.e., n¼5; curves are representative
for at least five experiments. One-way ANOVAs followed by Tukey HSD tests were applied to data related to unstimulated
controls in (b) and (e) *Po0.05 or **Po0.01.
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inhibition, n¼3) and in the absence of Ca
2þ (54711%
inhibition, n¼3). An equal reduction was found for the
thrombin response (not shown). Collectively, our data indicate
that Ca
2þ mobilisation induced by b-BA is mediated by the
PLC/IP3 signalling pathway.
Since b-BA could first induce the generation of an
endogenous platelet agonist that in turn causes PLC/IP3-coupled
Figure 3 Modulation of b-BA-induced Ca
2þ mobilisation by pharmacological inhibitors. (a) Effects of U-73122. Fura-2-loaded
platelets (10
8ml
 1 PG buffer) were preincubated with U-73122 (3mM, trace labelled ‘þU’) or vehicle (DMSO) for 15min. CaCl2
(1mM) was added 2min prior stimulation with thrombin (0.5Uml
 1), thapsigargin (0.1mM), or BAs (10mM, each), and [Ca
2þ]i was
determined. Curves are representative for at least five experiments. (b) Effects of argatroban (100ngml
 1), WEB 2086 (30mM), NF
449 (1mM), or MRS-2179 (10mM). Fura-2-loaded platelets (10
8ml
 1 PG buffer) were preincubated with the indicated compounds or
vehicle (DMSO) for 15min. CaCl2 (1mM) was added 2min prior stimulation with 10mM b-BA. The maximal increase in [Ca
2þ]i
determined within 100s of measurement is expressed as percentage of control (10mM b-BA). Values are given as meanþs.e., n¼5.
(c) Effects of Src family kinase inhibitors. Fura-2-loaded platelets (10
8ml
 1 PG buffer) were preincubated with PP2 (3mM), PP3
(3mM), SU6656 (10mM), or vehicle (DMSO) for 15min. CaCl2 (1mM) and b-BA (10mM) were added, and [Ca
2þ]i was determined.
Curves are representative for at least four experiments.
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2þ]i, antagonists of typical platelet stimuli were
utilised to unravel such an autocrine mode of action. The
thrombin antagonist argatroban (100ngml
 1) failed to sig-
nificantly suppress the effects of b-BA (Figure 3b), whereas it
completely blocked thrombin-induced Ca
2þ mobilisation (not
shown). Similarly, the PAF receptor antagonist WEB 2086
(30mM) as well as the purinergic receptor antagonists NF-449
(1mM, targeting P2X1) and MRS-2179 (10mM, targeting P2Y1,
and P2Y12) did not markedly affect b-BA-induced elevation of
[Ca
2þ]i (Figure 3b), although these compounds abolished the
responses induced by their respective agonists (not shown).
Src family kinases are involved in b-BA-induced Ca
2þ
mobilisation
The role of Src family kinases in b-BA-induced Ca
2þ
mobilisation was assessed using the selective Src family kinase
inhibitors PP2 (and its inactive analogue PP3) (Hanke et al.,
1996) and SU6656 (Blake et al., 2000). PP2 (3mM) blunted the
Ca
2þ response initiated by b-BA (9272% inhibition, n¼7, see
Figure 3c) whereas the inactive analogue PP3 (3mM) was
hardly effective (8978% residual activity, n¼4, see
Figure 3c). Also, the structurally unrelated Src kinase inhibitor
SU6656 (10mM) likewise abolished the b-BA signal (9371%
inhibition, n¼4, Figure 3c). In sharp contrast, no such
inhibitory effects of PP2 on Ca
2þ signals induced by thrombin,
PAF, or AKBA were apparent (not shown).
b-BA induces MAPK activation and Akt/PKB
phosphorylation
All BAs tested led to a concentration-dependent activation of
p38 MAPK in platelets (Figure 4a). Moreover, b-BA (and Ab-
BA, not shown) also concentration-dependently (10–100mM)
activated ERK2 (Figure 4b), which was maximal 30–60s upon
stimulation, slightly preceding thrombin-induced ERK2
activation (maximum after 2min) (Figure 4c). The EC50 for
thrombin to activate p38 MAPK and ERK2 was determined at
E1Uml
 1 (not shown). AKBA (and KBA, not shown) were
virtually ineffective to activate ERK2. U-73122 (not shown) as
well as the Ca
2þ chelators EDTA and BAPTA/AM, moderately
reduced b-BA-induced ERK2 activation (Figure 4d and e),
indicating that PLC and Ca
2þ may contribute, but are not
absolutely required.
b-BA concentration-dependently increased the phosphor-
ylation of Akt at Ser473, whereas AKBA had no significant
effect (Figure 5a). Again, the effects of b-BA were comparable
to thrombin. Thus, Akt phosphorylation induced by b-BA was
Table 1 Effects of U-73122 on Ca
2+ mobilisation in
the absence and presence of Ca
2+
+Ca
2+ residual signal
(percentage of control)
 Ca
2+ (+EDTA)
residual signal
(percentage of control)
Thrombin 1074( n¼5)** 1273( n¼5)**
TG 90712 (n¼5) 116719 (n¼4)
b-BA 572( n¼6)** 2378( n¼6)**
AKBA 170768 (n¼5) 202741 (n¼5)
Fura-2-loaded platelets (10
8ml
 1 PG buffer) were preincu-
bated with U-73122 (3mM) for 15min. CaCl2 (1mM)o r
EDTA (1mM) were added, and after 2min, platelets were
stimulated with thrombin (0.5Uml
 1), TG (0.1mM), or BAs
(10mM, each). Maximum amplitudes were compared to
control measurements in the absence of U-73122. Data are
expressed as mean+s.e., n¼4–6 (see table). Statistical
analysis (t-tests for correlated samples, inhibitor versus
control samples for each stimulus) was performed prior to
data normalisation, **Po0.01.
Figure 4 BAs induce the activation of MAPKs. Activation of p38
MAPK (a) and ERK2 (b). Platelets (10
9ml
 1 PGC buffer) were
stimulated with the indicated concentrations of the BAs at 371C.
Reactions were terminated after 1min to assess ERK2 phosphor-
ylation, and after 1.5min to assess p38 MAPK phosphorylation.
Samples were subjected to SDS–PAGE and Western blotting using
phospho-specific antibodies against the dually phosphorylated form
of the MAPKs. (c) Time course of ERK2 activation in the presence
of Ca
2þ. Platelets (10
9ml
 1 PGC buffer) were stimulated with b-BA
(30mM) or thrombin (1Uml
 1)a t3 7 1C for the indicated times and
phosphorylation of ERK2 was determined. (d) ERK2 activation by
b-BA in the absence of Ca
2þ. Platelets (10
9ml
 1 PG buffer
containing 1mM EDTA and 30mM BAPTA/AM) were preincubated
for 15min at RT, stimulated with the indicated concentrations of b-
BA for 1min and phosphorylation of ERK2 was determined. (e)
Time course of ERK2 activation by b-BA in the absence of Ca
2þ.
Platelets (10
9ml
 1 PG buffer containing 1mM EDTA and 30mM
BAPTA/AM) were preincubated for 15min at RT, stimulated with
30mM b-BA, and phosphorylation of ERK2 was determined after
the times indicated. The relative intensities (rel. int.) of blot bands
were determined by densitometry using the BioRad Quantitate One
software. The results shown are representative of at least three
independent experiments.
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completely blocked by the PI 3-K inhibitor wortmannin
(wortm., 200nM) and strongly blunted by U-73122
(Figure 5c). Moreover, removal of total Ca
2þ with EDTA
and BAPTA/AM abolished the effect of b-BA (not shown).
Similar inhibitory effects on Akt phosphorylation by wort-
mannin and U-73122 (Figure 5c) as well as by Ca
2þ removal
(not shown) were seen when thrombin was used as stimulus.
Induction of cell viability assessment and AA release
The effects of BAs on platelet viability were determined by
analysis of the particle distribution pattern of washed platelet
samples treated with b-BA, AKBA (30mM, each), DMSO,
or Ca
2þ ionophore A23187 (5mM) for 15min at 371C. Particle
size spreading (given by the particle volume, unit: fl, horizontal
axis) and numbers were similar for b-BA, AKBA, and DMSO,
whereas ionophore-induced platelet lysis caused a hetero-
geneous dispersion (Figure 6a). Thus, exposition of platelets
to b-BA for 15min does not seem to affect cell viability.
An elevation of [Ca
2þ]i and/or activation of members of
the MAPK family are considered important for the liberation
of AA by the cPLA2 (Gijon & Leslie, 1999). Incubation of
[
3H]AA-labelled platelets with b-BA caused a concentration-
dependent increase in the amounts of [
3H]AA released into the
medium. At 30mM, b-BA was equipotent to 2Uml
 1 thrombin
(Figure 6b).
Effects of b-BA on aggregation
In recalcified (1.5mM CaCl2, free Ca
2þ was calculated as
approx. 1mM)P R P ,b-BA (10or 30 mM) stimulated aggregation
Figure 5 b-BA induces phosphorylation of Akt. (a) Concentra-
tion–response experiments. Platelets (10
9ml
 1 PGC buffer) were
stimulated with the indicated concentrations of BAs for 4min at
371C and Akt phosphorylated at Ser473 was assessed. (b) Time
course of Akt phosphorylation. Platelets (10
9ml
 1 PGC buffer) were
incubated with b-BA (30mM) or thrombin (1Uml
 1)a t3 7 1C for the
indicated times and Akt phosphorylation was assessed. (c) Effects of
U-73122 and wortmannin (wortm) on Akt phosphorylation.
Platelets (10
9ml
 1 PGC buffer) were preincubated with 3mM U-
73122 or 200nM wortmannin as indicated and then stimulated with
b-BA (30mM) or thrombin (1Uml
 1), respectively, for 4min at 371C
and Akt phosphorylation was assessed. The relative intensities (rel.
int.) of blot bands were determined by densitometry using the
BioRad Quantitate One software. Results are representative of at
least three independent experiments.
Figure 6 b-BA induces the liberation of AA; effects on cell viability. (a) Analysis of cell viability. Washed platelets were
resuspended in PGC buffer and exposed to the indicated stimuli (vehicle (DMSO), 30mM b-BA, 30mM AKBA, 5mM A23187, from
top) for 15min at 371C. The particle size distribution pattern and particle number in each sample was determined. DMSO (negative
control, viable cells) and A23187 samples (positive control, lysed cells) were used as reference. Curves are representative for at least
three independent determinations. Cell count values are given as meanþs.e., n¼3–4. (b) b-BA induces the release of AA. Platelets
were labelled with [
3H]AA for 2h. CaCl2 (1mM) was added to the cells (10
8 in 1ml PG buffer), and after 2.5min, cells were
stimulated with the indicated concentrations of b-BA or 2Uml
 1 thrombin (tb). [
3H]AA released into the medium was measured
after 5min at 371C. Data are expressed as increase over unstimulated cells, values are given as meanþs.e., n¼5. Statistical analysis
(directed t-tests for correlated samples) was applied to original data prior to normalisation, *Po0.05.
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contrast, aggregation induced by collagen (1mgml
 1) was
much more rapid (Figure 7a, middle right trace). Spontaneous
aggregation due to unspecific platelet activation (e.g. stirring)
occurred after 412–15min. Similarly, in samples that received
AKBA (30mM), aggregation was first evident after approx.
12min (Figure 7a, lower trace). In contrast, in citrate-chelated
PRP (no Ca
2þ), b-BA (30mM) caused no aggregation, whereas
collagen remained a full agonist (Figure 7b). Also, no
unspecific aggregation was observed in the absence of
extracellular Ca
2þ. The Ca
2þ dependency of the b-BA effect
was confirmed using PRP diluted in a Ca
2þ-containing
HEPES buffer (14% PRP, final concentration). Under these
conditions, aggregation induced by b-BA (30mM) was more
rapid (after 4–6min) than in pure PRP (Figure 7c). DMSO and
AKBA (30mM) were inactive, and collagen again acted as an
immediate and full agonist (Figure 7c). It should be noted that
in diluted PRP without Ca
2þ, none of the stimuli induced
aggregation (not shown). Together, b-BA-stimulated aggrega-
tion strictly depended on the presence of extracellular Ca
2þ.
Thrombin generation and expression of activation
markers
b-BA was tested for its ability to generate thrombin from PRP,
expressed as the ETP. b-BA (10mM) potently stimulated
thrombin generation, whereas AKBA (10mM) was inactive
(Figure 8a, left panel). Although collagen was only moderately
superior to b-BA in the peak thrombin generation velocity,
there was again a delayed onset of the b-BA effect, visualised
by the kinetic progression of the ETP (Figure 8b). In the
absence of Ca
2þ, neither stimulus induced a marked increase
in the ETP over time although analysis of the ETP-AUCs
revealed a slight stimulatory effect of b-BA (10mM)a s
compared to DMSO and collagen that both were inactive
(Figure 8a, right panel).
Finally, the expression of the activation markers PAC-1 (the
activated GPIIb/IIIa-receptor for fibrinogen) and CD62,
which indicates the release of platelet alpha-granules, were
assessed. Incubations were carried out in (I) whole blood
(containing 3.13% citrate), (II) recalcified PRP, and (III)
washed platelets in Ca
2þ-containing PGC buffer, for 2 or
15min. Neither b-BA (30or 10 0 mM) nor AKBA (30mM) led to
a significant expression of CD62 and PAC-1 under all
experimental settings (I–III), whereas TRAP (used as positive
control) was a strong activator (Figure 8c).
Discussion
We identified 11-me-BAs (i.e. b-BA) as naturally occurring
compounds that induce central signalling pathways and that
elicit select functions in human platelets. Depending on the
structure of the BAs, the effectiveness and the routes, utilised
to activate downstream signalling pathways and functional
responses, are highly distinct. For b-BA, Src family kinases
and the PLC/IP3 pathway seem to be involved in Ca
2þ
mobilisation, and b-BA causes activation of ERK2 and the
PI 3-K/Akt route. Moreover, b-BA induces the release of AA,
a pronounced generation of thrombin, and Ca
2þ-dependent
platelet aggregation. In contrast, AKBA-induced Ca
2þ mobi-
lisation is not connected to Src family kinases and PLC/IP3
Figure 7 Effects of b-BA on platelet aggregation. (a) Aggregation
in recalcified PRP (PRP
þ). Samples were stimulated with vehicle
(DMSO, 0.3%), b-BA (30mM), collagen (1mgml
 1), or AKBA
(30mM) as indicated and aggregation curves were recorded (max-
imum 15min). The aggregation response is given as per cent of the
maximal light transmission Amax. Curves are representative for at
least five independent determinations. (b) Aggregation in citrate-
chelated PRP. The experimental conditions were the same as above,
n¼4. (c) Aggregation in PRP diluted in Ca
2þ-containing HEPES
buffer, n¼5.
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and ERK2, as well as functional platelet responses.
Among the BAs tested for Ca
2þ mobilisation, b-BA is
the most potent analogue. At 10mM, the effectiveness of
b-BA exceeded that of PAF or collagen, and was comparable
with that of the potent platelet agonist thrombin. Such
b-BA concentrations are in the range of b-BA levels in
human plasma (10.1mM), determined after oral applica-
tion of 4 786mg BS extract/day within 10days (Buchele &
Simmet, 2003). The 3-O-acetyl group slightly hampers
(receptor-)activation and the 11-keto moiety significantly
decreases the potency and also alters the signalling routes in
platelets. In sharp contrast to platelets, only 11-keto BAs, but
not 11-me-BAs, caused stimulation of PMNL (Altmann et al.,
2002; 2004). Possibly, PMNL and platelets selectively express
closely related but not identical receptors specific for AKBA or
11-me-BAs, respectively. Important receptors for soluble
agonists known to regulate [Ca
2þ]i in platelets are the
purinergic P2X1 and P2Y1/12 receptors, the TXA2 receptor,
the PAF receptor, the 5-HT2A receptor, and the PAR-1 and -4
(Jackson et al., 2003). Whether b-BA acts at one (or more) of
these receptors is unknown. However, antagonists of thrombin
(argatroban), PAF (WEB 2086), and ADP (NF449 and
MRS2179) did not affect b-BA-induced Ca
2þ mobilisation.
Thrombin is the most potent platelet agonist acting via
PAR-1 and -4. PARs are coupled to trimeric Gq/Gi/G12/13
proteins enabling the Ga and Gbg subunits to stimulate PLC-b
subtypes (Lee et al., 1996; Coughlin, 2000), resulting in IP3-
dependent Ca
2þ mobilisation from intracellular storage sites
with concomitant store-operated Ca
2þ entry (Rosado & Sage,
2001). In analogy to thrombin, b-BA caused Ca
2þ mobilisa-
tion from internal stores, which was sensitive to U-73122 and
to 2-APB, confirming the involvement of PLC/IP3. However, it
should be noted that PLC/IP3-independent effects of U-73122
(Broad et al., 1999) and 2-APB on cellular Ca
2þ influx systems
have been reported (Dobrydneva & Blackmore, 2001). Of
interest, the proximal routes mediating PLC/IP3-dependent
Ca
2þ mobilisation appear to be different for b-BA and
thrombin (or PAF). Thus, Src family kinase inhibitors
abolished the b-BA-induced response, but not the responses
elicited by thrombin or PAF. PLC-g is the most abundant PLC
isoform in platelets (Lee et al., 1996) and is an operative
element in Ca
2þ mobilisation mediated by adhesion receptors
(Rhee, 2001). Whereas, soluble ligands such as thrombin,
ADP, PAF, or TXA2 act via GPCRs to stimulate PLC-b
isoenzymes, the PLC-g isoforms are regulated through
phosphorylation by Src family kinases (Rhee, 2001). In
analogy to agonists that act via adhesion receptors but unlike
thrombin, b-BA may utilise the Src family kinases/PLC-g
pathway to induce Ca
2þ mobilisation. Another difference
between b-BA- and thrombin-mediated Ca
2þ mobilisation is
Figure 8 Thrombin generation and activation marker expression.
(a) Thrombin generation was assessed in recalcified PRP (given as
ETP peak velocity, left bar chart), or citrate-chelated PRP (given as
ETP-AUC, right bar chart). PRP and buffer containing the
indicated stimuli were added to each well of a 96-well microtitre
plate. b-BA (10mM), AKBA (10mM), collagen (2mgml
 1, final
concentrations each), and vehicle (DMSO) were tested for their
ability to induce thrombin generation. Data are expressed as
meanþs.e., n¼4( b-BA, AKBA, collagen) or n¼8 (vehicle). One-
way ANOVA and Tukey HSD tests were performed, **Po0.01. (b)
Representative original traces of the ETP kinetic progression. Cells
in recalcified PRP were stimulated as described above. (c)
Expression of the platelet activation markers CD62 and PAC-1.
Flow cytometry in recalcified PRP was performed as described in
the Methods section. Expression of CD62 (left bar chart) and PAC-1
(right bar chart) after stimulation with vehicle (DMSO), b-BA
(30mM), AKBA (30mM), or TRAP (10mM) is given. The percentage
of CD62-positive cells (%) as well as their mean channel
fluorescence intensity (MFI) was determined (left diagram). Right,
a histogram of PAC1-FITC against cell events was generated and
MFI of total platelet population was recorded., n¼4. One-way
ANOVA and Tukey HSD tests were performed, *Po0.05 or
**Po0.01.
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the rapid effect of thrombin. Possibly, aside of acting as a
direct ligand at a certain (adhesion) receptor, b-BA may first
induce the generation of an endogenous agonist that in turn
causes PLC-g/IP3-coupled Ca
2þ mobilisation via (adhesion)
receptors. Attempts to unravel a putative autocrine mode of
action are in progress in our laboratory.
Typical platelet agonists such as thrombin, collagen, or
TXA2 activate PI 3-K and its downstream effector Akt,
important mediators of agonist-induced platelet activation
(Kim et al., 2004), as well as p38 MAPK and ERKs (Papkoff
et al., 1994; Kramer et al., 1995; Saklatvala et al., 1996). The
MAPK are a point of convergence of complex signalling
networks, regulating cell proliferation and differentiation
(Papkoff et al., 1994). In platelets, the functions of MAPK
are mainly uncharacterised and the signal transduction steps
are poorly understood. All BAs tested activated p38 MAPK
with similar efficacy, but only b-BA (and Ab-BA) rapidly and
significantly activated ERK2. Also, b-BA, but not AKBA,
evoked Akt phosphorylation, and in analogy to thrombin, the
PI 3-K and/or the PLC/Ca
2þ pathway is involved. Therefore,
the receptor for BAs mediating p38 MAPK activation might be
different from that transmitting signals to activate ERK2 and
Akt. The latter (11-me-BA specific) receptor may also mediate
increases in [Ca
2þ]i, generation of thrombin, release of AA and
aggregation, since AKBA and KBA failed to elicit these events.
Investigation of the platelet functions elicited by b-BA
provided controversial results. As a rule, the distinct responses
of activated platelets depend on the strength (potency) of the
agonist, and these responses can be ordered in an activation
sequence: (1) aggregation, (2) granule secretion, (3) AA
liberation, and (4) acid hydrolase secretion (Steen & Holmsen,
1987). For the induction of these responses, the magnitude of
Ca
2þ mobilisation is an important parameter. In fact, b-BA
(10–30mM) substantially elevated [Ca
2þ]i and potently induced
thrombin generation, being equipotent in this respect with
collagen at 2mgml
 1 in a model utilising native platelets. Also,
b-BA potently evoked the liberation of free AA from washed
platelets, although at concentrations slightly higher than those
required for Ca
2þ mobilisation, probably due to the presence
of fatty acid-free albumin that may bind BAs. In general,
liberation of free AA is a response distal of aggregation and
degranulation, and its induction normally requires a potent
agonist-activating platelets with high strength. Surprisingly,
however, the efficacy of b-BA was much reduced for the
induction of aggregation. In contrast to collagen, the response
of b-BA was strictly dependent on the presence of extracellular
Ca
2þ and was characterised by a prolonged lag phase
(4–8min), a rather slow initial decrease in light transmission,
and a submaximal slope of the aggregation curve. This
response in some way resembles the ‘unspecific’ aggregation
induced by shear stress (stirring), normally occurring after
12–15min, in contrast to the rapid (o1min) signal evoked by
a strong agonist (i.e. collagen). Therefore, b-BA may rather
facilitate aggregation by other factors than being a full agonist.
Moreover, b-BA failed to induce degranulation and fibrinogen
receptor activation (CD62, PAC-1 expression). Together,
despite the pronounced elevation of [Ca
2þ]i, only select
functional platelet responses were observed after stimulation
with b-BA. Along these lines it was found that platelets in
polycythaemia vera exhibit decreased aggregation after stimu-
lation with PAF, although an equal increase in [Ca
2þ]i was
seen as compared to platelets from healthy donors (Le Blanc
et al., 2000). Also, a patient was described with defective
platelet aggregation in response to ionophore A23187, despite
normal increases in [Ca
2þ]i (Fuse et al., 1999). Hence, elevation
of [Ca
2þ]i in platelets is one important signalling step for
eliciting various platelet responses, but must not necessarily lead
to the induction of all Ca
2þ-dependent platelet functions. It is
conceivable that b-BA on one hand is a platelet agonist that
potently induces central signalling pathways (Ca
2þ mobilisa-
tion, MAPK/Akt phosphorylation) and select responses such as
thrombin generation and AA release, but on the other hand
lacks the stimulation of certain signalling components or
executing molecules particularly important for a rapid aggrega-
tion, degranulation, and fibrinogen receptor activation.
At present, our findings cannot be readily related to the anti-
inflammatory properties of BS extracts, observed in animal
models or in studies with human subjects (Safayhi & Sailer,
1997). Nevertheless, due to its high effectiveness and the
importance of the signalling molecules and the select platelet
functions induced, the receptor(s) mediating the actions of b-
BA in platelets warrant further elucidation. Since the effective
concentrations of b-BA (10mM) are in range of b-BA levels in
human plasma (see above), one should be aware of its
pharmacological actions on platelets when administering BS
extracts to patients.
We thank Sven George for expert technical assistance and Dr Gu ¨ nter
Lambrecht for critical reading of the manuscript and helpful
discussion. This study was supported by grants from the Fonds der
Chemischen Industrie, from the Deutsche Forschungsgemeinschaft
(GRK 757), the Deutsche Pharmazeutische Gesellschaft, and from the
European Union (LEUCHRON, QLRT-2000-01521).
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ABSTRACT 
Boswellic acids (BAs) inhibit the transformation of 
arachidonic acid (AA) to leukotrienes via 5-
lipoxygenase but can also enhance the liberation of 
AA in human leukocytes and platelets. Utilizing 
human platelets, we explored the molecular 
mechanisms underlying the BA-induced release of 
AA and the subsequent metabolism by platelet-type 
12-lipoxygenase (p12-LO). Both, β-BA as well as 3-
O-acetyl-11-keto-BA (AKBA) markedly enhanced the 
release of AA via cytosolic phospholipase (PL)A2, 
whereas for generation of 12-hydro(pero)xy-
eicosatetraenoic acid (12-H(P)ETE), AKBA was less 
potent than β-BA and was without effect at higher 
concentrations (≥ 30 µM). In contrast to thrombin, β-
BA-induced release of AA and formation of 12-
H(P)ETE was more rapid and occurred also in the 
absence of Ca
2+. The Ca
2+-independent release of 
AA and 12-H(P)ETE production elicited by β-BA was 
not affected by pharmacological inhibitors of signaling 
molecules relevant for agonist-induced AA liberation 
and metabolism. Notably, in cell-free assays, β-BA 
increased p12-LO catalysis about two-fold in the 
absence, but not in the presence of Ca
2+, whereas 
AKBA inhibited p12-LO activity. No direct modulatory 
effects of BAs on cPLA2 activity in cell-free assays 
were evident. Accordingly, immobilized KBA (linked 
to sepharose beads) selectively precipitated p12-LO 
from platelet lysates but failed to bind cPLA2. Taken 
together, we show that BAs induce the release of AA 
and the synthesis of 12-H(P)ETE in human platelets 
by unique, Ca
2+-independent routes, and we 
identified p12-LO as a selective molecular target of 
BAs. 
 
 
The pentacyclic triterpenes boswellic acids (BAs) are 
regarded as the active pharmacological principles of 
ethanolic extracts of Boswellia serrata (B.S.), and there is 
accumulating evidence for anti-inflammatory and anti-
tumorigenic effects of BAs based on experimental cellular 
and animal models (Anthoni et al., 2006; Poeckel et al., 2006; 
Safayhi et al., 1992; Syrovets et al., 2005a; Syrovets et al., 
2005b; Winking et al., 2000). Attempts to identify the 
responsible molecular mechanisms and/or receptors 
revealed a number of proteins that may be targeted by BAs 
including 5-lipoxygenase (5-LO), human leukocyte elastase, 
topoisomerases and IκB kinases (Safayhi et al., 1997; Safayhi 
et al., 1995; Syrovets et al., 2000; Syrovets et al., 2005b). 
Interaction with these targets may indeed provide a 
molecular basis for the pharmacological effects observed in 
animals and human subjects. In particular suppression of 
leukotriene biosynthesis from arachidonic acid (AA) by inhi- 
_______________________ 
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 bition of 5-lipoxygenase is generally regarded as the most 
important pharmacological action of BAs accounting for 
their anti-inflammatory properties (Safayhi et al., 1997; 
Safayhi et al., 1995). 
Many cell types are able to release AA from phospholipids 
within cellular membranes by the action of specific 
phospholipases (PL)A2. AA is an important precursor for a 
number of highly bioactive metabolites formed by various 
oxygenases including cyclooxygenases (COX), LOs, and 
monooxygenases of the CYP family. The 85-kDa cytosolic 
PLA2 (cPLA2) has been accounted as responsible enzyme 
providing free AA as substrate for COX and LOs in 
leukocytes and platelets (Leslie, 2004). This soluble enzyme is 
distributed within the cytosol of resting cells and associates 
upon elevation of intracellular Ca2+ and/or phosphorylations 
of serine residues by members of the MAPK family (Gijon 
and Leslie, 1999), occurring in response to a number of 
GPCR agonists. In addition, binding to phosphytidylinositol-
4,5-bisphosphate (PIP2) (Balsinde et al., 2000) or 
ceramide(1-phosphate) (Huwiler et al., 2001; Pettus et al., 
2004; Subramanian et al., 2005) via specific binding-site(s) 
may promote cPLA2 catalysis.   
Exposure of leukocytes or platelets to BAs differentially 
affects certain signaling pathways and functional responses 
including Ca2+ mobilization, MAPK activation, formation of 
reactive oxygen species, release of AA and stimulation of 5-
LO product formation. Thus, stimulating properties 
(Altmann et al., 2002; Altmann et al., 2004; Poeckel et al., 
2005; Sailer et al., 1998) as well as inhibitory effects (Poeckel 
et al., 2006; Safayhi et al., 1992; Safayhi et al., 1995; Werz et 
al., 1998) of BAs have been reported for these functions, 
depending on the cell type investigated and the respective 
experimental settings. For example, inhibition of 5-LO by 
AKBA, IC50 values in the range of 1.5 µM (Safayhi et al., 
1995) up to 50 µM (Werz et al., 1997; Werz et al., 1998) were 
determined, but also 5-LO stimulatory effects in this 
concentration range were described (Altmann et al., 2004; 
Sailer et al., 1998). 
We recently observed that BAs are capable of elevating the 
release of AA in human isolated polymorphonuclear 
leukocytes (Altmann et al., 2004) and platelets (Poeckel et al., 
2005). Platelets do not express 5-LO, but contain the closely 
related p12-LO that converts AA to 12-
hydro(pero)xyeicosatetraenoic acid (12-H(P)ETE) 
(Yoshimoto and Takahashi, 2002). Unlike 5-LO, the activity 
of p12-LO is hardly dependent on co-factors such as ATP, 
FLAP etc., and in fact upon supply of AA, substantial 12-
H(P)ETE formation occurs in the platelet without the 
absolute requirement of induction of additional signaling 
pathways. Here we investigated the effects of BAs on the 
liberation of AA and its subsequent conversion by p12-LO, 
and we attempted to elucidate the underlying mechanisms 
and to identify molecular targets of BAs.  
 
 
Materials and Methods 
 
Materials. 
BAs were synthesized and prepared as described (Jauch and 
Bergmann, 2003). Antibodies against human p12-LO was kindly 
provided by Dr Colin D. Funk, Kingston, Canada. SB203580, PP2, 
PP3, SU6656, methyl-arachidonyl-fluorophosphonate (MAFP), 
bromoenol lactone (BEL), the cPLA2α inhibitor, and U0126, 
Calbiochem (Bad Soden, Germany); BAPTA/AM and Fura-2/AM, 
Alexis (Grünberg, Germany); wortmannin, Biotrend (Köln, 
Germany); cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC), 
Biomol (Plymouth Meeting, PA); EAH-Sepharose 4B, GE 
Healthcare Bio-Sciences (Freiburg, Germany); all other chemicals 
were obtained from Sigma (Deisenhofen, Germany). 
 
Cells. 
Platelets were freshly isolated from human venous blood of healthy 
adult donors (St. Markus Hospital, Frankfurt, Germany) as 
described (Poeckel et al., 2005). Washed platelets were finally 
resuspended in PBS pH 7.4 and 1 mg/ml glucose (PG buffer) or in 
PBS pH 7.4 and 1 mg/ml glucose plus 1 mM CaCl2 (PGC buffer). 
For incubations with solubilized compounds, ethanol or DMSO 
was used as vehicle, never exceeding 1 % (vol/vol). For AA release, 
platelet rich plasma (PRP) was prepared from freshly drawn blood 
(in 3.13% citrate) from healthy adult donors by centrifugation for 
10 min at 750 × g. 
 
Determination of release of [3H]-labeled arachidonic acid 
from intact platelets. 
PRP was labelled with 19.2 nM [3H]AA (1 µCi/ml, specific activity 
200 Ci/mmol) for 2 hours at 37°C in the presence of 100 µM 
aspirin to avoid clotting. Then, cells were washed twice with PBS 
pH 5.9 plus 1 mM MgCl2, 11.5 mM NaHCO3, 1 g/l glucose, and 1 
mg/ml fatty acid-free BSA, and finally resuspended in PG buffer 
(108/ml). Preparation of cells at this pH is thought to minimize 
temperature-induced activation. Platelets were incubated at 37°C 
with 1 mM EDTA plus 30 µM BAPTA/AM for 15 min or 
incubated with CaCl2 (1 mM) for 2.5 min prior stimulation with the 
indicated agents. After the indicated times, incubations were put on 
ice for 10 min, followed by centrifugation (5,000 × g, 15 min). 
Aliquots (300 µl) of the supernatants were measured (Micro Beta 
Trilux, Perkin Elmer) to detect the amounts of [3H]-labeled AA 
released into the medium. 
 
Determination of 12-lipoxygenase product formation.  
To determine 12-LO product formation in intact cells, freshly 
isolated platelets (108/ml PG buffer) were supplemented with either 
1 mM CaCl2,  1  m M  E D T A ,  o r  1  m M  E D T A  p l u s  3 0  µ M  
BAPTA/AM. Platelets were preincubated with the indicated agents 
for 15 min at 37°C. After addition of stimuli and further incubation 
at 37°C for the times indicated, 12-LO products (12(S)-
hydro(pero)xy-6-trans-8,11,14-cis-eicosatetraenoic acid (12-
H(P)ETE) were extracted and then analyzed by HPLC as described 
(Albert et al., 2002). 12-HETE plus 12-HPETE elute as one major 
peak, integration of this peak represents p12-LO product 
formation, expressed as ng metabolites per 108 cells.  
For determination of 12-LO product formation in broken cell 
preparations, platelets (108/ml PG buffer) were sonicated (3 × 10 
sec) and centrifuged (100,000×g/70 min/4°C). To the resulting 
100,000×g supernatant (S100), BAs were added and samples were 
pre-warmed at 37°C for 30 sec. CaCl2 (2 mM) was added as 
indicated and 12-LO product formation was started by addition of 
AA (10 µM). After 10 min at 37°C, the formation of 12-H(P)ETE 
was determined as described for intact cells. 
 
Immobilization of boswellic acids and protein pull-down 
assays. 
For immobilization of BAs at EAH Sepharose 4B beads, the free 3-
OH group of the BAs was used (manuscript in preparation: Kather, 
N., Tausch, L., Poeckel, D., Werz, O., and Jauch, J. (2006)). In 
brief, β-BA and KBA were treated with glutaric anhydride to form 
the half-esters Glut-BA and Glut-KBA, respectively, and analyzed 
by  1H- and 13C-NMR as well as by MS. These substances were 
ready for immobilization at EAH Sepharose 4B by standard amide 
coupling procedures. The carboxylic acid of the BA-core was 
unlikely to react under standard conditions due to steric crowding. 
The success of the coupling reaction was determined by two 
methods: a) Glut-BAs were used in defined excess (2 µmol of the 
Glut-BAS per 1 µmol NH2-groups of the EAH Sepharose 4B). 
After the coupling reaction, the hypothetical excess of Glut-BAs (1 µmol) could be indeed recovered. b) Treatment of Glut-BAs with 
KOH in iso-propanol under reflux for ca. 3 h cleaved the ester bond 
and gave BA and KBA respectively, analyzed by thin layer 
chromatography. 
For protein pull-down experiments, 109 platelets were lysed in 1 ml 
lysis buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 mM EDTA, 
1% Triton X-100, 2 mM PMSF, 2 µg/ml leupeptin, 120 µg/ml 
soybean trypsin inhibitor). After sonication, 3 × 8 s and 
centrifugation for 10 min at 12.000×g, 50 µl of the sepharose 
slurries (50 %, vol/vol) were added to supernatants and incubated 
at 4°C over night under continuous rotation. The Seph-beads were 
washed 3 times with binding buffer (HEPES pH 7.4, 200 mM 
NaCl, 1 mM EDTA) and precipitated proteins were finally 
separated and denatured by addition of SDS-b. After boiling (95°C, 
6 min), Seph-beads were removed by centrifugation and the 
supernatant containing proteins were separated by SDS PAGE and 
proteins were visualized by Western Blotting (WB) or Coomassie 
staining, respectively. 
Statistics. 
Statistical evaluation of the data was performed by one-way 
ANOVAs for independent or correlated samples followed by 
Tukey HSD post-hoc tests. Where appropriate, Student´s t test for 
paired and correlated samples was applied. A p value of <0.05 (*) or 
<0.01 (**) was considered significant. 
 
 
Results 
 
Boswellic acids induce AA release independent of Ca2+ 
In the presence of extracellular Ca2+ (1 mM), β-BA and its 
11-keto counterpart AKBA (fig. 1) concentration-
dependently increased the liberation of AA with significant 
effects at 10 µM, each (fig. 2A). No marked differences in 
the potencies between β-BA and AKBA were obvious and 
the efficacy of BAs was comparable to thrombin (2 U/ml) or 
Ca2+-ionophore A23187 (5 µM) (fig. 2A). Intriguingly, when 
cells were depleted from intracellular (chelation with 
BAPTA/AM) and extracellular (chelation with EDTA) Ca2+, 
BAs still exhibited a strong stimulatory effect on AA release 
with similar efficacies for β-BA and AKBA (fig. 2B). 
Although the absolute levels of AA released into the medium 
in response to β-BA or AKBA (30 µM, each) were higher in 
the presence of Ca2+, the relative increases in the absence of 
Ca2+ were more pronounced (4.6- to 5.4-fold), as when Ca2+ 
was present (2.1- and 2.4-fold), which apparently is due to 
reduced basal AA levels in unstimulated cells where Ca2+ has 
been depleted. However, the release of AA evoked by BAs in 
the absence of Ca2+ was much slower as compared to 
conditions where Ca2+ w a s  p r e s e n t .  N o t e  t h a t  i n  C a 2+-
depleted cells, thrombin and A23187 were much less active 
as compared to BAs, but still an about two-fold stimulation 
over untreated cells was evident (fig. 2B). This effect of 
A23187 is surprising and a plausible explanation can not be 
provided, but possibly could be caused by Ca2+-independent, 
unspecific actions on phospholipid membranes. Taken 
together, BAs are capable to substantially release AA from 
intact platelets, also in the absence of Ca2+. 
 
Effect of BAs on 12-H(P)ETE formation 
12-H(P)ETE is a major metabolite of AA in platelets 
produced by p12-LO (Hamberg and Samuelsson, 1974) that 
can be easily monitored by RP-HPLC representing a 
sensitive read out for evaluation of platelet AA metabolism. 
Washed platelets were incubated with vehicle (DMSO), β-
BA and AKBA (30 µM, each), thrombin (2 U/ml), or 
exogenous AA (10 µM, positive control), either in Ca2+-
containing medium or under Ca2+-free conditions (pre-
treatment with BAPTA/AM plus EDTA). As shown in fig. 
3A, β-BA strongly stimulated the formation of 12-H(P)ETE 
to a comparable level as thrombin. AKBA exerted a much 
weaker effect than β-BA. In Ca2+-depleted cells, stimulation 
with thrombin is virtually ineffective, whereas β-BA clearly 
stimulated 12-H(P)ETE formation, and a minor stimulation 
was also seen for AKBA (fig. 3A). BAs lacking the 11-keto 
group (β-BA and Aβ-BA) caused a concentration-dependent 
increase in 12-H(P)ETE formation, whereas BAs containing 
the 11-keto moiety (KBA and AKBA) were hardly effective, 
and for AKBA the formation of 12-H(P)ETE was even 
lower at higher concentrations (fig. 3B). Thus, the 11-keto 
group seemingly hampers the formation of 12-H(P)ETE. A 
similar pattern was found in Ca2+-depleted cells (not shown). 
Selective inhibitors of cPLA2 (cPLA2α inhibitor, 1 µM; 
MAFP, 10 µM) and 12-LO (CDC, 10 µM) strongly 
suppressed 12-H(P)ETE formation under all experimental 
conditions, whereas an inhibitor of the Ca2+-independent 
iPLA2 (BEL, 5 µM) caused no suppression (fig. 3C). In 
conclusion, both β-BA and AKBA induce the release of AA 
equally well, but only β-BA but AKBA potently stimulates 
12-H(P)ETE formation, which in part is Ca2+-independent. 
 
Kinetic analysis of 12-H(P)ETE formation 
The kinetics of 12-H(P)ETE formation in platelets was 
studied. The time necessary for half maximal 12-H(P)ETE 
synthesis (tmax1/2) was determined by regression analysis using 
a 3-parameter Hill equation (f(t) = a × t b/(cb + tb). In the 
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Fig. 2  BAs elevate the liberation of AA in platelets  
Platelets (108) were incubated at 37°C with 1 mM EDTA plus 30 µM 
BAPTA/AM for 15 min (white bars) or incubated with CaCl2 (1 
mM) for 2.5 min (black bars), and then stimulated with the indicated 
concentrations of β-BA or AKBA, thrombin (2 U/ml), or 
ionophore A23187 (5 µM). [3H]AA released into the medium was 
measured after 5 min in the presence of Ca2+ (black bars) or after 15 
min in the absence of Ca2+ (white bars). Data are given as cpm, 
mean + S.E., n = 5, p<0.05 (*). presence of Ca2+,  β-BA (30 µM) induced a rapid 12-
H(P)ETE generation (tmax1/2 = 37 s) entering a plateau phase 
after 3 min (fig. 4A). A similarly rapid 12-H(P)ETE 
production was recorded when AA (2 µM, tmax1/2 = 41 s, fig. 
4B) or ionophore A23187 (2.5 µM, tmax1/2 = 44 s, fig. 4E), 
were added to platelets. Importantly, the kinetic profile of 
thrombin was different and was considerably delayed (tmax1/2 
= 157 s, fig. 4C). AKBA (30 µM) gave a less consistent 
kinetic profile with a tmax1/2 of ≥ 100 s (fig. 4D). 
Lack of extracellular Ca2+ (1 mM EDTA) did not strongly 
alter the kinetic progression of 12-H(P)ETE formation 
induced by β-BA (tmax1/2 = 28 s, fig. 4A) or by exogenously 
added AA (tmax1/2 = 33 s, fig. 4B). However, when also 
intracellular Ca2+ was removed by BAPTA/AM, β-BA-, but 
not AA-induced 12-H(P)ETE formation was remarkably 
delayed but continuously increased. Long-term kinetic 
recordings show that whereas the 12-H(P)ETE level in Ca2+-
containing buffer gradually decreases after approx. 60 min, it 
continuously increases up to a plateau after 150 min in Ca2+-
depleted cells (fig. 4F). When Ca2+-depleted cells were 
stimulated with thrombin, no detectable increase in 12-
H(P)ETE formation was observed (fig. 4C). Together, β-BA 
induces AA liberation/12-H(P)ETE formation in platelets by 
a rapid Ca2+-mediated pathway as well as by a Ca2+-
independent route(s). 
 
Pharmacological dissection of signalling pathways 
activated by β-BA 
The signalling pathways underlying the Ca2+-dependent and 
Ca2+-independent mechanisms of AA liberation and 
generation of 12-H(P)ETE were investigated using a 
pharmacological inhibitor approach. In the presence of Ca2+, 
increased AA liberation due to β-BA was suppressed by the 
PI 3-K inhibitor wortmannin (fig. 5A). Also, the Src family 
kinase inhibitors SU6656 and PP2 (but not its inactive 
variant PP3) reduced the effects of β-BA. In contrast, 
inhibitors of MEK/ERK (U0126) and p38 MAPK 
(SB203580) failed in this respect. Note that in Ca2+-depleted 
cells, no significant suppression of β-BA-evoked AA release 
by any of the above inhibitors was observed (fig. 5A). 
In analogy to AA release, also the β-BA-evoked generation 
of 12-H(P)ETE (fig. 5B, left panel) was blocked by 
wortmannin, SU6656 and PP2 (but not by PP3), whereas 
U0126 or SB203580 were hardly active. Again, as observed 
for the release of AA, in the absence of Ca2+, β-BA-evoked 
12-LO product formation was not sensitive to any of these 
inhibitors (fig. 5B, left panel). Moreover, in control 
experiments, where 12-H(P)ETE was elicited by addition of 
exogenous AA in order to circumvent supply of endogenous 
substrate, no or only minor effects of the inhibitors were 
observed, regardless of the presence of Ca2+ (fig. 5B, right 
panel). Thus, the inhibitory effects of wortmannin, PP2 and 
SU6656 on β-BA-induced 12-H(P)ETE generation appear to 
primarily affect release of AA, rather than p12-LO activity. 
In conclusion, β-BA-evoked AA release/12-H(P)ETE 
formation in the presence of Ca2+ seemingly involves PI 3-K 
and Src family kinases, whereas in Ca2+-depleted cells none 
of these signalling molecules apparently contribute. 
 
Effects of BAs on cPLA2 and p12-LO activity in cell-free 
assays 
To test stimulation of cPLA2 by BAs in vitro, we determined 
the effects of β-BA or AKBA on AA release from platelet 
membrane lipids in the absence (inclusion of 1 mM EDTA) 
as well as in the presence of 2 mM Ca2+. AA release was 
increased by Ca2+ by about 2.4-fold, and was suppressed by 
the cPLA2α inhibitor, assuring that cPLA2 is the AA-
releasing enzyme in this assay. No significant and 
concentration-dependent modulation of the AA release was 
observed by 1 to 100 µM BA (not shown), regardless of the 
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Fig.  3  BAs stimulate the formation of p12-LO and COX-1 
products in intact platelets  
(A) 12-H(P)ETE formation. Platelets (108/ml PG buffer) were 
supplemented with either 1 mM CaCl2 or 1 mM EDTA plus 30 µM 
BAPTA/AM as indicated. After, 15 min at 37°C, β-BA (30 µM), 
AKBA (30 µM) thrombin (2 U/ml), AA (10 µM) or vehicle (DMSO) 
were added and after another 10 min, the reaction was terminated 
and 12-H(P)ETE formation was determined. (B) Concentration-
response experiments for 12-H(P)ETE formation. Platelets (108/ml 
PGC buffer) were treated with β-BA, Aβ-BA, KBA or AKBA at the 
indicated concentrations and after 10 min at 37°C, the reaction was 
terminated and 12-H(P)ETE formation was determined. (C) Effects 
of p12-LO and PLA2 inhibitors. Platelets were supplemented with 
either 1 mM CaCl2 or 1 mM EDTA plus 30 µM BAPTA/AM as 
indicated and preincubated with CDC (10 µM), MAFP (10 µM), 
cPLA2α inhibitor (1 µM), and BEL (5 µM). After 10 min β-BA (30 
µM) was added and 12-H(P)ETE formation was determined. Data 
are given as mean + S.E., n = 3-5. *p< 0.05; **, ## p< 0.01. presence of Ca2+, implying that BAs do not stimulate cPLA2 
activity in vitro. Also, there was no increased association of 
cPLA2 with platelet membranes after either incubation of 
platelet homogenates with BAs or after exposure of intact 
platelets to BAs (assessed by WB, not shown), independent 
of the presence of Ca2+, suggesting that BAs do not promote 
binding of cPLA2 to membrane phospholipids in vitro. 
The effects of BAs on p12-LO activity in the platelet S100 
were investigated. Platelet S100 was incubated with AKBA 
plus 2 µM AA in the presence of either 1 mM EDTA or 1 
mM Ca2+. 12-H(P)ETE formation was about 3-fold higher 
in the presence of Ca2+  (fig 6A). AKBA caused a 
concentration-dependent inhibition of p12-LO activity. In 
the presence of Ca2+, the IC50 was about 15 µM, whereas 
without Ca2+  the IC50 was approx. 50 µM. In contrast to 
AKBA, 12-H(P)ETE formation was differentially modulated 
by β-BA. Thus, only a weak inhibition of p12-LO activity by 
β-BA (IC50 > 100 µM) was detectable in the presence of 
Ca2+ ( fig 6B). However, in the absence of Ca2+,  β-BA 
elevated 12-H(P)ETE up to approx. 2-fold at a threshold 
concentration of 10 µM (fig 6B), which was sensitive to the 
p12-LO inhibitor CDC (not shown). Together, β-BA 
stimulates p12-LO catalysis in the absence of Ca2+, whereas 
AKBA generally suppresses the catalytic activity of p12-LO, 
and no direct modulation of cPLA2 is apparent for either 
BA. 
 
Interaction of BAs with cPLA2 and 12-LO 
To assess direct interaction of BAs with cPLA2 or p12-LO, a 
protein fishing assay was performed using KBA as bait that 
was covalently linked to EAH Sepharose 4B beads via a 
glutaric acid linker (KBA-Seph). EAH-Sepharose beads 
without ligand (Seph) were used as control, 
platelet 12,000×g supernatants served as 
protein source. Coomassie-staining of gels 
after SDS-PAGE or Ponceau S staining of 
membranes after blotting assured 
comparable unspecific protein-binding by 
Seph and KBA-Seph (not shown). As 
shown in fig. 7, no cPLA2 protein was 
detectable (by WB analysis) in precipitates 
using Seph or KBA-Seph. cPLA2 was 
abundantly present in the corresponding 
platelet lysates and clearly detectable. 
However, substantial amounts of 12-LO 
were present in KBA-Seph pull-downs, but 
not in precipitates using Seph as negative 
control. Since 5-LO was postulated as 
AKBA-binding protein (Sailer et al., 1998), 
we attempted to confirm 5-LO binding by 
our protein fishing strategy using 12,000×g 
supernatants of PMNL as source for 5-LO. 
Both Seph and KBA-Seph moderately 
bound 5-LO, without significant 
quantitative differences (fig. 7). In 
summary, p12-LO could be selectively 
precipitated by KBA immobilized to 
sepharose beads. 
 
 
Discussion 
 
Activation of platelets by adequate stimuli 
may lead to substantial release of AA by 
cPLA2, connected to subsequent 
conversion by COX-1 and p12-LO, 
depending on the strength of the stimuli 
and the nature of the signalling molecules 
involved (Coffey et al., 2004; Hamberg and 
Samuelsson, 1974; Holmsen, 1994). Ca2+ is 
a determinant for these processes, as it 
stimulates cellular activation and catalysis 
of both cPLA2 (Gijon and Leslie, 1999; 
Leslie, 2004) and p12-LO (Baba et al., 
1989). Besides Ca2+, serine 
phosphorylations by MAPK (Borsch-
Haubold et al., 1999) and interaction with 
PIP2 (Balsinde et al., 2000) or 
sphingolipids (Huwiler et al., 2001; Pettus 
et al., 2004; Subramanian et al., 2005) 
activate cPLA2. In contrast, for p12-LO, 
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Fig. 4 Kinetics of 12-H(P)ETE formation in intact platelets. Platelets (109) were 
resuspended in 10 ml PG buffer containing either 1 mM CaCl2 (filled circles), 1 mM EDTA 
(triangles), or 1 mM EDTA plus 30 µM BAPTA/AM (open symbols). After 15 min at 37°C, 
cells were stimulated with either β-BA (30 µM A, and 10 µM F), 2 µM AA (B), 1 U/ml 
thrombin (C), 30 µM AKBA (D), or 5 µM ionophore (E). Aliquots of 1 ml corresponding to 
108 cells were mixed with 1 ml of ice-cold methanol to stop the 12-LO reaction after the 
indicated times, and 12-H(P)ETE formation was determined. Data are given as mean + S.E., n 
= 3-5.  there is only limited information regarding cellular activation 
(Coffey et al., 2004), and except the redox-tone (Bryant et al., 
1982), which is of general importance for LO activation, only 
Ca2+ is known as (moderate) stimulatory cofactor (Baba et 
al., 1989). It is assumed that the capacity of platelets to form 
12-H(P)ETE is essentially linked to the supply of AA. Since 
BAs induce massive mobilization of Ca2+ and activate 
MAPK in platelets (Poeckel et al., 2005), it was reasonable 
that BAs as a result may elicit release of AA and 
concomitantly also 12-H(P)ETE synthesis.  
β-BA and AKBA evoked AA release with comparable 
potencies, similar as the strong platelet agonists thrombin or 
ionophore that act by recruiting cPLA2 via phosphorylation 
and/or elevation of [Ca2+]i (Borsch-Haubold et al., 1995; 
Kramer et al., 1996). The liberation of AA was rapid and 
sensitive to selective inhibitors of the Ca2+-dependent 
cPLA2, suggesting that in analogy to thrombin and 
ionophore, cPLA2  is the responsible PLA2 isoform. 
However, in contrast to thrombin and ionophore, BAs may 
induce cPLA2 activation,  at least in part, independent of 
Ca2+. Note that BEL did not compromise AA release in the 
absence of Ca2+, which excludes iPLA2 (Hazen et al., 1991) 
as responsible enzyme. Also, determination of 12-H(P)ETE 
shows that BAs but not thrombin partially act in a Ca2+-
independent  manner. AKBA failed to substantially induce 
12-H(P)ETE, probably related to its inhibitory action on 
p12-LO (discussed below). Moreover, our kinetic analysis of 
cellular 12-H(P)ETE production favours an additional, Ca2+-
independent cPLA2/12-LO activation pathway. Thus, 12-
H(P)ETE formation induced by β-BA was much more rapid 
than by thrombin, although increases in [Ca2+]i by β-BA are 
delayed as compared to thrombin (Poeckel et al., 2005). 
Therefore, it is unlikely that the rapid and robust 12-
H(P)ETE synthesis induced by β-BA is mediated solely by 
elevation of [Ca2+]i.  
The Ca2+-dependency of cPLA2 in platelets is well 
established, but alternate signaling routes such as 
phosphorylation by MAPKs contribute (Borsch-Haubold et 
al., 1999; Borsch-Haubold et al., 1995; Kramer et al., 1996). 
In fact, BAs activate MAPK in platelets (Poeckel et al., 
2005), however, MAPK inhibitors failed to suppress β-BA-
induced AA release and 12-H(P)ETE synthesis. 
Nevertheless, our inhibitor approach indicate that PI 3-K 
and Src family kinases may be integrated in β-BA-evoked 
responses, at least under conditions where Ca2+ is present. 
Since Src family kinases and PI 3-K are also involved in β-
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Fig. 5  Effects of relevant pharmacological inhibitors on β-BA-
induced AA release and 12-H(P)ETE formation. 
(A) AA release. Platelets were labelled with [3H]AA as described in 
the legend of fig. 2. After washing, cells were either left untreated 
(black bars) or 1 mM EDTA plus 30 µM BAPTA/AM (white bars). 
Then, cells were preincubated with 200 nM wortmannin (wort), 3 µM 
PP2 or PP3, 5 µM SU6656, 3 µM U-0126, 10 µM SB203580, or 
vehicle (DMSO, negative/positive) as indicated for 15 min at 37°C. 
CaCl2 (1 mM) was added to the cells as indicated and after 2.5 min, 
cells were stimulated with 30 µM β-BA. [3H]AA released into the 
medium was measured after 5 min (black bars) or 15 min (white 
bars), respectively. (B) 12-H(P)ETE formation. Platelets were 
resuspended in 1 ml PG buffer plus 1 mM CaCl2 (black bars) or in 
PG buffer containing 1 mM EDTA plus 30 µM BAPTA/AM (white 
bars) and preincubated with 200 nM wortmannin (wort), 3 µM PP2 
or PP3, 5 µM SU6656, 3 µM U-0126, 10 µM SB203580 or vehicle 
(DMSO) as indicated. Then, 30 µM β-BA (left panel) or 2 µM AA 
(right panel) was added and 12-H(P)ETE formation was determined. 
Data are expressed as percentage of control (100 %, vehicle) and 
values are given as mean + S.E., n = 3-4. *p< 0.05; **p< 0.01. 
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Fig. 6  Effects of BAs on the activity of p12-LO in cell free 
assays 
Platelets were sonicated and S100 was prepared. AKBA (A) or β-BA 
(B) were added to the S100 at the indicated concentrations, and the 
synthesis of 12-H(P)ETE was started by addition of AA (2 µM) with 
or without 2 mM CaCl2, as indicated. 12-H(P)ETE was determined 
by HPLC. Data are given as mean + S.E., n = 3-5, *p< 0.05; **p< 
0.01. BA-induced Ca2+ mobilisation (Poeckel et al., 2005), the 
suppressive effects of the respective inhibitors are likely to 
be due to inhibition of Ca2+ mobilisation, rather than 
uncoupling Ca2+-independent signals to cPLA2. This is 
supported by the fact that the inhibitors completely failed to 
suppress  β-BA-induced responses in the absence of Ca2+. 
Moreover, no inhibition of 12-H(P)ETE formation was 
evident after stimulation with exogenous AA, implying that 
AA release rather than p12-LO activation is primarily 
affected by the inhibitors. PI 3-K and Src family kinases have 
also been implicated in the formation of 12-H(P)ETE from 
endogenous AA in platelets stimulated by collagen and 
collagen-related peptide (Coffey et al., 2004).  
Apart from Ca2+ and phosphorylation, cPLA2 is activated by 
direct interaction with PIP2 or ceramide and ceramide 1-
phosphate (Huwiler et al., 2001; Pettus et al., 2004; 
Subramanian et al., 2005), and it appeared possible that also 
BAs could activate cPLA2 by direct interactions. However, 
cPLA2 failed to bind KBA-Seph and BAs did not stimulate 
cPLA2 activity in cell-free assays, excluding such 
interrelations. Collectively, we conclude that BAs activate 
cPLA2 independent of Ca2+ and phosphorylation by a yet 
unrecognized mechanism.  
Initially, BAs were identified as inhibitors of 5-LO (Safayhi et 
al., 1992; Safayhi et al., 1995) that may interfere with a 
regulatory AA-binding site in a Ca2+-dependent manner 
(Sailer et al., 1998). Among the BAs, AKBA is the most 
potent 5-LO inhibitor with high selectivity for 5-LO whereas 
inhibition of p12-LO in intact platelets was excluded (Safayhi 
et al., 1992). We found that AKBA inhibits p12-LO in cell-
free assays with an IC 50 value (15 µM), significantly below 
the values determined for 5-LO under comparable assay 
conditions (50 µM) (Werz et al., 1997; Werz et al., 1998). Of 
interest, p12-LO bound to KBA-Seph, but was absent in 
pull-downs using Seph, implying a rather selective interaction 
between KBA-Seph and p12-LO. Note that the amounts of 
5-LO in KBA-Seph and Seph precipitates from 12,000×g 
supernatants of PMNL lysates were about the same, implying 
unspecific binding of 5-LO to KBA-Seph.  
Direct suppression of p12-LO a c t i v i t y  b y  A K B A  m a y  
explain why despite induction of marked AA release in intact 
platelets, no subsequent conversion to 12-H(P)ETE was 
evident, whereas β-BA (or Aβ-BA) concentration-
dependently induced 12-H(P)ETE formation. In agreement 
with others (Baba et al., 1989), Ca2+ increased p12-LO 
activity in platelet S100 about 3-fold, and β-BA mimicked 
this effect as it stimulated p12-LO activity without Ca2+. In 
contrast, in the presence of Ca2+,  β-BA did not further 
stimulate p12-LO. Apparently, the 11-keto moiety 
determines the quality of p12-LO modulation by BAs, and 
contrasting effects of BAs depending on the 11-keto moiety 
were observed before also in other experimental settings 
(Altmann et al., 2004; Poeckel et al., 2005; Poeckel et al., 
2006).  
The conclusions from our results deviate from the long 
established view of BAs as negative modulatory agents of the 
AA cascade, as we demonstrate strong induction of AA 
release and formation of 12-H(P)ETE by BAs in platelets. 
Also, we suggest p12-LO as a definite target of BAs with 
superior susceptibility as compared to 5-LO. The question of 
the pharmacological consequence resulting from the 
divergent effects of β-BA and AKBA on 12-H(P)ETE 
biosynthesis in vivo remains to be answered. After oral intake 
of 4 × 786 mg B.S. extracts (containing about 3.7% AKBA, 
10.5% Aβ-BA, 6.1% KBA and 18.2% β-BA) per day, the 
plasma levels of AKBA (0.1 µM) (Buchele and Simmet, 
2003) are far below the concentrations required to efficiently 
suppress p12-LO (IC50 = 15 µM). On the other hand, β-BA 
reached plasma levels (10.1 µM), virtually sufficient to induce 
12-H(P)ETE formation. In our in vitro assays, relevant 
amounts (approx. 5 µg/ml) of B.S. extracts, containing 
diverse BAs, strongly induced AA release as well as 12-
H(P)ETE synthesis (not shown). 12-H(P)ETE may act as 
chemoattractant for leukocytes (Goetzl, 1980), mediates 
angiogenesis and tumour metastasis (Honn et al., 1994), 
possesses inhibitory neuromodulatory effects (Piomelli et al., 
1987) and is involved in cardiovascular diseases (Gonzalez-
Nunez et al., 2001), which should be taken into account 
when administering BA-containing medicine. Besides the 
dissection of the influences of BAs on 12-H(P)ETE as 
mediator in (patho-)physiology applied as complex 
composed extracts of B.S., it also remains a future challenge 
to fully elucidate the Ca2+/phosphorylation-independent 
signalling routes leading to cPLA2 activation and increased 
release of AA by BAs. 
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Abstract 
Boswellic acids are known as potent anti-inflammatory drugs. In order to identify their molecular target 
proteins, a “target fishing” approach is suitable where boswellic acids are immobilized at Sepharose
TM as 
bait. Here, we present the chemical part of the project: synthesis of glutaroyl-boswellic acids and 
immobilization to EAH Sepharose
TM. 
 
 
Introduction 
Chronic inflammatory diseases
[1] like rheumatoid arthritis, chronic bronchitis, asthma, chronic inflammatory 
bowel diseases (ulcerative colitis and Crohn’s Disease) as well as chronic inflammatory skin diseases (e.g. 
neurodermitis) are a major challenge for medical science. The Indian folk medicine Ayurveda treats these 
diseases with extracts of frankincense from Boswellia serrata, which is also used in Western medicine with 
great success.
[2]  
Ethanolic extracts of Boswellia serrata contain –among others– the pentacyclic triterpenes boswellic acids 
(BAs),
[3] which are regarded as pharmacological principles of the resins of Boswellia serrata and other 
Boswellia species. The chemical structure of the β-boswellic acids are shown in Fig. 1.  
 
 
 
 
 
Figure 1. Structures of the four β-boswellic acids found in incense (major components); Abbreviations: BA: boswellic 
acid; ABA: 3-Acetoxy-boswellic acid; KBA: 11-Keto-boswellic acid; AKBA: 3-Acetoxy-11-keto-boswellic acid 
 
 
Although anti-inflammatory and anti-tumorigenic effects of BAs have been stated in several reports,
[4] the 
underlying molecular mechanisms and in particular the molecular targets of BAs are still elusive. 
Nevertheless, a number of proteins related to inflammation and/or cancer including 5-lipoxygenase (5-LO), 
human leukocyte elastase, topoisomerases and IκB kinases have been postulated as targets of BAs.
[4c, 4d, 5] 
However, there is only limited and indirect proof for direct binding of BA to these proteins. One approach 
that can be utilized for fishing of target proteins using small molecular weight compounds (ligands) as bait is 
the immobilization of the ligand to an insoluble biocompatible resin via a linker molecule.
[6] So, in order to 
identify target proteins of BAs, we had to immobilize BAs connected to an appropriate linker to a suitable 
resin.  
Here, we wish to report our synthetic results towards this end. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Scheme 1. Plan of immobilizing boswellic acids to EAH Sepharose for target fishing. 
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Results and Discussion 
As biocompatible resin we chose EAH Sepharose 4B
TM (Scheme 1), since this agarose-based resin is quite 
often used in gel filtration and affinity chromatography and does not denaturate any proteins and enzymes.
[7] 
For the immobilization of BAs we decided to couple the free 3-OH group of BA and KBA with glutaric 
anhydride (Scheme 1) to obtain the glutaric acid half esters of BA and KBA respectively, which still have 
one primary carboxyl group useful to build an amide with the amino group of EAH Sepharose 4B
TM (Scheme 
1).  
First, we had to prepare glutaroyl-KBA 2 and glutaroyl-BA 3, respectively. Neither of these substances is 
known. However, some derivatives of glycyrrhetinic acid and steroids with succinyl linker are known
8. 
Treatment of KBA 1c with glutaric anhydride in pyridine as solvent was very sluggish at reflux temperature 
using catalytic amounts of DMAP
[9]. Switching to 4-pyrrolidino-pyridine
[10] as catalyst accelerated the 
reaction, but reaction times still were in the range of approx. 20 hours (h). Using 1.5 equivalents of 4-
pyrrolidino-pyridine lowered the reaction time to acceptable 7 h with 75% yield of 3. Glutaroyl-KBA 3 
fortunately crystallized from acetone and yielded suitable crystals for X-ray analysis. The molecular 
structure is shown in Fig. 2. 
 
Figure 2. ORTEP style plot of glutaroyl-KBA 3 in the solid state. Thermal ellipsoids are drawn at the 50% probability 
level. Crystal acetone and hydrogen atoms are omitted for clarity. 
 
 
Treatment of BA 1a under the conditions developed for the reaction of KBA with glutaric anhydride yielded 
glutaroyl-BA 2 in 76% yield. 
With glutaroyl-BA 2 and glutaroyl-KBA 3 in hand, we tried to couple these substances to EAH sepharose
TM. 
Usually, this coupling is done with EDC in aqueous solution, acidified to pH 4.5, as recommended by the 
supplier of EAH sepharose
TM. Unfortunately, glutaroyl-BA as well as glutaroyl-KBA are poorly soluble in 
water. In cases where the substance to be coupled to sepharose is hardly soluble in water, dioxane can be 
used as cosolvent up to a final concentration of 50% (v/v). Even in water/dioxane 50/50 (v/v), the glutaroyl-
BA 2 and glutaroyl-KBA 3 are not completely soluble in the concentration required for efficient coupling. 
Using a larger amount of dioxane gave a homogenous solution with 2 and 3, but coupling did not occur and 
the glutaroyl-BAs could be recovered quantitatively. So, we had to run the coupling of glutaroyl-BA 2 and  
glutaroyl-KBA 3 under heterogeneous conditions, where the glutaroyl-BAs dissolve only partially at the 
beginning of the reaction and the remaining residue dissolves during the reaction as glutaroyl-BAs are 
coupled to the sepharose beads. 
The complete synthesis is shown in scheme 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of glutaric acid half esters of boswellic acids and immobilization thereof at EAH Sepharose 4B
TM. 
 
 
Characterization of the immobilized BAs by spectroscopic methods is difficult and not informative. 
Therefore, we decided to determine the turnover of the coupling reaction as follows: as we used two 
equivalents of glutaroyl-BAs for coupling to one equivalent of EAH sepharose, the not consumed excess of 
glutaroyl-BAs should be recovered. This is indeed the case (see experimental part). Additionally, cleavage of 
the immobilized BAs with KOH/iPrOH/reflux was also successful. 
In biochemical studies (
[11] and ongoing investigations) it is attempted to pull down proteins that specifically 
bind to the immobilized BAs. Such protein pull-downs can be separated by gel electrophoresis and after 
comparison with pull-downs utilizing crude EAH sepharose beads (lacking BAs as bait, negative control), 
the respective proteins are then selected and identified by MALDI mass spectrometry.  
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EAH Sepharose 4B : 
Experimental Section 
 
General Remarks:  
Peroxides in dioxane were removed by filtration through basic aluminium oxide. Reactions with dioxane as 
solvent were run under N2 to prevent peroxide formation. Flash chromatography is performed with silica gel 
from Merck, Darmstadt, Germany, with particle size 40-63 µm (normal phase) and with RP18 silica gel 
prepared according to the literature. For the complete assignment of the NMR-signals, 
1H-spectra, 
13C-
spectra, DEPT90- and DEPT135-spectra, H,H-COSY, HMQC, HMBC, HMQC-COSY and NOESY-spectra 
(Bruker AV 500) were processed with the program MestReC.
[12] Mass spectra were recorded on a Bruker 
MAT 95S.  
EAH Sepharose 4B
TM was purchased from Amersham Biosciences, Freiburg, Germany, and EDC was 
purchased from Fluka, Taufkirchen, Germany. Boswellic acids were synthesized as described previously.
[13] 
 
Glutaroyl-β-boswellic acid 2: β-boswellic acid (742.3 mg, 1.6 mmol) was dissolved in dry pyridine (16 ml). 
To this solution glutaric anhydride (1.826 g, 16 mmol) and 4-pyrrolidino-pyridine (336.0 mg, 2.3 mmol) 
were added successively. The reaction mixture was heated to reflux for 7 h. After cooling to room 
temperature, the brown mixture was diluted with diethyl ether (ca. 100-200 ml) and washed with 1 N HCl (3 
x 100 ml). The combined HCl-solution was re-extracted once with diethyl ether (ca. 100 ml). The combined 
organic phases were washed with water to remove traces of HCl and with brine (ca. 50 ml) and finally dried 
(MgSO4). After evaporating the solvent, the orange-brown residue (ca. 800 mg) was chromatographed on 
silica gel and eluted with pentane / diethyl ether 2:1 (v/v) + 1% HOAc. Yield: 694.0 mg (75%) as a white 
powder. Crystals could be obtained from chloroform by slowly evaporating the solvent. 
1H-NMR ((CD3)2CO, 500.13 MHz, δ in ppm): δ = 5.30 (t, J = 2.4 Hz, 1H, H-3); 5.20 (t, J = 3.4 Hz, 1H, H-
12); 2.46 (t, J = 7.4 Hz, 2H, H-34); 2.40 (t, J = 7.4 Hz, 2H, H-32); 2.21-2.14 (m, 1H, H-2β); 2.11-2.07 (m, 
1H, H-16α); 2.00-1.86 (m, 6H, H-6β, H-11α, H-11β, H-15β, H-33); 1.78-1.75 (m, 1H, H-6α); 1.70-1.67 (m, 
1H, H-9); 1.64-1.58 (m, 2H, H-2α, H-7α); 1.55-1.49 (m, 2H, H-1β, H-5α); 1.47-1.26 (m, 8H, H-1α, H-7β, H-
18, H-19, H-21α, H-21β, H-22α, H-22β); 1.23 (s, 3H, H-23); 1.15 (s, 3H, H-27); 1.09 (s, 3H, H-26); 1.07-
1.02 (m, 1H, H-15α); 0.98 (s, 3H, H-25); 0.94-0.89 (m, 5H, H-16β, H-20, H-30); 0.84 (s, 3H, H-28); 0.84 (d, 
J = 5.8 Hz, 3H, H-29). 
13C-NMR ((CD3)2CO, 125.76 MHz): δ = 179.0 (C-24, COOH); 175.1 (C-35, COOH (glutaroyl)); 173.6 (C-
31, >C=O (glutaroyl)); 141.4 (C-13, H>C=C<); 126.6 (C-12, -HC=C<); 75.0 (C-3, HO-CH-); 61.1 (C-18, 
>CH-); 52.3 (C-5, >CH-); 48.7 (C-9, >CH-); 48.2 (C-4, >C<); 44.0 (C-8, >C<); 43.3 (C-22, -CH2-); 41.9 (C-
14, >C<); 41.5 (C-19, >CH-); 41.4 (C-20, >CH-); 39.1 (C-10, >C<); 36.5 (C-1, -CH2-); 35.5 (C-17, >C<); 
35.1 (C-34, -CH2- (glutaroyl)); 34.9 (C-7, -CH2-); 34.3 (C-32, -CH2- (glutaroyl)); 32.9 (C-21, -CH2-); 30.3 
(C-28, -CH3); 29.8 (C-16, -CH2-); 28.3 (C-15, -CH2-); 25.2 (C-23, -CH3); 25.4 (C-2, -CH2-); 25.1 (C-11, -
CH2-); 24.7 (C-27, -CH3); 22.7 (C-30, -CH3, 22.1 (C-33, -CH2 (glutaroyl)); 21.6 (C-6, -CH2); 18.9 (C-29, -
CH3); 18.4 (C-26, -CH3); 14.9 (C-25, -CH3). 
MS (EI, 70 eV): m/z = 570 (8, [M
+]); 471 (8); 454 (12); 438 (28); 423 (19); 394 (25); 379 (15); 218 (100); 
203 (33); 189 (22). 
HRMS (EI, 70 eV): calc.: 570,3982 for C35H54O6 ; obs.: 570,3951 
 
Glutaroyl-11-keto-β-boswellic acid 3: same procedure as for 2.  
1H-NMR ((CD3)2CO, 500.13 MHz, δ in ppm): δ = 5.49 (s, 1H, H-12); 5.29 (t, J = 2.6 Hz, 1H, H-3); 2.53-
2.48 (m, 2H, H-1β, H-9); 2.44 (t, J = 7.4 Hz, 2H, H-34); 2.39 (t, J = 7.4 Hz, 2H, H-32); 2.27-2.16 (m, 2H, H-
2β, H-16α); 1.97-1.88 (m, 4H, H-6β, H-15β, H-33); 1.80-1.74 (m, 2H, H-6α, H-7α); 1.61-1.43 (m, 7H, H-2α, 
H-5α, H-7β, H-18, H-19, H-21β, H-22α); 1.40-1.36 (m, 5H, H-21β, H-22α, H-27); 1.33-1.25 (m, 2H, H-1α,  
H-15α); 1.23 (s, 3H, H-23); 1.21 (s, 3H, H-26); 1.18 (s, 3H, H-25); 1.07-1.02 (m, 1H, H-16β); 0.98-0.94 (m, 
4H, H-20, H-30); 0.86 (s, 3H, H-28); 0.83 (d, J = 6.4 Hz, 3H, H-29). 
13C-NMR ((CD3)2CO, 125.76 MHz, δ in ppm): δ = 199.8 (C-11, >C=O); 178.8 (C-24, COOH); 175.1 (C-35, 
COOH (glutaroyl)); 173.7 (C-31, >C=O (glutaroyl)); 165.8 (C-13, H>C=C<); 132.2 (C-12, H>C=C<); 74.9 
(C-3, HO>CH-); 62.0 (C-9, >CH-); 60.8 (C-18, >CH-); 52.0 (C-5, >CH-); 48.1 (C-4, >C<); 46.7 (C-8, >C<); 
45.5 (C-14, >C<); 42.7 (C-22, -CH2-); 41.1 (C-19, >CH-); 40.9 (C-20, >CH-); 39.2 (C-10, >C<); 36.4 (C-1, -
CH2-); 35.7 (C-17, >C<); 35.1 (C-34, -CH2- (glutaroyl)); 34.5 (C-7, -CH2-); 34.3 (C-32, -CH2- (glutaroyl)); 
32.6 (C-21, -CH2-); 30.2 (C-28, -CH3); 29.2 (C-16, -CH2-); 28.9 (C-15, -CH2-); 25.3 (C-23, -CH3); 25.2 (C-2, 
-CH2-); 22.4 (C-30, -CH3); 22.1 (C-33, -CH2- (glutaroyl)); 21.9 (C-27, -CH3); 21.9 (C-6, -CH2-); 18.7 (C-29, 
-CH3); 19.9 (C-26, -CH3); 14.8 (C-25, -CH3). 
MS (EI, 70 eV): m/z = 584 (4; [M+]); 452 (15); 408 (18); 273 (19); 232 (39); 228 (60); 182 (100) 
HRMS (EI, 70 eV): calc.: 584,3713 for C35H52O7; obs.: 584,3713 
 
Immobilization of glutaroyl-β-boswellic acid at EAH Sepharose 4B: First, EAH Sepharose 4B (10 ml) 
was washed with 0.5 M aqueous NaCl (800 ml) in a sintered glass filter and drained. Second, distilled water 
(100 ml) was acidified to pH 4 by dropwise addition of 1 N HCl. Additionally, dioxane was added (100 ml) 
with stirring. This dioxane/water-mixture was used as reaction medium and as solvent to wash the product. 
Glutaroyl-β-boswellic acid (102.7 mg, 0.18 mmol) was dissolved in the dioxane/water mixture (15 ml) by 
vigorous shaking or stirring, giving a slightly turbid emulsion. This is added to the drained EAH-Sepharose 
4B with shaking (stirring with a magnetic stirring bar will destroy the Sepharose beads). Next, EDC (354.1 
mg, 1.85 mmol) was dissolved in the dioxane/water mixture (5 ml) and this solution was added dropwise to 
the reaction mixture. Now, the complete reaction mixture was shaken over night. The solvent was stripped 
off
 * (sintered glass filter) and the drained glutaroyl-BA-Sepharose was washed with dioxane/water * (3 x 80 
ml), with water (3 x 80 ml) and finally with 1M aqueous NaCl, which contained 20 vol.% ethanol (3 x 80 
ml). The product was stored as suspension in the above mentioned NaCl solution (ca. 5-10 ml). 
 
*These combined filtrates were evaporated to remove most of the dioxane and then re-extracted with diethyl 
ether. The etheral phase was dried with MgSO4 and evaporated to leave 49.8 mg of glutaroyl-β-boswellic 
acid. So, approx. 53 mg of glutaroyl-β-boswellic acid (0.093 mmol) were immobilized at Sepharose. 
Sepharose contains 7-10 µmol NH2 groups per ml, i.e. immobilization is almost quantitative. 
 
Immobilization of glutaroyl-11-keto-β-boswellic acid at EAH Sepharose 4B: same procedure as above. 
 
Single crystal X-ray structure determination of glutaroyl-KBA 3: Crystal data and details of the structure 
determination are presented in Table 3. Suitable single crystals for the X-ray diffraction study were grown 
from acetone. A clear colourless fragment was stored under perfluorinated ether, transferred in a Lindemann 
capillary, fixed, and sealed. Preliminary examination and data collection were carried out on an area 
detecting system (NONIUS, MACH3, κ−CCD) at the window of a rotating anode (NONIUS, FR591) and 
graphite monochromated MoKα radiation (λ = 0.71073 Å). The unit cell parameters were obtained by full-
matrix least-squares refinement of 3285 reflections. Data collection were performed at 123 K (OXFORD 
CRYOSYSTEMS) within a Θ-range of 1.77°< Θ < 25.28. Nine data sets were measured in rotation scan 
modus with ∆φ /∆Ω = 1.0. A total number of 40471 intensities were integrated. Raw data were corrected for 
Lorentz, polarization, and, arising from the scaling procedure, for latent decay and absorption effects. After 
merging (Rint = 0.035) a sum of 6340 (all data) and 6155 [I>2σ(I)], respectively, remained and all data were 
used. The structure was solved by a combination of direct methods and difference Fourier syntheses. All 
non-hydrogen atoms were refined with anisotropic displacement parameters. All hydrogen atom positions 
were found in the difference Fourier map calculated from the model containing all non-hydrogen atoms. The  
hydrogen positions were refined with individual isotropic displacement parameters. Full-matrix least-squares 
refinements with 647 parameters were carried out by minimizing Σw(Fo
2-Fc
2)
2 with SHELXL-97 weighting 
scheme and stopped at shift/err < 0.001. The final residual electron density maps showed no remarkable 
features. The correct enantiomere is given by synthesis. Neutral atom scattering factors for all atoms and 
anomalous dispersion corrections for the non-hydrogen atoms were taken from International Tables for 
Crystallography. All calculations were performed on an Intel Pentium II PC, with the STRUX-V system, 
including the programs PLATON, SIR92, and SHELXL-97
[14]. 
 
 
Table 3.  Summary of the crystal data and details of data collection and refinement for glutaroyl-KBA. 
 
Empirical formula  C35H52O7, C3H6O 
Formula mass  642.84 
Crystal system  monoclinic 
Space group  P21 (no. 4) 
a [Å]  8.0205(1) 
b [Å]  18.8900(1) 
c [Å]  11.8491(1) 
β [°]  103.2313(3) 
V [Å
3] 1747.57(3) 
Z 2 
ρ
calcd [g cm
–3]  1.222 
µ [mm
–1]  0.084 
T [K]  123 
F(000) 700 
Crystal size [mm]  0.51×0.53×0.56 
Θ-range [°]  1.77/25.28 
Index ranges   h:±9/k:±22/l:±14 
Reflections collected  40471 
Independent reflections [Io>2σ(Io)/all data/Rint]  6155/6340/0.035 
Data / restraints / parameters  6340/1/647 
R1 [Io>2σ(Io)/all data]  0.0270/0.0282 
wR2 [Io>2σ(Io)/all data]  0.0665/0.0675 
GOF  1.041 
Weights a/b 0.0373/0.2932 
∆ρmax/min [e·Å
–3]  0.17/-0.16 
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ABSTRACT
Previously, we showed that 11-keto-boswellic acid and 3-O-
acetyl-11-keto-BA (AKBA) stimulate Ca
2 mobilization and ac-
tivate mitogen-activated protein kinases (MAPKs) in human
polymorphonuclear leukocytes (PMNLs). Here, we addressed
the effects of boswellic acids on the intracellular Ca
2 concen-
tration ([Ca
2]i) and on the activation of p38
MAPK and extracel-
lular signal-regulated kinase (ERK) in the human monocytic cell
line Mono Mac (MM) 6. In contrast to PMNLs, AKBA concen-
tration dependently (1–30 M) decreased the basal [Ca
2]i in
resting MM6 cells but also in cells where [Ca
2]i had been
elevated by stimulation with platelet-activating factor (PAF).
AKBA also strongly suppressed the subsequent elevation of
[Ca
2]i induced by N-formyl-methionyl-leucyl-phenylalanine
(fMLP), PAF, or by the direct phospholipase C activator 2,4,
6-trimethyl-N-(meta-3-trifluoromethyl-phenyl)-benzenesulfon-
amide, but AKBA failed to prevent Ca
2 signals induced by
thapsigargin or ionomycin. Suppression of Ca
2 homeostasis
by AKBA was also observed in primary monocytes, isolated
from human blood. Moreover, AKBA inhibited the activation of
p38
MAPK and ERKs in fMLP-stimulated MM6 cells. Although the
effects of AKBA could be mimicked by the putative phospho-
lipase C (PLC) inhibitor U-73122 (1-[6-[[17-methoxyestra-
1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione), AKBA
appears to operate independent of PLC activity since the re-
lease of intracellular inositol-1,4,5-trisphosphate evoked by
2,4,6-trimethyl-N-(meta-3-trifluoromethyl-phenyl)-benzenesul-
fonamide was hardly diminished by AKBA. Inhibitor studies
indicate that AKBA may decrease [Ca
2]i by blocking store-
operated Ca
2 and/or nonselective cation channels. Together,
AKBA interferes with pivotal signaling events in monocytic cells
that are usually required for monocyte activation by proinflam-
matory stimuli. Interruption of these events may represent a
possible mechanism underlying the reported anti-inflammatory
properties of AKBA.
Boswellia serrata gum resin extracts have been tradition-
ally applied in folk medicine for centuries to treat various
chronic inflammatory diseases, and experimental data from
animal models and clinical studies on humans confirmed an
anti-inflammatory potential of B. serrata extracts (for re-
view, see Safayhi and Sailer, 1997; Ammon, 2002). Detailed
analysis of the ingredients of these extracts revealed that the
pentacyclic triterpenes boswellic acids (BAs) possess phar-
macological activities and may be responsible for the respec-
tive anti-inflammatory properties (Safayhi and Sailer, 1997).
Approaches to elucidate the cellular and molecular mecha-
This work was supported by Deutsche Forschungsgemeinschaft Grants WE
2260/4-1 and GRK 757.
Article, publication date, and citation information can be found at
http://jpet.aspetjournals.org.
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N-formyl-methionyl-leucyl-phenylalanine; MAPK, mitogen-activated protein kinase; PMNL, polymorphonuclear leukocyte; MM, Mono Mac; AKBA,
3-O-acetyl-11-keto-boswellic acid; ERK, extracellular signal-regulated kinase; m-3M3FBS, 2,4,6-trimethyl-N-(meta-3-trifluoromethyl-phenyl)-
benzenesulfonamide; U-73122, 1-[6-[[17-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione; 2-APB, 2-aminoethoxydiphe-
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224nisms underlying the clinical effects of BAs identified 5-li-
poxygenase (5-LO) (Safayhi et al., 1992), human leukocyte
elastase (Safayhi et al., 1997), topoisomerase I and II (Syr-
ovets et al., 2000), and IB kinases (Syrovets et al., 2005) as
molecular targets. Accordingly, it is speculated that BAs may
exert their anti-inflammatory effect mainly by inhibiting the
release of proinflammatory leukotrienes from leukocytes
(Safayhi et al., 1992) and/or by inhibition of NF-B and
subsequent down-regulation of TNF expression in activated
monocytes (Syrovets et al., 2005).
Stimulation of inflammatory cells by an adequate agonist
may evoke a number of functional responses including che-
motaxis, phagocytosis, degranulation, formation of reactive
oxygen species, release of cytokines and chemokines, and
liberation of lipid mediators. The transduction and mediation
of such agonist-induced responses requires appropriate in-
tracellular signaling systems that operate at multiple levels.
Elevation of the intracellular Ca
2 concentration ([Ca
2]i)i s
one central signaling event for cell activation (Li et al., 2002),
being involved in the regulation of functional responses such
as degranulation or the generation of reactive oxygen species
in agonist-challenged leukocytes (Bernardo et al., 1988). Ex-
tracellular stimuli, including the platelet-activating factor
(PAF) or N-formyl-methionyl-leucyl-phenylalanine (fMLP),
increase the [Ca
2]i in monocytes/macrophages, which is
composed of a rapid release of Ca
2 from intracellular stores
a n daC a
2 influx through plasma membrane Ca
2 channels
(Randriamampita and Trautmann, 1989). Besides Ca
2, pro-
tein phosphorylation is a common signal transduction mech-
anism integrating extracellular inflammatory signals into
leukocyte functions; in particular, MAPK pathways have
been shown to play important roles in this respect (Herlaar
and Brown, 1999; Johnson and Druey, 2002). Accordingly,
inhibitors of these kinases have been developed to intervene
with inflammatory disorders.
We have recently shown that 11-keto-BAs can activate
MAPK and induce Ca
2 mobilization in human isolated poly-
morphonuclear leukocytes (PMNLs) and granulocytic HL-60
cells, which could be linked to various functional responses,
including release of arachidonic acid, increased formation of
leukotrienes, and generation of reactive oxygen species (Alt-
mann et al., 2002, 2004). Since monocytes play key roles in
the course of inflammatory processes, we examined the effect
of BAs on the Ca
2 homeostasis and MAPK pathways in
human monocytic Mono Mac (MM) 6 cells. Interestingly, in
contrast to PMNLs or HL-60 cells, AKBA exerted opposite
effects in MM6 cells, inasmuch as it decreased basal [Ca
2]i,
inhibited agonist-induced Ca
2 mobilization, and blocked
agonist-induced activation of p38
MAPK and ERKs. These
findings support an anti-inflammatory potential of AKBA.
Materials and Methods
Materials. BAs were prepared as described previously (Jauch and
Bergmann, 2003). 2,4,6-Trimethyl-N-(meta-3-trifluoromethyl-phe-
nyl)-benzenesulfonamide (m-3M3FBS) was a generous gift from Dr.
T.G. Lee (SIGMOL, Pohang, Korea). U-73122 and SK&F96365 were
purchased from Calbiochem (San Diego, CA), Fura-2/AM was from
Alexis Corporation (La ¨ufelfingen, Switzerland), PAF was from Cay-
man Chemical (Ann Arbor, MI), 2-aminoethoxydiphenylborate (2-
APB) was from Tocris Cookson Inc. (Bristol, UK), and all other
chemicals were obtained from Sigma Chemie (Deisenhofen, Ger-
many).
Cells. MM6 cells were maintained in RPMI 1640 medium with
glutamine supplemented with 10% fetal calf serum, 100 g/ml strep-
tomycin, 100 U/ml penicillin, 1 mM sodium pyruvate, 1 nonessen-
tial amino acids, 1 mM oxalacetic acid, and 10 g/ml bovine insulin.
All cultures were seeded at a density of 2  10
5 cells/ml. MM6 cells
were treated with 2 ng/ml transforming growth factor  and 50 nM
calcitriol for 4 days. Cells were harvested by centrifugation (200g,1 0
min at room temperature) and washed once in phosphate-buffered
saline (PBS), pH 7.4. To exclude toxic effects of BAs during various
incubation periods, the viability of MM6 cells was analyzed by
trypan blue exclusion. Incubation with 30 M AKBA or 3 M
U-73122 at 37°C for up to 30 min caused no significant change in the
number of viable cells.
Human PMNLs were freshly isolated from leukocyte concentrates
obtained at St. Markus Hospital (Frankfurt, Germany) as described
(Werz et al., 2002). In brief, venous blood was taken from healthy
adult donors, and leukocyte concentrates were prepared by centrif-
ugation at 4000g/20 min/20°C. PMNLs were immediately isolated by
dextran sedimentation, centrifugation on Nycoprep cushions (PAA
Laboratories GmbH, Linz, Austria), and hypotonic lysis of erythro-
cytes. Monocytes were obtained from the same leukocyte concen-
trates after dextran sedimentation and centrifugation on Nycoprep
cushions. The mononuclear cells including lymphocytes and mono-
cytes appear as a layer on Nycoprep cushion after centrifugation.
The cells were washed twice with PBS, pH 5.9, containing 2 mM
EDTA, resuspended in RPMI-1640 supplemented with 2 mM glu-
tamine, 100 g/ml streptomycin, 100 U/ml penicillin, and 20% hu-
man plasma, and spread in cell culture flasks at 37°C and 5% CO2.
After 3 h, lymphocytes in suspension were removed, and adhered
monocytes were gently detached and resuspended in PBS plus 1
mg/ml glucose and 1 mM CaCl2 (PGC buffer).
Measurement of Intracellular Ca
2 Levels. MM6 cells or
blood monocytes (3  10
7/ml PG buffer) were incubated with 2 M
Fura-2/AM for 30 min at 37°C. After washing, 3  10
6 cells/ml PG
buffer were incubated in a thermally controlled (37°C) fluorometer
cuvette in a spectrofluorometer (Aminco-Bowman series 2; Thermo
Electron Corporation, Waltham, MA) with continuous stirring. Two
min prior to stimulation, 1 mM CaCl2 or 1 mM EDTA was added. The
fluorescence emission at 510 nm was measured after excitation at
340 and 380 nm, respectively, and [Ca
2]i was calculated according
to Grynkiewicz et al. (1985). Fmax (maximal fluorescence) was ob-
tained by lysing the cells with 1% Triton X-100 and Fmin by chelating
Ca
2 with 10 mM EDTA.
SDS-Polyacrylamide Gel Electrophoresis and Western
Blotting. Prewarmed (37°C) MM6 cells were preincubated with the
indicated concentrations of AKBA or vehicle [DMSO, final concen-
tration 1% (v/v)] for 5 min prior to stimulation with fMLP (1 M)
for 1 min at 37°C. The reaction was stopped by addition of the same
volume of ice-cold 2 SDS-polyacrylamide gel electrophoresis
(PAGE) sample loading buffer (SDS-b), samples for SDS-PAGE (ali-
quots corresponding to 2  10
6 cells in 20 l SDS-b) were prepared,
and proteins were separated as described (Werz et al., 2002). Correct
loading of the gel and transfer of proteins to the nitrocellulose mem-
brane was confirmed by Ponceau staining. Western blotting using
phosphospecific antibodies (1:1000 dilution, each; New England Bio-
labs, Beverly, MA) against pERK1/2 (Thr202/Tyr204) and pp38
MAPK
(Thr180/Tyr182) was performed using a Li-Cor Odyssey two-color
Western detection system (Li-Cor, Lincoln, NE), according to the
instructions of the manufacturer. Alternatively, detection of immu-
noreactive proteins was performed as described previously using
alkaline phosphatase-conjugated secondary antibody (Werz et al.,
2002).
Determination of IP3 Formation. Prewarmed (37°C) MM6 cells
(1.2  10
7/ml PGC buffer) were either preincubated with the indi-
cated compounds [or vehicle, DMSO  1% (v/v)] for 20 s and then
subsequently stimulated with m-3M3FBS (100 M) for 15 s or di-
rectly stimulated with the indicated compounds for 15 s at 37°C.
Incubations were stopped by the addition of 0.2 volumes of ice-cold
Effects of Boswellic Acids in Monocytic Cells 225HClO4 [20% (v/v)] and kept on ice for 20 min. Further extraction and
evaluation of IP3 released into the medium was determined using an
[
3H]IP3 Biotrak Assay System (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) according to the manufacturer’s instructions.
Data are expressed as percentage of vehicle-treated controls  S.E.,
n  3 to 4. Statistical analysis was performed prior to normalization,
p  0.05 ()o r0.01 ().
Statistics. Statistical evaluation of the data were performed by
one-way analysis of variance for independent or correlated samples
followed by Tukey honestly significant difference post hoc tests.
Where appropriate, Student’s t test for paired observations was
applied. p  0.05 ()o r0.01 () was considered significant.
Results
AKBA Decreases Basal [Ca
2]i of Resting MM6 Cells.
In our previous reports, we showed that AKBA and KBA, but
not ABA and BA (lacking the 11-keto group), cause a
marked mobilization of Ca
2 in human isolated PMNLs or in
the granulocytic cell line HL-60 (Altmann et al., 2002, 2004).
Accordingly, 30 M AKBA induced a rapid and pronounced
elevation of [Ca
2]i in PMNLs, whereas ABA was hardly
effective (Fig. 1A, left panel). In contrast, exposure of differ-
entiated MM6 cells to AKBA (30 M) resulted in a sudden
drop of resting [Ca
2]i from 155  8t o7 3 7 nM (Fig. 1A,
right panel). This decrease in [Ca
2]i was sustained, and
markedly reduced levels of basal [Ca
2]i were still detectable
20 min after exposure to AKBA (see below). In a previous
study using MM6 cells (Feisst and Werz, 2004), we observed
a similar drop of [Ca
2]i, when the PLC inhibitor U-73122 (3
M) was added to the cells, which was confirmed in the
present experiments (Fig. 1A, right panel). Of interest, in
PMNLs, U-73122 (3 M) caused no decrease in [Ca
2]i (Fig.
1A, left panel). The effect of AKBA on resting [Ca
2]i was
concentration-dependent and was clearly detectable already
at 1 M (Fig. 1B). Combined addition of 30 M AKBA plus
3 M U-73122 gave no additive effects versus AKBA or
U-73122 alone (data not shown).
In analogy to PMNLs, the effectiveness of the BAs to affect
[Ca
2]i in MM6 cells depended on the presence of the 11-keto
group and the 3-O-acetyl moiety. Thus, the 11-keto-free coun-
terpart of AKBA, namely ABA (30 M), hardly decreased
[Ca
2]i, and KBA, lacking the 3-O-acetyl moiety, was less
efficient than AKBA with respect to this response (Fig. 1, A
and C). Finally, no effect was detectable for BA (30 M).
AKBA Decreases Elevated [Ca
2]i in PAF-Activated
MM6 Cells. To evaluate whether AKBA also affects elevated
[Ca
2]i induced by an agonist, MM6 cells were first treated
with 100 nM PAF that raises [Ca
2]i, and AKBA, ABA, or
U-73122 was added 50 s later. Addition of AKBA or U-73122
evoked an immediate drop of [Ca
2]i in a concentration-
dependent manner (Fig. 2). Notably, the minimum [Ca
2]i
attained after AKBA or U-73122 addition (78  10 and 99 
9 nM, respectively) was lower than the basal Ca
2 levels
Fig. 1. Effects of BAs and U-73122 on
basal [Ca
2]i in resting PMNLs and
MM6 cells. Fura-2-loaded PMNLs
(10
7/ml PG buffer, A, left panel) or
MM6 cells (3  10
6/ml PG buffer, A,
right panel, B, and C), were supple-
mented with 1 mM CaCl2, 2 min prior
to stimulation, and [Ca
2]i was deter-
mined. A, addition of AKBA, ABA
(30 M, each), U-73122 (3 M), or ve-
hicle (DMSO) to resting PMNLs (left
panel) or MM6 cells (right panel) is
indicated by the arrow. Traces are
representative for three to six inde-
pendent recordings. B, concentration-
response curves of AKBA on [Ca
2]i in
resting MM6 cells. The minimum
[Ca
2]i within 30 s after addition was
determined. C, structure-activity re-
lationship of BAs on [Ca
2]i of resting
MM6 cells. Vehicle (veh, DMSO),
AKBA, KBA, ABA, BA (30 M,
each), or U-73122 (3 M) was added
as described above. The amplitude or
an average value of the Ca
2 decrease
(in nanomolar) was determined. Val-
ues in (B and C) are given as mean 
S.E., n  4 to 5. Statistically different
values compared with vehicle-treated
controls are marked (, p  0.01).
226 Poeckel et al.prior to stimulation with PAF (157  14 nM) and approached
similar levels as found for cells exposed only to AKBA (73 
7 nM) or U-73122 (88  8 nM), respectively (Fig. 2, compare
with Fig. 1C). Thus, AKBA decreases [Ca
2]i in MM6 cells to
a comparable extent as U-73122, apparently regardless of the
activation state of the cell.
AKBA Attenuates Agonist-Induced Elevation of
[Ca
2]i.. We sought to investigate whether AKBA could also
prevent agonist-induced elevations of [Ca
2]i. Agents that
elevate [Ca
2]i involving PLC/IP3 signaling (e.g., PAF, fMLP,
and m-3M3FBS) but also stimuli that raise [Ca
2]i indepen-
dent of the PLC/IP3 pathway like ionomycin or thapsigargin
(TG) were added to MM6 cells that received BAs or U-73122,
20 s prior to agonist addition. As shown in Fig. 3A, AKBA and
U-73122, but not ABA, potently inhibited the subsequent
Ca
2 mobilization induced by the physiological agonists PAF
or fMLP as well as by the direct PLC activator m-3M3FBS
(Bae et al., 2003). The IC50 value for AKBA was in the range
of 10 to 30 M, depending on the stimulus. Representative
[Ca
2]i traces of PAF-stimulated samples are displayed in
Fig. 3B, left panel. In contrast, initial elevation of [Ca
2]i
induced by the ER/SR-Ca
2-ATPase inhibitor TG or by the
Ca
2-ionophore ionomycin were not affected (Fig. 3A). Closer
examination revealed that AKBA transforms the sustained
elevation of [Ca
2]i evoked by TG to a transient signal (Fig.
3B, right panel).
The amplitudes of the Ca
2 transients of the physiological
stimuli PAF and fMLP were still strongly attenuated by
AKBA, when the preincubation period was expanded from
20 s to 20 min (Fig. 3C). In contrast, the suppressive effects
of U-73122 were seemingly transient and markedly declined
within 20 min for PAF-stimulated cells, but not so for cells
challenged with fMLP (Fig. 3C). Similarly, the decrease in
basal [Ca
2]i of (unstimulated) MM6 cells after prolonged (20
min) exposure to 30 M AKBA was sustained, whereas for
U-73122, the strong initial reduction of basal [Ca
2]i de-
tected right after exposure appeared to be transient and
again was almost reversed after 20 min (Table 1). Therefore,
AKBA exerts a sustained suppression on Ca
2 homeostasis
by decreasing basal [Ca
2]i as well as by attenuating (PLC/
IP3-mediated) Ca
2 mobilization.
It appeared possible that the suppressive effects of AKBA
observed in MM6 could be related to the fact that MM6 is a
human leukemia cell line. Therefore, we used primary mono-
cytes isolated from human blood to investigate effects of
AKBA on [Ca
2]i. As shown in Fig. 3D, AKBA (3 or 10 M)
rapidly decreased basal [Ca
2]i and prevented PAF-induced
Ca
2 mobilization in the same manner as observed for MM6
cells. ABA was without effect, and higher AKBA concentra-
tions ( 30 M) caused a rather slow but continuous increase
in [Ca
2]i seemingly related to cell lysis or unspecific toxic
effects of the compound (data not shown).
AKBA Attenuates Ca
2 Mobilization from Intracellu-
lar Stores. Next, we investigated if AKBA may also affect
the PAF-induced release of Ca
2 from intracellular stores, a
process that is typically PLC/IP3-dependent. MM6 cells were
resuspended in Ca
2-free buffer containing 1 mM EDTA and
treated with AKBA (ABA or U-73122), followed by the ad-
dition of PAF after another 20 s. Neither AKBA (or ABA)
nor U-73122 exhibited an effect on basal [Ca
2]i in resting
cells under these conditions. However, AKBA or U-73122
reduced the release of Ca
2 from internal stores elicited by
PAF (Fig. 4, A and B, left panel), although slightly higher
concentrations of AKBA and U-73122 were required as com-
pared with those needed to suppress total Ca
2 mobilization
in the presence of extracellular Ca
2. Surprisingly, also,
Ca
2 mobilization from internal storage sites induced by TG
(Fig. 4B, right panel) was partly antagonized by AKBA, im-
plying that PLC inhibition may not be the sole mechanism by
which AKBA affects [Ca
2]i since TG-mediated Ca
2 mobili-
zation circumvents the PLC/IP3 route.
AKBA Attenuates fMLP-Evoked MAPK Activation.
Cell activation, reflected by elevations in [Ca
2]i, is often
accompanied by induction of signaling pathways leading to
enhanced levels of phosphorylated members of the MAPK
family (Belcheva and Coscia, 2002). The p38
MAPK and ERKs
are key effectors in the cellular signaling network of leuko-
cytes. Addition of AKBA to resting MM6 cells caused a re-
duction of the basal levels of phosphorylated ERK-2, whereas
phosphorylation of p38
MAPK was not affected (Fig. 5A). Note
that the phosphorylation state of MAPK solely indicates the
activation of the kinases but might not exactly reflect the
protein kinase activity toward its substrate(s).
Next, we examined whether AKBA prevents the activation
of p38
MAPK and ERKs induced by fMLP that, in contrast to
PAF, causes prominent phosphorylation of the MAPK in
MM6 cells (D. Poeckel and O. Werz, unpublished data). In-
deed, activation of ERKs was potently prevented by AKBA;
again, the amounts of phosphorylated ERK-2 were lower
after preincubation with AKBA (10 and 30 M) as compared
with vehicle-treated control cells (Fig. 5B). AKBA also atten-
uated fMLP-induced phosphorylation of p38
MAPK (Fig. 5B). It
was shown that U-73122 substantially reduces the activation
of p38
MAPK in monocytic cells stimulated by lysophosphati-
dylcholine (Jing et al., 2000), and we found significant inhi-
bition of fMLP-induced ERK2 activation by U-73122 in MM6
Fig. 2. Effects of BAs and U-73122 on
elevated [Ca
2]i in stimulated MM6 cells.
MM6 cells were prepared as described in
Fig. 1. PAF (0.1 M) was added as indi-
cated, followed by vehicle (veh) or AKBA
(3–30 M, left panel); ABA (30 M) or
U-73122 (1–10 M, right panel) after an-
other 50 s. Curves are representative for
three to five independent determinations.
Effects of Boswellic Acids in Monocytic Cells 227cells (data not shown). ABA, however, was inactive (data
not shown).
Effects of Boswellic Acids on Cellular PLC Activity.
To test whether AKBA (in analogy to U-73122) inhibits cel-
lular PLC activity, we assayed the effects of AKBA on the IP3
formation in intact MM6 cells. Cellular PLC was directly
activated using 100 M m-3M3FBS to obtain a prominent
increase in IP3 production (7.9-fold elevation, Fig. 6B). In
agreement with its ability to block total Ca
2 mobilization,
U-73122 (5 M) inhibited m-3M3FBS-induced IP3 formation
(80%, Fig. 6A). In contrast to its ability to decrease [Ca
2]i,
AKBA failed to significantly suppress IP3 formation. Intrigu-
ingly, ABA, which hardly affected Ca
2 homeostasis, inhib-
ited m-3M3FBS-induced IP3 generation (50%, Fig. 6A).
We then examined whether AKBA, ABA, or U-73122
could also affect the basal IP3 turnover in resting cells. In
contrast to m-3M3FBS-activated MM6 cells, no significant
stimulatory effect was observed for U-73122 (5 M) or ABA.
However, AKBA caused a concentration-dependent increase
in IP3 formation as compared with vehicle-treated control
Fig. 3. AKBA and U-73122 antagonize agonist-induced Ca
2 mobilization. MM6 cells were prepared as described in Fig. 1. A, cells were treated with
vehicle (v), AKBA (3, 10, and 30 M), ABA (A,3 0M), or U-73122 (U, 3 M) followed by the addition of PAF (0.1 M), fMLP (0.1 M), m-3M3FBS
(50 M), thapsigargin (TG, 0.1 M), or ionomycin (0.2 M) after 20 s as indicated. The amplitude of the agonist-induced elevation of [Ca
2]i was
determined. Values are given as mean  S.E., n  4 to 5, and compared with the positive controls, p  0.05 ()o r0.01 (). B, original Ca
2 recordings
of measurements conducted for Fig. 3A. Left, cells were pretreated with vehicle (veh), AKBA (3, 10, and 30 M), ABA (30 M), or U-73122 (3 M)
for 20 s, and PAF (0.1 M) was added as indicated by the arrows. Right, cells were pretreated with vehicle (veh), AKBA (30 M), ABA (30 M), or
U-73122 (3 M) for 20 s, and thapsigargin (TG, 0.1 M) was added as indicated by the arrows. Curves are representative for three to five independent
determinations. C, efficacy of AKBA and U-73122 to inhibit agonist-induced Ca
2 mobilization depends on the preincubation period. Cells were
incubated with AKBA (30 M) or U-73122 (3 M). Then, PAF or fMLP (0.1 M, each) was added as indicated either 20 s (black bars) or 20 min (white
bars) after AKBA or U-73122. The resulting maximum increase in [Ca
2]i was determined and compared with vehicle-treated controls, given as
percentage of control  S.E., n  3 to 5. Statistical analysis was performed prior to normalization, p  0.05 ()o rp  0.01 (). D, Fura-2-loaded
primary monocytes (3  10
6/ml PGC buffer), freshly isolated from human blood, were treated with vehicle (v) or AKBA (3 or 10 M), followed by the
addition of PAF (0.1 M) after 20 s, as indicated by the arrows. Curves are representative for three independent determinations.
TABLE 1
AKBA but not U-73122 causes sustained depression of Ca
2i
MM6 cells in PGC buffer were preincubated with vehicle (DMSO), AKBA, ABA, or
U-73122 for 20 s or 20 min, and Ca
2i was determined, given as mean  S.E.. n 
4t o6 ,p  0.01 (**).
Agonist
Ca
2i after Addition of Agonist
20 s 20 min
nM
Vehicle (DMSO) 162  4 157  14
AKBA (30 M) 73  8** 83  5**
ABA (30 M) 139  4 146  16
U-73122 (3 M) 87  10** 132  13
228 Poeckel et al.cells (Fig. 6B). Possibly, this elevation of IP3 might compro-
mise the inhibitory effect of AKBA on the m-3M3FBS signal
as shown in Fig. 6A, leading to an apparent weaker inhibi-
tion due to inherent AKBA-induced IP3 production. Thus, a
correlation between the suppression of Ca
2 homeostasis and
inhibition of PLC by AKBA is not readily apparent, suggest-
ing that AKBA operates at alternate targets than PLC to
impair [Ca
2]i.
Inhibitors of Plasma Membrane Ca
2 Channels
Mimic the Effects of AKBA and Abolish AKBA-Induced
Decrease of [Ca
2]i. The fact that AKBA attenuates the
secondary phase of TG-induced Ca
2 mobilization, which
represents Ca
2 influx from the extracellular space,
prompted us to elucidate if the AKBA-induced loss of intra-
cellular (cytoplasmic) Ca
2 may be due to inhibition of
plasma membrane Ca
2 influx channels such as store-oper-
ated Ca
2 channels (SOCCs), nonselective cation channels
(NSCCs), or voltage-gated Ca
2 channels. SK&F96365, an
inhibitor of NSCC and SOCC, reduced basal [Ca
2]i in MM6
cells and was able to prevent the subsequent decrease of
[Ca
2]i induced by AKBA (Fig. 7). To distinguish between
NSCC and SOCC, we applied 2-APB (50 M), which blocks
SOCCs and, on the other hand, LOE908 (10 M), which
selectively inhibits NSCC. Both 2-APB and LOE908 de-
creased basal [Ca
2]i and prevented the effects of AKBA (Fig.
7). In contrast, inhibitors of voltage-gated Ca
2 channels
(300 nM -conotoxin MVIIA or 1 M verapamil, which block
L- or N-type channels, respectively), SR-Ca
2 release chan-
nels (10 M neomycin), or blockers of the Na
-Ca
2 ex-
changer (SEA0400 or KB-R7943, 10 M each) failed to sig-
nificantly decrease basal [Ca
2]i and to prevent effects of
AKBA (data not shown). Together, these results indicate that
AKBA may mediate the decrease of [Ca
2]i by blocking Ca
2
influx from the extracellular space via inhibition of SOCC/
NSCC.
Discussion
AKBA and KBA were shown to induce Ca
2 mobilization
and activation of MAPK in primary PMNLs and granulocytic
HL-60 cells, involving pertussis toxin-sensitive proximal sig-
naling pathways (Altmann et al., 2002, 2004). Activation of
these central signaling events were linked to typical func-
tional responses of granulocytes, including peroxide forma-
tion and enhanced metabolism of arachidonic acid; in partic-
ular, an increased activity of 5-LO was evident (Altmann et
al., 2004). Such an activation of granulocytes opposes the
general observation that extracts of B. serrata or isolated
BAs exert anti-inflammatory properties in several cellular
experimental settings (Krieglstein et al., 2001; Syrovets et
al., 2005) or animal models (Sharma et al., 1989; Gupta et al.,
1994) and finally also in studies on human subjects (Gupta et
al., 1998; Gerhardt et al., 2001).
Recently, Syrovets et al. (2005) showed that in activated
human monocytes, BAs down-regulate TNF expression via
a direct inhibition of IB kinases, providing a molecular basis
for the anti-inflammatory properties of BAs. The result from
the present investigation focusing on central signaling path-
ways in monocytes provides additional evidence for an anti-
inflammatory implication of AKBA at the cellular level.
Thus, AKBA decreased the basal [Ca
2]i, prevented agonist-
Fig. 5. AKBA attenuates the activation of ERK1/2 and p38
MAPK.A ,
prewarmed MM6 cells (2  10
6/100 l PGC buffer) were incubated with
the indicated concentrations of AKBA or vehicle (DMSO) for 5 min. B,
prewarmed MM6 cells were first incubated with the indicated concentra-
tions of AKBA or vehicle (DMSO) for 15 min prior to stimulation with
fMLP (1 M) at 37°C for 1 min. Reactions were terminated by addition of
equal volumes of SDS-b. Samples were subjected to SDS-PAGE and
Western blotting using phosphospecific antibodies against the dually
phosphorylated form of the MAPKs. Samples were concurrently analyzed
for p38
MAPK and ERK1/2 activation using the 2-color Western detection
system of Li-Cor (Odyssey), hence, loading control (L.C.) bands refer to
both antibodies. The results shown are representative of at least three
independent experiments.
Fig. 4. Effects of BAs on Ca
2 release from internal stores. MM6 cells
were prepared as described in Fig. 1, except that 1 mM EDTA was added
instead of 1 mM Ca
2. A, original Ca
2 recordings of samples stimulated
by PAF (0.1 M) after preincubation with vehicle (veh), AKBA (3, 10, and
30 M), ABA (30 M), or U-73122 (3 M) for 20 s. Curves are repre-
sentative for three to four independent determinations. B, cells were
treated with vehicle (v), AKBA (3, 10, and 30 M), ABA (A,3 0M), or
U-73122 (U, 3 M) followed by the addition of PAF (0.1 M, left panel),
or thapsigargin (TG, 0.1 M, right panel). The amplitude of the stimulus-
induced elevation of [Ca
2]i was determined. Values are given as mean 
S.E., n  4, p  0.05 ()o r0.01 ().
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2 mobilization, and blocked the activation of
ERK1/2 and p38
MAPK, signaling events that are determi-
nants for typical functional monocyte/macrophage responses
(Gijon and Leslie, 1999; Chen et al., 2001). Interestingly,
TNF generation and NF-B activation in monocytic cells
may depend on Ca
2 (Pollaud-Cherion et al., 1998; See et al.,
2004), providing a possible link between interference with
Ca
2 and down-regulation of NF-B and TNF.
Apparently, in view of the opposite, agonistic effects on
PMNLs and HL-60 cells, AKBA and KBA exert disparate
effects on certain cellular processes, depending on the cell
type. Thus, in monocytic cells, AKBA may be regarded as
pharmacologically active compound that suppresses impor-
tant signaling events, implying anti-inflammatory function-
ality. PMNLs that are terminally differentiated are involved
in acute inflammatory responses, whereas monocytes act
more in chronic inflammation and can undergo differentia-
tion prior to function. Indeed, opposite effects on Ca
2 ho-
meostasis in analogy to AKBA are obvious in leukocytes
exposed to arachidonic acid that decreases [Ca
2]i in perito-
neal macrophages (Randriamampita and Trautmann, 1990)
and in MM6 cells (D. Poeckel and O. Werz, unpublished data)
but on the other hand evokes Ca
2 mobilization in PMNLs
(Naccache et al., 1989).
Many effector enzymes like phospholipases, 5-LO, and pro-
tein kinases respond to and are regulated by an elevation of
[Ca
2]i, leading to functional monocyte responses including
lipid mediator and superoxide release, degranulation, and
cytokine generation (Bernardo et al., 1988; Pollaud-Cherion
et al., 1998). Among the four major -configurated BAs
present in ethanolic extracts of B. serrata gum, AKBA was
most potent, whereas the 11-methylene derivatives were
hardly active; also, the absence of the 3-O-acetyl group led to
a loss of efficacy. Similarly, for interference with so far all
defined molecular pharmacological targets, i.e., 5-LO
(Safayhi et al., 1992), human leukocyte elastase (Safayhi et
al., 1997), topoisomerases I and II (Syrovets et al., 2000), as
well as IB kinases (Syrovets et al., 2005), AKBA possesses
the highest potency, being of considerable pharmacological
interest (Ammon, 2002).
The effects of AKBA in MM6 cells showed similar charac-
teristics as the PLC inhibitor U-73122 (Bleasdale et al., 1990)
that was found to block acute and chronic inflammatory
responses in vivo (Hou et al., 2004). Indeed, both U-73122
and AKBA rapidly decreased the basal [Ca
2]i of resting cells
but also caused an immediate drop of the elevated [Ca
2]i
after challenge with PAF, displaying comparable kinetics.
Moreover, both agents reduced agonist-evoked Ca
2 mobili-
zation, which in fact is a characteristic for monocyte activa-
tion by external stimuli (Kim et al., 1992; Bernardo et al.,
1997; Li et al., 2002). Such Ca
2-antagonizing activity of
AKBA or U-73122 was evident for agonists (fMLP, PAF, or
m-3M3FBS) that act via the PLC/IP3 pathway. In contrast,
initial Ca
2 fluxes induced by the ER/SR-Ca
2-ATPase in-
hibitor TG or by the Ca
2-ionophore ionomycin, which both
Fig. 6. Effects of BAs on IP3 formation. A, prewarmed MM6 cells (1.2  10
7/ml PGC buffer) were treated with vehicle (DMSO), AKBA (30 M), ABA
(30 M), or U-73122 (5 M) for 20 s prior to stimulation with m-3M3FBS (100 M) for 15 s. Incubations were stopped by the addition of 0.2 volumes
of ice-cold HClO4 (20%, v/v), and extraction and evaluation of IP3 released were determined according to the manufacturer’s instructions (IP3 [
3H]
Biotrak Assay System; GE Healthcare). Data are expressed as percentage of vehicle-treated (m-3M3FBS-stimulated) control  S.E., n  3t o4 .
Statistical analysis was performed prior to normalization, p  0.05 ()o r0.01 (). B, prewarmed MM6 cells (1.2  10
7/ml PGC buffer) were
incubated with vehicle (DMSO), AKBA (3, 10, and 30 M), ABA (30 M), U-73122 (5 M), or m-3M3FBS (100 M) for 15 s. Incubations were stopped
by the addition of 0.2 volumes of ice-cold HClO4 (20%, v/v). The subsequent extraction procedure is identical to the description in A. Data are expressed
as percentage of vehicle-treated (unstimulated) control  S.E., n  3 to 4. Statistical analysis was performed prior to normalization, p  0.05 ()o r
0.01 ().
Fig. 7. Effects of plasma membrane Ca
2 channel inhibitors on Ca
2
homeostasis and on the actions of AKBA. Fura-2-loaded MM6 cells (3 
10
6/ml PG buffer) were preincubated with vehicle (veh, DMSO),
SK&F96365 (10 or 30 M), 2-APB (50 M), or LOE908 (10 M) for 2 min
at 37°C in the presence of 1 mM CaCl2. Then, cells were stimulated with
AKBA (30 M), and [Ca
2]i was determined. Traces are representative
for three to four independent determinations.
230 Poeckel et al.circumvent PLC/IP3 for Ca
2 mobilization (Gouy et al.,
1990), were unaffected by either U-73122 or AKBA. Experi-
ments conducted to determine the duration of the Ca
2 sup-
pressing effects, either in resting or in agonist-challenged
cells, revealed rather transient efficacy of U-73122, whereas
AKBA-mediated antagonism was sustained and long-lasting,
implying that the compounds most likely operate through
differing mechanisms.
Another common feature of U-73122 and AKBA was their
ability to inhibit the PAF-induced release of Ca
2 from in-
ternal storage sites. Hence, based on the inhibitory profile
and characteristics to affect Ca
2 homeostasis, it first ap-
peared reasonable that the Ca
2-modulating effects of AKBA
could be due to interference with PLC, which is a defined
molecular target of U-73122 (Bleasdale et al., 1990). On the
other hand, interference of AKBA with the IP3 receptor could
be a plausible explanation. Surprisingly, however, AKBA
significantly inhibited TG-induced Ca
2 mobilization from
internal stores and also the sustained elevation of [Ca
2]i of
TG-treated cells in Ca
2-containing buffer, suggesting that
AKBA may influence Ca
2 homeostasis, at least in part,
independent of PLC or IP3. An important finding that favors
a PLC-independent mechanism is the failure of AKBA to
efficiently suppress the release of intracellular IP3. Strik-
ingly, in contrast to AKBA, ABA clearly failed to counteract
m-3M3FBS-induced Ca
2 mobilization, even though it was
more efficient than AKBA in inhibiting m-3M3FBS-evoked
IP3 formation. Based on these discrepancies, inhibition of
PLC is no satisfying explanation for the potent impairment of
[Ca
2]i induced by AKBA. This hypothesis is further sup-
ported by the fact that AKBA on one hand even slightly
increased basal IP3 levels about 2-fold, which should actually
lead to Ca
2 release from internal storage sites. However, in
contrast, there is a strong decrease in the basal [Ca
2]i under
these conditions.
The AKBA-induced loss of intracellular (cytoplasmic) Ca
2
may result from different processes such as extrusion of
intracellular Ca
2 to the extracellular space, stimulation of
Ca
2 storage (uptake) into intracellular sites (e.g., by activa-
tion of a Ca
2/ATPase), or interference with ion channels
allowing Ca
2 influx. Our studies using selective inhibitors
of various plasma membrane Ca
2 influx channels imply
that AKBA might act (at least in part) by inhibition of SOCC
and/or NSCC. Thus, inhibitors of SOCC and/or NSCC mim-
icked the loss of [Ca
2]i observed with AKBA and were able
to inhibit the subsequent decrease of [Ca
2]i induced by
AKBA. Of interest, also for U-73122, inhibition of plasma
membrane Ca
2 channels has been accounted for reduced
[Ca
2]i (see Feisst et al., 2005, and references therein). In
contrast, voltage-gated N-and L-type Ca
2 channels, SR-
Ca
2 release channels (neomycin), or the Na
-Ca
2 ex-
changer do not seem to mediate the effects of AKBA. It is
conceivable that a block of SOCC/NSCC may shift the bal-
ance between Ca
2 influx and Ca
2 extrusion toward pre-
dominant extrusion that, as a result, leads to impaired
[Ca
2]i. However, more detailed experiments are required to
elucidate the molecular targets and mechanisms underlying
the complex regulation of Ca
2 homeostasis by AKBA in
MM6 cells, which would go beyond the scope of this study.
Besides antagonizing Ca
2, AKBA potently prevented
fMLP-induced activation of p38
MAPK and ERKs. These
MAPK pathways play pivotal roles in the transduction of
external mediators to many cellular processes and are
strongly implicated in inflammatory disorders (Herlaar and
Brown, 1999; Johnson and Druey, 2002). Among the phar-
macological strategies for intervention with inflammation,
inhibitors of ERKs may possess potential for the treatment of
inflammatory and neuropathic pain (Ji, 2004). p38
MAPK in-
hibitors have been developed to treat for example rheumatoid
arthritis (Pargellis and Regan, 2003) and Crohn’s disease
(Hommes et al., 2002), inflammatory disorders that in fact
have been successfully treated with B. serrata extracts (Ger-
hardt et al., 2001). Of interest, recently also U-73122 was
shown to reduce lysophosphatidylcholine-induced p38
MAPK
activation in monocytic THP-1 cells (Jing et al., 2000).
In summary, our data show that AKBA is capable to sup-
press central signaling events in human monocytic cells,
typically important for functional monocyte responses at in-
flammatory sites. These findings may be added to the list of
pharmacological actions of BAs assumed to contribute to the
effects of B. serrata extracts observed in animal models and
in clinical studies of humans and may be another step for-
ward to the elucidation of the cellular and molecular basis of
the anti-inflammatory properties of BAs.
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